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Abstract 
 
Inflammatory processes are critical components of many illnesses, and dietary n-3 
fatty acids have been shown to contribute to a reduction of the inflammatory 
status, both in in vivo and in vitro studies. The mechanisms underlying the 
modulation of inflammation are not completely understood, but it is clear that 
dietary n-3 fatty acids alter the eicosanoid metabolome profile, resulting in 
increased levels of n-3 fatty acid eicosanoids, whereas eicosanoids from other 
fatty acids are decreased. Until now, the anti-inflammatory properties of n-3 fatty 
acids had not been  linked to an interaction with endocannabinoids/N-acyl 
ethanolamides (NAEs) levels before. This thesis describes a series of studies on 
the link between dietary fatty acids, endocannabinoids/NAEs, and inflammation.  
Previous research indicated that dietary fatty acids alter the profile of 
endocannabinoids/NAEs rather than just affecting single compounds such as 
arachidonoyl ethanolamide (AEA) and 2-arachidonoyl glycerol (2-AG) as suggested 
before, and therefore a method based on liquid chromatography coupled to mass 
spectrometry (LC-MS/MS) to quantify a broad range of endocannabinoids/NAEs 
was developed. This method was used to demonstrate that n-3 fatty acids are 
converted to their endocannabinoid derivates by adipocytes in vitro. These n-3 
derived NAEs, docosahexaenoyl ethanolamide (DHEA) and eicosapentaenoyl 
ethanolamide (EPEA), were shown to have anti-inflammatory properties in 
lipopolysaccharide (LPS)-stimulated adipocytes by reducing interleukin-6 (IL-6) 
and monocyte chemotactic protein-1 (MCP-1) excretion. Further studies showed 
that serum free fatty acid levels and plasma NAE levels are correlated under both 
fasting and post-prandial conditions in women, and demonstrated that plasma 
AEA and oleoyl ethanolamide (OEA) correlated with body mass index (BMI).  
Considering the complexity of endocannabinoid and eicosanoid metabolism, it is 
likely that their concentrations are dynamic over time and tissue-specific during 
inflammation. So far, most studies had focused on limited numbers of 
endocannabinoids and eicosanoids in restricted numbers of tissues or plasma, and 
the effect of inflammation on DHEA and EPEA levels had not been studied before. 
Therefore, an animal study was conducted which investigated in detail the time-
dependent effects of i.p. LPS on the levels of lipid derived mediators 
(endocannabinoids/NAEs and eicosanoids) in plasma, liver, ileum and adipose 
tissue in mice fed with a diet rich in fish oil. The results demonstrated that both 
 
 
DHEA and EPEA levels were increased after LPS treatment, but also time- and 
tissue dependent effects were observed. Based on these data, another study was 
performed which investigated the combined effect of different fish oil diets and 
inflammation on the profiles of endocannabinoids and eicosanoids using the same 
multi-compartment targeted lipidomics approach. The data indicated that that 
dietary n-3 fatty acids and inflammation alter both the endocannabinoid and 
eicosanoid metabolomes towards higher levels of n-3 derived metabolites at the 
expense of metabolites derived from other fatty acids. Multivariate data analysis 
revealed that under normal conditions the diet groups were primarily separated 
based on decreased levels of other than n-3 derived metabolites. However, during 
inflammation, the separation was primarily explained by increases in n-3 derived 
compounds. Finally, additional analyses demonstrated that plasma and 
erythrocytes contain significant levels of esterified NAEs. The esterified levels 
were approximately 20-60 fold higher than the free NAE levels, and their profiles 
resembles the free NAE profiles.  
In conclusion, (dietary) n-3 fatty acids increased the levels of DHEA and EPEA, and 
these metabolites displayed anti-inflammatory properties. Although the n-3 fatty 
acids are likely to be converted to a variety of other metabolites, the work in this 
thesis suggests that ‘fish oil-derived’ endocannabinoids are a new link between 
fish oil and its anti-inflammatory properties. Further research is needed to relate 
nutrition-based modulation of endocannabinoid profiles to more specific effects 
on health and disease. 
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The interface between nutrition and pharmacology: an emerging 
scientific field 
 
Nutrition belongs to the most important factors determining (human) health, and 
‘unhealthy’ nutritional habits are linked to the development of various illnesses 
like diabetes, cancer, cardiovascular diseases, and deficiency syndromes. On the 
other hand, several food components are associated with positive health effects, 
like anti-oxidants, vitamins, calcium, probiotics, certain proteins, or omega-3 fatty 
acids. For many of these compounds, their normal physiological role is obvious at 
first glance; bone consists largely of calcium salts, so it is not surprising that the 
National Health Council advises people at risk for bone-degenerative diseases, like 
osteoporosis, to ensure sufficient intake of calcium [1]. However, several food 
components are more than just ‘building blocks’ for cells and tissues. Many 
molecules in our diet are capable of binding to macromolecules, including cellular 
receptors and enzymes, thereby evoking specific biological responses or 
modulating (patho-) physiological processes. For example, caffeine from coffee 
and other sources increases alertness by antagonizing the brain adenosine 
receptors [2], and thus represents a well-known example of a dietary compound 
with pharmacological properties. Compared to the ‘classical’ pharmacological 
approach, where the ‘one target–one drug’ concept has been a central principle, 
nutrition shows a more subtle and broader mode of action in influencing health, 
acting at multiple sites and producing smaller effects [3]. In their search for 
products with additional beneficial health effects, many food companies have 
engaged themselves in pharma-like strategies to discover nutrients and other bio-
actives with biological effects that go beyond nutritional properties. During the 
last decades different nutritional product categories have evolved which claim to 
provide some form of specific health benefit. In the European Union (EU) for 
instance, a ‘health claim’ is any message or representation that states, suggests or 
implies that a relationship exists between a food category, a food or one of its 
constituents and health. A ‘reduction of disease risk’ claim is defined as any health 
claim that states, suggests or implies that the consumption of a food category, a 
food or one of its constituents significantly reduces a risk factor in the 
development of a human disease. In the EU, the European Food Safety Authority 
(EFSA; httt://www.efsa.europa.eu) is responsible for verifying that health claims 
made on a food label are substantiated by scientific evidence. In addition to these 
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food products, functional foods or supplements with health claims, there is an 
increasing activity in the area of clinical and medical nutrition, i.e. nutritional 
strategies with therapeutic claims. For example in diabetes, cardiovascular disease 
or cancer, some people benefit from more intensive forms of nutritional support 
as part of the therapy [3]. It is expected that better, healthier nutrition will be part 
of future advances in the prevention and treatment of disorders mentioned 
before. However, it is clear that more research is needed to better understand the 
often very complex and subtle mechanisms of action of nutrients or food products 
and to evaluate their biological effectiveness. 
 
Inflammation: more than just a defense mechanism 
Inflammation is an organisms’ response to a noxious stimulus, such as invasion by 
micro-organisms or traumatic tissue damage [4]. Its purpose is to limit ongoing 
damage, and to initiate the processes which should lead to repair or regeneration 
of the damaged tissue. Inflammation involves vascular effects and the action of 
different cells of the (innate) immune system, including macrophages and 
granulocytes. The communication between these various cells is regulated by 
signaling molecules such as interleukins, prostaglandins and leukotrienes. 
Normally, inflammation is considered to be beneficial as it helps organisms to 
overcome e.g. pathogenic infection. However, several diseases are associated 
with dysregulated inflammatory processes, such as allergies, rheumatoid arthritis, 
inflammatory bowel disease, and obesity [5]. These diseases can greatly affect the 
quality of life of people suffering these, and together represent a significant 
burden on health care economics. For several conditions, pharmacological 
therapy is used to treat the symptoms of inflammation [6], and a wide range of 
anti-inflammatory agents is currently available, as over-the-counter or 
prescription drugs. Although these agents are generally effective, adverse effects 
associated with their (chronic) use could limit their applicability. 
Over the last years, it has become evident that inflammation can be regarded as 
an overarching process involved in the development, progression and resolution 
of many pathological conditions. Depending on the situation, modulation of 
inflammation can be clinically advantageous. For example, patients suffering from 
solid tumors displayed prolonged survival when treated with anti-inflammatory 
drugs [7]. Furthermore, blockade of the cytokine interleukin-6 (IL-6) was shown to 
improve metabolic parameters in an experimental model of cancer cachexia [8]. 
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Cachexia is commonly observed in advanced stages of cancer, and is associated 
with e.g. reduced effectiveness of anticancer therapies, and increased incidence 
of side-effects [3]. In addition to treatment with medication, nutrients like omega-
3 fatty acids and amino acids are also effective against cancer cachexia, and 
(early) nutritional support has been associated with an improved response to 
therapy and quality of life [9, 10].  
Type 2 diabetes (T2D) represents another example of a complex disease in which 
inflammation is involved as one of the key pathological processes [11, 12]. Insulin 
resistance or T2D can be part of a larger constellation of metabolic abnormalities 
known as the metabolic syndrome. There are several definitions of the metabolic 
syndrome, and numbers on its prevalence may differ as different definitions are 
used. The US National Cholesterol Education Program Adult Treatment Panel III 
(NCEP – ATP III) definition includes criteria for central obesity, dyslipidemia, 
hypertension and hyperglycemia. But also other definitions are used, including 
criteria for insulin sensitivity or body mass index (BMI). Nevertheless, it is clear 
that the metabolic syndrome is characterized by metabolic disturbances at the 
systemic level, and multiple sites like liver, pancreas, skeletal muscle and adipose 
tissue are involved in its etiology.  
In a publication by Weisberg et al, a link between obesity and inflammation was 
established for the first time since obesity was related to increased macrophage 
infiltration in adipose tissue of mice [13]. Adipose tissue is capable of secreting 
pro-inflammatory compounds like tumour necrosis factor-α (TNF-α), IL-6 and 
monocyte chemotactic protein-1 (MCP-1), which are delivered to the bloodstream 
and can act on distant targets like liver and skeletal muscle [14-17]. This might in 
part lead to the increased plasma IL-6 and MCP-1 levels which are observed in 
obesity, and it is now well established that obesity is associated with a systemic 
low grade inflammation. MCP-1 is involved in the recruitment of macrophages to 
extra-vasal sites, including adipose tissue, which can lead to further macrophage 
infiltration of adipose tissue [17]. In vitro experiments showed that there is cross-
talk between macrophages and adipocytes, leading to increased synthesis of 
inflammatory cytokines when they are allowed to make physical contact [18]. IL-6 
and TNF-α are pro-inflammatory proteins, but also reduce insulin sensitivity in 
skeletal muscle cells, linking obesity to the development of insulin resistance and 
eventually type 2 diabetes (T2D) and the metabolic syndrome [11, 12]. Anti-
inflammatory treatments, such as inhibiting the IL-1 receptor or inhibiting the NF-
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κB pathway, are effective in reducing blood sugar levels and systemic 
inflammation, thereby reducing insulin resistance in diabetes [11]. 
 
Modulation of inflammation by dietary fatty acids 
Nutrition provides an alternative way to attenuate inflammation and its 
complications. Dietary intake of the omega-3 ‘fish-oil’ fatty acids docosahexaenoic 
acid (DHA) and eicosapentaenoic acid (EPA) is associated with positive health 
effects, including improvement of metabolic parameters in obesity and anti-
inflammatory effects [5, 19-21]. The mechanisms underlying the immune-
modulating properties of omega-3 fatty acids are not completely understood, but 
it is clear multiple receptors and pathways are involved (see Figure 1.1 for an 
overview of established pathways).  
One of these proposed pathways involves binding of DHA and EPA to peroxisome 
proliferator-activated receptor-γ (PPAR-γ), which results in anti-inflammatory 
effects [22]. More recently, also the orphan receptor GP120 was indicated as a 
mediator of the anti-inflammatory properties of DHA and EPA in RAW264.7 and 
primary intraperitoneal macrophages [23]. At the same time, GP120 was also 
implicated in the insulin sensitizing effects of omega-3 fatty acids in obesity, again 
attesting to the mechanistic relation between inflammation and insulin resistance.  
 
 
 
 
 
 
 
 
Figure 1.1: Established mechanisms through which n-3 fatty acids modulate inflammatory 
processes. 
 
Another line of evidence points to a link with the synthesis of lipids with biological 
activity (‘bioactive lipids’), such as the eicosanoids. For example, arachidonic acid 
(ARA; 20:4 omega-6), can be converted by cyclo-oxygenase (COX), lipo-oxygenase 
(LOX), and/or cytochrome P450 (CYP) to form prostaglandins (PGs), leukotrienes 
(LTs), and epoxyeicosatrienoic acids (EETs), respectively (see Figure 1.2 for an 
n-3 fatty acids Eicosanoid synthesis 
Binding to Transcription factors / receptors 
Resolvin synthesis 
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overview) [5, 24-26]. These classes of compounds are involved in inflammatory 
signaling and are generally (except the EETs) assumed to be pro-inflammatory. 
The synthesis of these compounds starts within the cell membrane, were fatty 
acids are released from membrane phospholipids and are eventually converted to 
the above mentioned COX or LOX metabolites. Dietary intervention studies have 
clearly demonstrated the link between dietary fatty acid intake, cell membrane 
fatty acid composition, and subsequent prostaglandin levels [27]. Increasing 
dietary intake of n-3 fatty acids reduced the levels of ARA in plasma membrane 
phospholipids. At the same time, ex vivo stimulated immune cells produced lower 
quantities of the ARA-derived metabolite PGE2 and cytokines, but higher levels of 
n-3 fatty acid derived eicosanoids were found. These compounds, also referred to 
as the ‘3-series’ of prostaglandins (see Figure 1.3 for a full overview of n-3 fatty 
acid derived metabolites), are less potent inflammatory molecules than ARA-
derived metabolites, thus indicating that manipulation of dietary fatty acid intake 
shifts the profile of released prostaglandins to a ‘less inflammatory’ phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Overview of the enzymatic pathways involved the metabolism of arachidonic 
acid (ARA) to bioactive lipids, and their principal metabolites. Several enzymes, e.g. COX, 
CYP and LOX, can metabolize ARA, yielding a variety of bioactive lipids. 
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Recently, evidence has emerged that n-3 fatty acids can be converted to a class of 
compounds called resolvins, which have anti-inflammatory properties and could 
also contribute to the anti-inflammatory effects which are related to dietary 
intake of n-3 fatty acids [28]. Resolvins are synthesized from the COX-2 and LOX 
pathways when aspirin is present. Their anti-inflammatory properties have been 
demonstrated in a murine model of inflammatory bowel disease, where e.g. 
pretreatment with certain resolvins protected against wasting, inflammatory cell 
infiltration, and colonic damage [22].  
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Figure 1.3: Overview of the enzymatic 
pathways involved the metabolism of the n-3 
fatty acids docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) to bioactive lipids. 
In general, the n-3 derived metabolites are less 
potent pro-inflammatory compounds 
compared to their ARA-derived counterparts 
(e.g. 5-HEPE), or have anti-inflammatory 
properties (e.g. resolvins). 
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Finally, fatty acids also serve as precursors for the synthesis of the so-called 
endocannabinoids, another class of compounds known for its role in metabolism 
and inflammation. The potential relation between dietary n-3 fatty acids, 
endocannabinoids, and inflammation has not received much attention yet. The 
endocannabinoid system will be introduced in more detail in the next section. 
 
The endocannabinoid system 
Over the last years, the so-called endocannabinoid system (ECS) has received 
much interest for its role in metabolism and inflammation. Studies into the effects 
of smoking marijuana led to the discovery of the cannabinoid receptor type 1 
(CB1) in brain [29]. CB1 was found to be responsible for mediating the effects of 
∆-9 tetrahydrocannabinol, one of the major active compounds released from 
smoking Cannabis sativa. Later, the endogenous ligands for CB1, the so-called 
endocannabinoids, were identified. The first identified endocannabinoid was 
arachidonoyl ethanolamide (AEA), which is also known as anandamide (Sanskrit 
for ‘inner bliss’) and belongs to the class of fatty acid N-acyl ethanolamines (NAEs) 
[30]. AEA does not only bind to CB1, but also to other receptors, such as PPAR-
α and PPAR-γ, and the ligand-gated ion channel transient receptor potential 
vanilloid-1 (TRPV-1) [31-33]. Subsequently, another ‘classic’ endocannabinoid 2-
arachidonoyl glycerol (2-AG), and a second endocannabinoid receptor, CB2, were 
identified [34]. In addition to these two established cannabinoid receptors, there 
is now data suggesting that there are more cannabinoid receptor types, with 
GPR18 [35] and GPR55 [36] being candidates to be recognized as cannabinoid 
receptors, and other orphan receptors might follow. Other currently known 
endocannabinoids are N-arachidonoyl dopamine (NADA), 2-arachidonoyl glycerol 
ether (2-AG ether, noladin ether), O-arachidonoyl ethanolamide (O-AEA; 
virodhamine), dihomo-γ-linolenoyl ethanolamide (DLE) and docosatetraenoyl 
ethanolamide (DEA) [30, 34, 37-39] (see Figure 1.4 for these endocannabinoids 
and chemically related structures). Together, the endocannabinoids, the enzymes 
involved in their metabolism, and the cannabinoid receptors, are referred to as 
the endocannabinoid system (ECS). The endocannabinoid system is widely present 
throughout the body and is involved in a variety of physiological processes, 
including the regulation of food intake, metabolism and inflammation. The 
synthesis of endocannabinoids, their roles in metabolism and inflammation, and 
the relation with dietary fatty acids will be discussed in the next sections. 
Chapter 1 
19 
 
 
 
 
 
Figure 1.4: Overview of several endocannabinoids and related structures. Anandamide 
(AEA) is the best studied endocannabinoid and belongs to the group of N-acyl 
ethanolamines. Other known compounds with affinity for either CB1 and/or CB2 in this 
figure include DHEA, EPEA, DLE, 2-AG, O-AEA, and NADA. Other structures, such as OEA, 
PEA and SEA, do not display any significant affinity for CB1 or CB2, but can bind to other 
receptors, including PPARs or TRPV-1, which are also targets for e.g. AEA.  
 
 
Synthesis and breakdown of endocannabinoids 
Similar to the prostaglandins, the endocannabinoids are synthesized from fatty 
acids which are initially esterified to membrane phospholipids. NAEs are 
synthesized on demand, and it is likely that their levels are regulated by enzymes 
which are responsible for their release and breakdown. Several mechanisms are 
described through which AEA and 2-AG can be synthesized, involving the action of 
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multiple enzymes and the formation of several lipid intermediates [34, 37, 40]. For 
NAEs, the transacylation-phosphodiesterase pathway is the most studied route. 
Here, NAEs are released in a two-step process [37]. First, Ca2+-dependent 
N-acyltransferase (Ca-NAT) transfers the fatty acyl chain from the sn-1 position of 
a glycerophospholipid to the ethanolamine moiety of phosphatidylethanolamine 
(PE), to form N-acylphosphatidylethanolamine (NAPE). In the second step, NAPE is 
broken down by NAPE-hydrolyzing phospholipase D (NAPE-PLD), which releases 
phosphatidic acid and the NAE. Several alternatives to this pathway have been 
described in literature, requiring the action of other enzymes such as 
phospholipase A2 (PLA2) which yield other distinct lipid intermediates [40].  
After release, NAEs are immediately exposed to enzymes that are able to break 
them down, thereby terminating their action. The primary NAE degrading enzyme 
is fatty acid amide hydrolase (FAAH), which is located at the surface of the 
endoplasmatic reticulum membrane [41]. FAAH hydrolyses the NAE to its 
corresponding fatty acid and ethanolamine. Due to the intracellular location of 
FAAH, the NAE must get back into the cell through an as yet not completely 
understood process. There is debate on the existence of the ‘anandamide 
membrane transporter’ (AMT), which is predicted to exist based on experimental 
data that point to a transporter-dependent mechanism. Several inhibitors of this 
alleged transporter have been described, contributing to this idea. However, so 
far, such a membrane transporter has not been identified yet, and evidence 
supporting a simple transmembrane diffusion model is growing. Anandamide was 
shown to diffuse across membranes in a transporter-independent fashion [42]. In 
addition, several purported transport inhibitors in fact inhibit FAAH, thereby 
preventing the development of a concentration gradient across the membrane 
and thus stopping the NAE transmembrane movement [43]. Future research 
should establish if the AMT truly exists or whether data supporting its existence 
are in fact pointing to FAAH as the principal bottleneck in NAE hydrolysis.  
Recently, FAAH-2, a second NAE degrading enzyme, was discovered. FAAH-2 is 
localized on cytoplasmic lipid droplets, and displayed slower NAE hydrolysis rates 
compared to FAAH [41]. Interestingly, FAAH-2 is also expressed in heart and ovary 
tissue, where FAAH is not detected [44]. 
Finally, next to enzymatic breakdown, NAEs are also substrates for COX-2, LOX 
and CYP, yielding e.g. prostamides and n-hydroperoxyanandamides [45, 46], 
representing another pathway to clear NAEs. 
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Endocannabinoids and related compounds as important regulators 
of metabolism 
In addition to AEA, DEA and DLE, other fatty acids can also couple to 
ethanolamine to form a NAE. Known examples include oleoyl ethanolamide 
(OEA), palmitoyl ethanolamide (PEA), and stearoyl ethanolamide (SEA), which are 
present in higher concentrations in blood that AEA [47] (see Figure 1.4). These 
compounds do not have any significant affinity for either CB1 or CB2, but can bind 
to other receptors which are also targets for e.g. AEA, including PPARs and 
TRPV-1. Moreover, it has been hypothesized that PEA can potentiate the action of 
AEA due to competition at the breakdown level; increasing relative PEA levels 
would result in reduced breakdown of AEA, elevating its levels and potentially 
leading to increased CB1 stimulation. 
OEA is known for reducing appetite, body weight gain and mesenteric fat 
deposition [48, 49]. Gut levels of OEA are decreased by fasting and increased after 
eating, and i.p. administration of OEA results in acute reduction of food intake. 
These effects are in part mediated by PPAR-α, TRPV-1 and possibly GPR119, but it 
is likely that other receptors are also involved as these effects were not 
completely blocked with antagonists or knock-out models. The effects of OEA are 
in contrast to the appetite-inducing properties of AEA [50]. When in the fasting 
state, endocannabinoid levels are increased in the limbic forebrain, and are 
decreased upon eating [51]. Exogenous administration of 2-AG in the brain 
stimulated appetite, which was attenuated with co-administration of the CB1 
inverse agonist SR141716 (also known as Rimonabant; see below for further 
details) [51]. This relates to the sudden strong desire for food (‘munchies’) which 
is observed after the use of marijuana. AEA levels are increased in the small 
intestine upon food deprivation, and normalized after eating, and this might be 
involved in gut-to-brain signaling.  
In addition to effects on food intake and satiety, endocannabinoids are also active 
in other tissues which are involved in energy homeostasis. Levels of AEA and 2-AG 
display peak concentrations just before differentiation in 3T3-F442A adipocytes, 
with 2-AG levels remaining relatively high [52], and pharmacological stimulation 
of CB1 increased lipid droplet formation in differentiating adipocytes. 
Interestingly, PPARs are also involved in adipocyte differentiation and energy 
homeostasis, linking both endocannabinoids and non-endocannabinoid NAEs to 
adipose tissue biology [53].  
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CB1 receptors are also present in pancreatic tissue, skeletal muscle and liver [54, 
55]. In the liver, endocannabinoids stimulate lipogenesis and are believed to be 
involved in the development of steatosis. In skeletal muscle, the endocannabinoid 
system affects oxidative metabolism by decreasing glucose uptake and 
metabolism, and increased levels of endocannabinoids might interfere with 
insulin signaling.  
 
The ECS in relation to metabolic diseases and inflammation  
Dysregulation of the endocannabinoid system is associated with metabolic 
diseases such as obesity. Increased plasma levels of AEA and 2-AG were observed 
in obese subjects [56, 57], leading to the hypothesis that the ECS is ‘overactivated’ 
in obesity. Another study from Côté and coworkers, investigating correlations 
between plasma endocannabinoids and cardiometabolic risk factors in obese 
men, demonstrated that plasma 2-AG levels correlated positively with BMI, waist 
girth, intra-abdominal adiposity (IAA), plasma triglyceride and insulin levels, but 
correlated negatively with high-density lipoprotein (HDL) cholesterol and 
adiponectin [58]. Visceral adipose tissue of obese subjects had increased levels of 
2-AG. Interestingly, no relation between AEA and BMI, waist circumference, HDL 
cholesterol, or adiponectin was found. To the contrary, AEA was negatively 
related to IAA. Work from Di Marzo and coworkers showed that a life style 
intervention in obesity improved cardiometabolic risk factors in parallel to 
decreases in plasma AEA and 2-AG levels [59].  
The involvement of CB1 in food intake and energy metabolism led to the 
hypothesis that CB1 would be a target for the treatment of obesity, leading to the 
development of CB1 blockers. Rimonabant (Acomplia® by Sanofi-Aventis) was the 
first CB1 inverse agonist to be approved as an adjunctive therapy in addition to 
life style interventions against obesity. One-year use of Rimonabant combined 
with caloric restriction resulted in increased weight loss and HDL cholesterol 
levels, and decreased plasma triglycerides and fasting insulin levels compared to 
placebo [60]. However, after its market approval in Europe, several reports 
emerged indicating that the use of Rimonabant was associated with depression or 
even suicidal thoughts in certain sub-populations of patients [61]. This eventually 
led to the withdrawal of Rimonabant from the European market in 2008, and it is 
currently no longer produced by Sanofi-Aventis. Despite this, the search for CB1 
antagonists with actions restricted to peripheral tissues is ongoing. 
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In addition to a link with energy homeostasis, endocannabinoids and related 
structures are also important in inflammation. In this respect, PEA is the best 
studied compound, with demonstrated anti-inflammatory properties using in vitro 
models of human adipocytes [62] and anti-inflammatory and anti-nociceptive 
effects in animal models of in vivo inflammation, including carrageenan-induced 
joint inflammation [63]. Anti-inflammatory or immune-modulatory properties of 
AEA and 2-AG have also been described in several in vitro models using ex vivo 
immune cells, typically demonstrating reduced cytokine synthesis, decreased 
proliferation, or decreased chemotactic capacity after stimulation with e.g. 
lipopolysaccharide (LPS) or mitogenic substances [32, 64, 65]. The mono-
unsaturated compound OEA displayed anti-nociceptive properties in animal 
models of visceral and joint inflammation [66].  However, another report, using a 
paw edema model of inflammation using other parameters, observed less reliable 
anti-edema effects of OEA [67]. Finally, SEA displayed anti-edema effects in a 
murine model of skin allergy [68].  
 
Dietary fatty acids, endocannabinoids, and their analogues – do 
nutrition and pharmacology meet? 
As with the prostaglandins, manipulation of dietary fatty acid intake could also 
represent a way to modify the in vivo NAE profile, and some studies have already 
demonstrated this link [69]. Supplementing AA to milk fed to piglets increased 
brain AEA levels, but feeding a milk formula deficient in AA led to decreased AEA 
and 2-AG brain levels [70]. In a study published by Artmann et al., the effect of 
different fatty acid diets on NAE levels in rat tissues was investigated 
systematically [71]. This study showed that e.g. a fish-oil rich diet decreased 
jejunal levels of AEA, OEA and PEA, but at the same time increased the levels of 
the fish-oil derived NAEs docosahexaenoyl ethanolamide (DHEA) and 
eicosapentaenoyl ethanolamide (EPEA). This showed that diet altered the profile 
of endocannabinoids rather than individual compounds. Another dietary study 
from Batetta et al. used Zucker rats to demonstrate that dietary n-3 fatty acids 
reduced liver triglyceride levels and the macrophage inflammatory response, and 
that this was associated with reduced tissue AEA and 2-AG levels, but no data on 
DHEA or EPEA was reported [21]. More recently, similar findings were reported by 
Banni et al. in obese human subjects, were krill oil consumption resulted in 
decreased plasma 2-AG levels [72]. Again, levels of DHEA and EPEA were not 
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reported. Taken together, it seems that in vivo endocannabinoid levels are a 
reflection of the relative abundance of fatty acids in the diet, thus altering the 
endocannabinoid profile rather than individual compounds. 
Considering the biological properties of endocannabinoids, their modulation by 
e.g. dietary n-3 fatty acids could affect processes like energy metabolism and 
inflammation, it has been hypothesized that endocannabinoids are the link 
between dietary n-3 fatty acids and their health effects [21]. Interestingly, a role 
for the fish oil derived DHEA and EPEA in this relation has barely received 
attention as most publications focused on levels and effects of the ‘classical’ 
endocannabinoids AEA and 2-AG. Similar to the above-mentioned resolvins and n-
3 derived eicosanoids, DHEA and EPEA could potentially have anti-inflammatory 
properties, but until the start of this research project no reports on the biological 
effects of DHEA or EPEA were available in scientific literature. In addition to 
understanding their biological properties, data on the levels of DHEA and EPEA 
were limited, underlining the importance of an analytical technique which is 
capable of quantifying a broad range of endocannabinoids, including DHEA and 
EPEA 
 
Quantification of endocannabinoids and eicosanoids using mass 
spectrometry 
Plasma and tissue levels of endocannabinoids, NAEs and eicosanoids are generally 
low, and their quantification requires adequate technology. A triple-quad mass 
spectrometry-based technique is usually the first choice because this allows the 
simultaneous quantification of multiple compounds. A mass spectrometer (MS) 
can differentiate between compounds based on their molecular weight. This is 
used for identification of molecules, since the molecular weight can be regarded 
as its ‘fingerprint’. The MS is mostly coupled after a liquid chromatography system 
(LC) to separate compounds based on their physical properties (e.g. 
hydrophobicity). The MS can only detect molecules which are electrically charged, 
thus requiring an ionization step. For example, AEA has a molecular weight of 347 
Da, and the ionization step (attraction of one proton under the appropriate 
conditions) gives AEA a mass-to-charge (m/z) ratio of 348 ((347 + 1)/1). 
Different types of MS are available, such as high-resolution MS, iontrap MS, and 
triple-quadrupole MS. For the analysis of low-abundant compounds like 
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endocannabinoids, triple-quadrupole MS would be the first choice due to its 
superior sensitivity.  
A typical triple-quad MS system contains three quadrupoles (‘quads’) Q1, Q2, and 
Q3, through which ions are accelerated. A quadrupole consists of four parallel 
metal rods, over which a voltage is applied. This induces a complex electrical field 
within the quad, causing ions flowing through them to oscillate. Depending on the 
quad voltage and the ion’s m/z value, an ion will either have a stable flight 
through the quad and should reach the detector, or an unstable trajectory. In the 
last case, the ions will (eventually) collide to the rods and are therefore lost. By 
carefully choosing the rod voltage, a quadrupole can serve as an ion filter, only 
allowing ions of a certain m/z value to be detected by the MS. 
In a triple-quad, three quads are connected in linear series. Q1 and Q3 serve as 
m/z filters, and Q2 is used as a collision cell to fragment the ions, that are pre-
selected in Q1. These pre-selected ions (parent ions) are fragmented in Q2 with 
e.g. argon gas, and all fragments are passed on to Q3, which can be set to filter 
specific fragments. Fragmentation dissociation analysis gives additional structural 
information, increasing the specificity of the MS analysis. In case of AEA, several 
dissociation fragments (daughter ions) are found, but the most dominant 
fragment is at m/z 62, which represents the ethanolamine moiety of AEA. The 
dissociation pattern, combined with the retention time, makes triple-quad MS a 
highly sensitive and specific technique. Triple-quadrupole MS is also known as 
tandem MS or MS/MS. 
Several factors can negatively influence the performance of MS analysis. Among 
these, ion suppression is a well-known phenomenon. Ion suppression refers to the 
sub-optimal ionization of analytes, thereby hampering the detection since non-
charged molecules are not detected by the MS. Ionization is a saturable process, 
and the presence of compounds other than the analytes of interest could 
potentially cause ion suppression. Therefore, adequate sample clean-up is of 
great importance when using the extracts for MS analysis. The extraction 
procedure should ensure maximum recovery of the analytes, but minimize co-
extraction of other compounds that could potentially cause ion suppression. 
There are several ways to extract endocannabinoids and eicosanoids from plasma 
or tissue, using organic solvents, solid phase extraction (SPE) or a combination of 
these.  
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MS method development should also include optimizing chromatography 
conditions, such as choice of eluents, chromatographic gradient and analytical 
column, to ensure good peak shape and separation of (all) extracted compounds. 
In addition, other variables such as (long term) stability and choice of labware 
(glass, plastic) should also be investigated, since certain compounds can be prone 
to oxidation or are known to adhere to glass or plastic.  
In literature, several analysis techniques are described for the quantitation of 
endocannabinoids/NAEs in a variety of biological matrices, often using LC-MS or 
LC-MS/MS based methods [73-80]. However, few of the published methods are 
developed and validated for the simultaneous detection of a broad range of 
endocannabinoids and related structures. As described above, concentrations of a 
certain NAE might depend on levels of other NAEs, and different NAEs can 
activate the same receptors, making it of biological relevance to have a LC-MS/MS 
method which is capable of simultaneously quantifying multiple 
endocannabinoids and eicosanoids. Such methods are also known as ‘targeted 
metabolomics’ platforms. 
 
Dealing with large datasets: multivariate data analysis helps out! 
Targeted metabolomics platforms can quantify dozens of compounds from one 
sample, which results in large datasets, especially when multiple platforms are 
used in parallel. Advanced statistical tools, such as multivariate data analysis, are 
useful for extracting relevant information, e.g. differences in metabolic profiles 
between intervention groups, from large amounts of data. A well-established 
multivariate data analysis approach is ‘principal component discriminant analysis’ 
(PCDA), which assesses separation of intervention groups and identifies variables 
which are responsible for this. The PCDA algorithm summarizes all variables into a 
single variable (the principal component) which accounts for the variance in the 
data, also considering the original group designation of the individual samples. As 
a result, it generates lists of compounds which account for the separation of 
groups, ranking the compounds based on their relevance for the group 
separation. As such, PCDA is useful for identifying and ranking compounds which 
are affected by fatty acids.  
Chapter 1 
27 
 
Aims and outline of this thesis 
 
As discussed above, dietary intake of n-3 fatty acids is associated with beneficial 
effects on metabolism and inflammation. The molecular mechanisms underlying 
this are not completely understood, but it is clear that there is a link with fatty 
acid derived bioactive lipids, such as endocannabinoids and eicosanoids. However, 
so far very little data on ‘fish oil-derived’ endocannabinoids has been presented, 
and their biological properties have not been described in literature.  
In this thesis, the relation between dietary fatty acids and endocannabinoids is 
investigated, with special attention for ‘fish oil-derived’ endocannabinoids and 
inflammation. First, we developed a LC-MS/MS based analytical method for the 
simultaneous quantification of 12 endocannabinoids and related compounds, 
with special attention for SPE clean-up and sample evaporation, which will be 
presented in chapter 2 of this thesis. Next, we investigated the formation of DHEA 
and EPEA from their fatty acids, DHA and EPA, respectively, and possible immune-
modulating properties. For this, we used 3T3-L1 murine adipocytes, an 
established model of in vitro endocannabinoid biosynthesis. The findings of this 
work are described in chapter 3.  
In chapter 4 we investigated the relation between serum free fatty acid levels and 
plasma NAE levels under both fasting and postprandial conditions.  
The findings from chapters 2 and 3 prompted us to study the relation between 
dietary fatty acid intake and endocannabinoid levels in an in vivo setting, 
investigating the effect of dietary fatty acids on eicosanoid and endocannabinoid 
levels. Here, we also investigated the effect of inflammatory stress on this 
relation. In chapter 5, we report on a pilot study in which we explore the time-
dependent effects of a single i.p. dose of LPS or saline on plasma and tissue 
eicosanoid and endocannabinoid levels in C57Bl/6 mice. We used this work for a 
second in vivo study, in which we compared the effect of different fish-oil 
containing diets on plasma and tissue eicosanoid and endocannabinoid balance, 
after a single i.p. dose of either LPS or saline. The results of this study are 
presented in chapter 6. Finally, we demonstrate in chapter 7 that plasma contains 
previously ignored pools of esterified NAEs, which closely resembled patterns 
observed for free NAE levels.  
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Abstract 
A sensitive and specific LC-MS/MS method for the quantification of the 
endocannabinoids and related structures anandamide, 2-arachidonoyl glycerol, 
2-arachidonyl glycerol ether, O-arachidonoyl ethanolamide, dihomo-γ-linolenoyl 
ethanolamide, docosatetraenoyl ethanolamide, N-arachidonoyl dopamine, 
N-arachidonyl glycine, N-oleoyl dopamine, oleoyl ethanolamide, palmitoyl 
ethanolamide, and stearoyl ethanolamide in human plasma was developed and 
validated. Compounds were extracted using acetonitrile followed by solid-phase 
extraction. Separation was performed on a XTerra C8 column using gradient 
elution coupled to a triple-quadrupole MS. LLOQ levels ranged from 0.02-1.75 
µg/mL, LODs ranged from 0.0002-0.1266 ng/mL, and accuracies were > 80% 
(except stearoyl ethanolamide at lowest spike level) at all spike levels.  
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Introduction 
Almost two decades after the identification of the cannabinoid type 1 (CB1) 
receptor in 1990 as  mediator of the psychotropic effects of marijuana, research 
on the endocannabinoid system has increased spectacularly [1]. In the meantime 
a second cannabinoid (CB2) receptor has been characterized and probably more 
receptors, including GPR55, will follow [2]. A significant body of evidence now 
suggests that the endocannabinoid system plays an essential role in many 
physiological processes, including energy metabolism and neurological 
functioning, and in several pathological conditions, including inflammation, 
cardiovascular diseases, cancer, neurological disorders, obesity, and the metabolic 
syndrome [3-7]. Anandamide (arachidonoyl ethanolamide, AEA) was the first 
endocannabinoid discovered. It is a fatty acid amide, thought to be formed from 
phospholipid-esterified arachidonic acid and phosphatidylethanolamine [8]. In 
addition to anandamide the search for endogenous ligands has revealed a number 
of so-called endocannabinoids. These include 2-arachidonoyl glycerol (2-AG), 2-
arachidonyl glycerol ether (noladin ether, 2-AG ether), O-arachidonoyl 
ethanolamide (virodhamine, O-AEA), dihomo-γ-linolenoyl ethanolamide (DLE), 
docosatetraenoyl ethanolamide (DEA), and N-arachidonoyl dopamine (NADA) [8-
12] (see Figure 2.1 for structures). In addition, compounds structurally related to 
AEA and NADA have been found, including N-arachidonyl glycine (NAGly), N-
oleoyl dopamine (OLDA), oleoyl ethanolamide (OEA), palmitoyl ethanolamide 
(PEA), and stearoyl ethanolamide (SEA) [3, 5-7]. These compounds were found to 
lack significant affinity for CB1 or CB2, but may potentiate the effects of the 
endocannabinoids by competing for hydrolysis by the membrane-bound fatty-acid 
amide hydrolase (FAAH) or possess affinity for other receptors, such as TPRV1, 
PPAR-α or PPAR-γ [4, 8, 10, 13].  
Some fatty acid amides have been shown to have significant biological activity. 
For example, PEA and SEA are known for their anti-inflammatory properties [14, 
15]. Oleoyl ethanolamide has been described to have potent anorexogenic 
properties [16]. A similar activity has been proposed for SEA, but less is known 
about this [17]. 
Taken together, amides, esters and ethers of fatty acids and amines represent an 
important group of bio-active molecules.  These compounds are considered to be 
synthesized “on demand” in various tissues and are rapidly broken down by FAAH 
and monoacylglycerol lipases (MAGLs) [3, 4, 9, 18]. The combination of biogenic 
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amines with fatty acids can be regarded as a form of “natural combinatorial 
chemistry” since it may lead to the formation of numerous different compounds 
[19]. As many of these compounds are produced in specific tissues only, and due 
to their instability, their biological role has often not been clarified yet and their 
presence in plasma not been confirmed. However, for many other compounds, 
including those described in this paper, an association between (patho-) 
physiological factors and plasma concentration has either been proven or seems 
at least likely. The latter refers to the fatty acid amides of common fatty acids like 
oleic acid, palmitic acid, and stearic acid. A number of GC-MS or LC-MS based 
methods to quantify endocannabinoids and related compounds have been 
described. Often, these methods are limited to detecting AEA and 2-AG in e.g. 
brain tissue, adipose tissue or plasma [20-25]. Only few methods are designed to 
quantify a broader range of endocannabinoids, but only in brain tissue, liver, small 
intestine or adipose tissue [26-30]. Furthermore, extensive validation data are 
often lacking in these publications.  
 
 
 
Figure 2.1: Structures of the endocannabinoids and related compounds described in this 
chapter. 
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To the best of our knowledge, no method is published which is capable of 
detecting a wide range of structurally differing endocannabinoids and related 
compounds in human plasma using a single clean-up procedure. Here we report a 
validated sample clean-up procedure and quantitative LC-ESI-tandem MS based 
method for the analysis of AEA, 2-AG, 2-AG ether, O-AEA, NADA, DEA, DLE, NAGly, 
OLDA, OEA, PEA, and SEA in human plasma. 
 
Experimental 
Chemicals and reagents 
Endocannabinoid stock solutions including deuterated standard solutions for 2-
AG, 2-AG-d8, 2-AG ether, AEA, AEA-d8, DEA, DLE, NADA, NADA-d8, NAGly, NAGly-
d8, OLDA, OEA, PEA, PEA-d4, and SEA were purchased from Cayman Chemical 
(Ann Arbor, MI, USA). O-AEA (virodhamine) was obtained from Tocris Cookson 
Ltd. (Bristol, UK). Acetonitrile (HPLC-S grade) was purchased from Biosolve 
(Valkenswaard, The Netherlands). Methanol was from Riedel-de-Häen (Steinheim, 
Germany). Milli-Q water (Milli-Q Advantage unit, Millipore, Amsterdam, The 
Netherlands) was used in all analyses. Phenylmethanesulfonyl fluoride (PMSF), a 
serine protease inhibitor used to prevent enzymatic endocannabinoid breakdown 
by FAAH, was purchased from Fluka (Steinheim, Germany). Stock solution (100 
mM) of PMSF was prepared in isopropanol and stored at 4-8°C. Trifluoro acetic 
acid (TFA) was from Sigma. Human pooled EDTA-plasma was obtained from 
Bioreclamation Inc. (Westburry, NY, USA).  
 
LC-MS/MS system 
The LC-MS/MS measurements were conducted on a Thermo Finnigan TSQ 
Quantum triple quadrupole mass spectrometer (San Jose, CA, USA) coupled to a 
Thermo Finnigan Surveyor autosampler and a Surveyor MS pump using an 
electrospray ionization source. Liquid chromatography was performed on a XTerra 
MS C8 guard column (particle size 3.5 µm, column dimensions 2.1 x 10 mm) 
coupled to a XTerra MS C8 analytical column (particle size 3.5 µm, column 
dimensions 2.1 x 150 mm). Both columns were from Waters (Milford, MA, USA). 
LCquan software® (version 2.5, Thermo Electron) was used for data acquisition 
and processing.  
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LC-MS/MS conditions 
The autosampler temperature was set at 4 °C and the columns were maintained 
at 40°C during the whole analysis. Gradient elution was applied with a constant 
flow of 150 µL/min, starting with 40% A (1 g/L ammonium acetate and 0.1% v/v 
formic acid in 95:5 v/v milli-Q water-methanol), 40% B (1 g/L ammonium acetate 
and 0.1% v/v formic acid in methanol) and 20% C (1 g/L ammonium acetate and 
0.1% v/v formic acid in 95:5 v/v acetonitrile-milli-Q water) for the first two 
minutes followed by a linear increase towards 70% B and 30% C which is achieved 
in 6 minutes. At minute 16 the gradient changed linear to the initial setting which 
is achieved after 5 minutes. This gradient allows the chromatographic separation 
of AEA and O-AEA, which have identical masses and transition characteristics (see 
Figure 2.1). 
The electrospray interface was operated in positive ion mode and an ion-spray 
voltage of 4.5 kV was applied. Capillary temperature was set at 350 °C. Other 
analysis parameters, such as skimmer offset and argon-mediated collision-induced 
dissociation (CID) energy, were optimized for each endocannabinoid separately by 
direct infusion of standard solution into the MS to ensure maximum product ion 
formation for each endocannabinoid. See Table 2.1 for details concerning 
precursor and product ion m/z values and CID values. 
 
Plasma extraction 
Different extraction protocols were investigated to determine optimal conditions 
for maximum endocannabinoid recovery and detection in human EDTA plasma. 
The effect of different solvents (acetonitrile, methanol, isopropanol, 
ethylacetate), evaporation techniques (freeze-drying, evaporation under nitrogen, 
vacuum concentrator) lab ware materials (glass, polypropylene) and various SPE 
(C18, C8, silica) protocols on recovery and matrix effect were investigated. In the 
final protocol, 1 mL plasma containing 100 µM PMSF was extracted in a 
polypropylene tube by adding 4 mL acetonitrile spiked with the internal standards 
2-AG-d8, AEA-d8, NADA-d8, and NAGly-d8 and 100 µM PMSF. The extract was 
centrifuged for 5’ at 3000 x g and 15 mL water containing 0.133% TFA was added 
to the supernatant to dilute the acetonitrile prior to SPE clean-up. 
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Figure 2.2a: Base peak chromatograms for all endocannabinoids and related compound 
from direct injection of standard solutions. Retention time (RT) and product ion m/z value 
are depicted for each peak. 
 
SPE was performed using Bond Elute C8 (Varian Incorporated, Lake Forest, CA, 
USA) by activating the column first with 1 mL methanol followed by a washing 
step with 1 mL water. The whole diluted extract (20 mL) was subsequently applied 
on the column and washed with 2 mL 20% v/v acetonitrile in water containing 
0.1% TFA. Finally the endocannabinoids were eluted from the column using 2 mL 
80% v/v acetonitrile in water containing 0.1% TFA and this endocannabinoid 
containing fraction was evaporated to dryness using a vacuum concentrator 
(MAXI Dry Plus, Heto-Holten, Denmark) and stored at -80 °C until further analysis. 
Immediately before analysis, the pellet was reconstituted in 100 µL PEA-d4 spiked 
acetonitrile with 0.1% TFA, mixed thoroughly using an ultrasonic bath and 
vortexer and transferred to a glass autosampler vial. Finally 5 µL was injected on 
the analytical column for analysis.  
 
Validation 
The validation procedure consisted of the preparation of one batch per day for 
three consecutive days. Each batch included two seven-point calibration curves 
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prepared in plasma and in acetonitrile, quality controls at three different levels in 
five-fold, and miscellaneous quality control samples, including stability- and 
freeze-thaw control samples. Peak identification and quantification was 
performed using LCquan 2.5 software®. Data processing was performed using in-
house programmed calculation Excel sheets for regression analysis, calculation of 
accuracy, and inter- and intra-batch variation (MS Excel, Microsoft Corporation, 
Redmond, WA, USA).  
 
Linearity 
Quantification of endocannabinoid levels was performed using linear regression 
on the response ratios (peak area analyte/peak area internal standard) from the 
calibration curve as a function of the corresponding endocannabinoid 
concentration. Duplicate calibration curves were analyzed to obtain one 
regression equation. Data was 1/x2-weighted and linear regression was used since 
this resulted in the higher accuracy of back-calculated concentrations than 1/x 
weighting or quadratic regression. Deviations from the actual concentrations 
within 20% for all calibration points were considered acceptable. If necessary, 
correction for the endogenous presence of endocannabinoids in the reference 
plasma was performed in regression analysis of the calibration curves. The lower 
limit of quantification (LLOQ) was defined as the lowest calibration point that 
would result in an accuracy of more than 80% compared to the actual 
concentration. The limit of detection (LOD) was defined as the concentration that 
resulted in a peak having a greater than 3:1 signal-noise ratio as obtained from 
direct injection of standards prepared in acetonitrile. 
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Compound Precursor ion (m/z) Product ion (m/z) CID-energy (eV) 
2-AG 396 287 15 
2-AG ether 382 91 27 
AEA 348 62 15 
DEA 376 62 15 
DLE 350 62 15 
NADA 440 137 26 
NAGly 362 287 10 
O-AEA 348 62 15 
OLDA 418 137 28 
OEA 326 62 16 
PEA 300 62 15 
SEA 328 62 15 
2-AG-d8 404 294 12 
AEA-d8 356 294 7 
NADA-d8 448 137 27 
NAGly-d8 370 294 10 
PEA-d4 304 62 15 
 
Table 2.1: m/z Values for precursor- and product ions and used collision-induced 
dissociation (CID energies for the MS/MS analysis of the 17 endocannabinoids and related 
compounds. 
 
Accuracy and precision 
Accuracy and precision of the method were determined using quality control (QC) 
samples spiked at three concentrations levels of endocannabinoids (see Table 2 
for concentrations). QC samples were prepared by spiking reference plasma 
containing 100 µM PMSF with 10 µL acetonitrile containing endocannabinoids 
prior to plasma extraction as described. The QC’s were analyzed in five-fold and 
multiple batch analysis (n=3) was performed. Endocannabinoid concentrations in 
the QC samples were calculated using the plasma and acetonitrile calibration 
curve that was prepared on the same day and analyzed in the same analytical run.  
A deviation from the actual concentration of less than 20% was considered 
acceptable, otherwise concentrations should be corrected for the deviation 
determined by analyzing QC samples. Inter- and intra-batch precision was 
expressed as the variation coefficient (CV) within (n=5) and between the batches 
(n=3), respectively. The inter- and intra-batch precision was considered 
acceptable when the CV was less than 20%. 
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Stability 
Stability was evaluated using QC samples after storage at -80 °C for one week and 
two months, after three freeze-thaw cycles, and for processed samples after one 
week in the autosampler at 4 °C.  
 
 
 
Figure 2.2b: Base peak chromatograms for AEA, 2-AG, DLE, OEA, PEA, and SEA in human 
EDTA plasma. Non-spiked plasma (1 mL) was extracted using 4 mL of acetonitrile, 
subsequently subjected to SPE sample clean up, and the endocannabinoid containing 
fraction was evaporated to dryness using a vacuum concentrator. Dried extracts were 
reconstituted in 100 µL acetonitrile containing 0.1% v/v TFA and 5 µL was injected on 
column. MS settings were as described in experimental section. Retention times are 
depicted for each peak. 
 
Human plasma samples 
The levels of endocannabinoids and related compounds in human plasma were 
analyzed in 23 healthy postmenopausal female volunteers in order to study the 
appropriateness of the validated method. Blood samples were obtained (after 
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informed consent) from the anticubital vein of the forearm and collected in ice-
chilled tubes containing Potassium Ethylene Diamine Tetra Acid (K3EDTA) for 
plasma (Vacutainer Systems, Becton Dickinson, Plymouth, UK). Blood was 
centrifuged for 15 minutes at 2.000 g at 4 °C, within 15-30 minutes after collection 
and stored at -80 °C. PMSF was added to plasma prior to storage (final 
concentration of 100 µM). Endocannabinoids and related compounds were 
extracted from 1 mL plasma and measured using the final protocol.  
 
Results and discussion 
MS/MS- and LC optimisation 
Conditions for MS/MS detection were optimized for maximum product ion 
formation and detection by direct infusion of standard solution into the MS. The 
product ion masses shown in table 2.1 correspond with loss of ethanolamine (m/z 
62), glycerol (m/z 91), dopamine (m/z 137), and the arachidonic acid moiety (m/z 
287 or 294 for deuterated standards). 
Several protocols for quantifying endocannabinoids are described in literature, 
including reversed-phase silver chromatography and several SIM and SRM-based 
methods [20-30]. Silver ions are thought to overcome inefficient protonation of 2-
AG and 2-AG ether in reversed-phase chromatography which is due to their lack 
of structural elements with a high proton affinity. However, in our hands this 
method was not successful. The intensities of 2-AG and 2-AG ether were indeed 
enhanced, however we encountered problems with clogged transfer tubes due to 
silver deposits. Therefore, an alternative reversed-phase chromatography method 
was developed using methanol and acetonitrile in the gradient elution of 
endocannabinoids. With the XTerra C8 columns and the specified gradient a good 
separation of AEA and O-AEA was obtained while maintaining optimal peak 
intensities. However, this gradient did not separate 2-AG from its isomer 1-AG 
(data not shown).  It is not known to what extend 2-AG isomerizes to 1-AG during 
the extraction procedure or whether 1-AG is already present in human plasma. 
Moreover, protic solvents are believed to enhance the rate of isomerization, and 
in this sample pre-treatment acetonitrile is used, which should keep possible 
isomerization limited. We used the combined peak for determining 2-AG as is 
described by other authors [29, 31]. See Figure 2.2a for base peak chromatograms 
obtained from direct injection of standard solutions prepared in acetonitrile and 
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Figure 2.2b for blank human EDTA plasma after sample pre-treatment as 
described in section experimental using the final protocol.  
 
Sample pre-treatment 
Different sample pre-treatment protocols were tested to optimize recovery for all 
specified endocannabinoids and yield clean samples to minimize ion suppression 
and prolong column life. To this extend, several extraction procedures were 
tested, including different solvents, SPE protocols, and evaporation techniques.  
For liquid-liquid extraction of plasma, the following solvents acetonitrile, 
isopropanol, methanol, acetone, ethylacetate, and chloroform-methanol were 
investigated. The aim was to maximize recovery of the low-abundant 
endocannabinoids while minimizing co-extraction of the high-abundant 
triglycerides and cholesterol esters which cause interfering ion suppression. 
Acetonitrile proved to be the best solvent since the least proteins, triglycerides 
and cholesterol esters are maintained in solution while providing optimal recovery 
of endocannabinoids (see Figure 2.3a). Other solvents used in previously 
published reports, such as isopropanol and methanol, are more hydrophobic and 
thus able to dissolve more triglycerides and cholesterol esters. These compounds 
may increase ion suppression or contaminate the column and LC-MS/MS system.  
To further clean up acetonitrile extracts, several SPE protocols were investigated 
using C18-based and mixed-phase cation exchange columns from various 
manufacturers. Unfortunately, none of these columns proved to recover all 12 
endocannabinoids satisfactory. Especially O-AEA, NAGly, NADA, and OLDA showed 
variable results and low recoveries (see Figure 2.3b). These differences were not 
consistent between the C18 columns obtained from different manufacturers; 
some endocannabinoids showed good retention and elution on a particular 
column while performing insufficiently on a column from another manufacturer. 
Finally we obtained good results with the Bond Elut® C8 (200 mg, 3 mL, Varian 
Inc.). Acceptable recoveries (>75%) were obtained for all endocannabinoids, 
including NAGly, NADA and OLDA. It is difficult to compare the performance of the 
C8 column to other published SPE protocols since validation data are often lacking 
or other methods are not optimized for recovery of a broad range of 
endocannabinoids. 
Another cause of endocannabinoid loss during sample preparation was the 
evaporation step. Evaporation under a gentle stream of nitrogen, freeze dryer and 
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using a vacuum concentrator were investigated. The recoveries obtained with 
freeze drying and the nitrogen method were obviously lower compared to the 
vacuum concentrator. Again, NADA and OLDA showed to be critical structures 
(Figure 2.3c).  
The vacuum concentrator yielded recoveries of typically >90% for all 
endocannabinoids and related structures. Evaporation under nitrogen should 
therefore be avoided, but is used in many other publications [21-23, 25, 29]. A 
drop of glycerol could be useful but was not miscible in acetonitrile. Moreover, 
regular glassware should be avoided since this causes NADA and OLDA to be lost 
(data not shown). The use of polypropylene-based plastics showed improved 
recoveries of all endocannabinoids.  
In conclusion, several critical factors for the extraction of a broad range of 
endocannabinoids (including dopamine-containing structures) from human 
plasma were identified during sample pre-treatment optimization, such as choice 
of solvent, SPE-column and evaporation technique.  
 
Validation 
The analytical performance of the final protocol was investigated by performing a 
comprehensive validation. Linearity, accuracy, precision, LLOQ, LOD, and stability 
under different conditions were determined. Due to the endogenous presence of 
some endocannabinoids, it was necessary to correct the calibration curves 
prepared in plasma and QCs for the levels in blank plasma. Detector responses for 
each endocannabinoid were corrected for the appropriate internal standard. 
Correction for detector responses using different internal standards was 
investigated and proved that structurally-related internal standards provide the 
most stable response ratio. Therefore, all ethanolamides were corrected using 
AEA-d8, NAGly-d8 was used for the glycine-containing endocannabinoid NAGly, 2-
AG-d8 was used for the correction of glycerol-containing compounds (2-AG and 2-
AG ether), and NADA-d8 for the dopamine-containing compounds (NADA and 
OLDA).  
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 R2 (±SD, 
n=3) 
Slope 
(±SD, n=3)  
QC 
spiked 
(ng) 
Accuracy  
(%, n=15) 
plasma 
Accuracy 
(%, n=15) 
acetonitrile 
Intra-batch 
variation 
(% CV, n=15) 
Inter-batch 
variation 
(% CV, n=3) 
2-AG 0.976 
(±0.016) 
10.473 
(±2.15) 
35.11 156 130 18 25 
140.43 141 118 18 27 
561.71 139 120 20 23 
2-AG 
ether 
0.971 
(±0.024) 
4.263 
(±0.80) 
25.87 102 72 18 18 
103.48 96 65 15 15 
413.9 103 69 17 20 
AEA 0.983 
(±0.006) 
132.494 
(±20.91) 
2.54 181 222 12 13 
10.16 177 212 9 11 
40.65 187 229 11 15 
DEA 0.983 
(±0.010) 
55.778 
(±3.15) 
0.88 103 62 16 16 
3.51 100 58 14 14 
14.04 101 59 11 11 
DLE 0.970 
(±0.030) 
308.571 
(±33.97) 
0.88 101 177 14 16 
3.51 106 187 10 12 
14.04 105 188 12 12 
NADA 0.978 
(±0.005) 
127.060 
(±52.93) 
1.20 115 470 11 30 
4.81 103 552 8 11 
19.22 99 580 8 8 
NAGly 0.988 
(±0.011) 
2.264 
(±0.18) 
12.8 107 86 11 27 
51.18 100 82 13 13 
204.73 102 82 8 9 
O-AEA 0.990 
(±0.001) 
35.398 
(±2.97) 
2.36 83 117 18 22 
9.42 84 116 8 8 
37.69 85 119 12 14 
OLDA 0.970 
(±0.015) 
83.327 
(±22.75) 
2.22 106 538 13 22 
8.87 106 574 7 13 
35.48 112 596 8 9 
OEA 0.971 
(±0.018) 
328.686 
(±47.40) 
0.88 97 104 25 25 
3.51 105 109 12 12 
14.04 110 117 12 13 
PEA 0.970 
(±0.021) 
478.844 
(±86.91) 
0.88 83 139 40 40 
3.51 106 184 13 13 
14.04 107 175 13 16 
SEA 0.953 
(±0.034) 
857.468 
(±221.31) 
0.43 69 153 50 57 
1.74 118 199 12 22 
6.95 98 209 13 24 
Table 2.2: Linearity (n=3), accuracy and intra- and inter-batch variation of the analytical 
method. Values in column ‘QC spiked’ represent the amount of analyte added to 1 mL 
plasma prior to sample clean-up. Accuracies were calculated using a calibration curve 
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spiked in plasma or prepared in acetonitrile and results for both are depicted. Intra- and 
inter-batch variations are only shown for results obtained after calculating with the 
calibration curve spiked in plasma. 
 
 
Linearity 
Data concerning the linearity of the method are shown in Table 2.2. The results 
show that the method offers good linearity for all structures which was found to 
be reproducible between the batches. Higher R2 values could be obtained when 
1/x weighing was applied, but this also resulted in higher deviations in back-
calculated concentrations compared to the actual concentration, which was 
undesirable.  
Values for LLOQ and LOD are presented in Table 2.3. The LLOQ for the 
endocannabinoids was set at the lowest calibration point when spiked to plasma, 
except for NADA and OLDA (second calibration point) due to lack of accuracy at 
the lowest calibration point. It is difficult to validate the method for lower 
endocannabinoid levels due to basal levels of these compounds in plasma. Using 
an calibration curve in acetonitrile it is possible to determine the concentration of 
endocannabinoids at lower levels, however correction for accuracy is necessary 
due to differences in matrix effect (see also Table 2.2 and section ‘accuracy and 
precision’ ). The presented values here are difficult to compare to other published 
methods due to differences in matrix, sample-pre treatment and LC-MS 
conditions. The LOD values for AEA, 2-AG, NAGly, O-AEA, OEA and PEA obtained 
with our method are lower than reported for other methods [20, 21, 29, 30].  
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Figure 2.3a: Effect of solvent on endocannabinoid recovery. Non-spiked plasma (100 µL) 
was extracted with different solvents and the recovery for isopropanol was set at 100%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3b: Effect of type of SPE column on endocannabinoid recovery. The recovery is 
expressed as percentage response compared to direct injection of standard. 
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Figure 2.3c: Effect of evaporation technique on endocannabinoid recovery. The recovery 
evaporation technique is expressed as percentage response compared to direct injection of 
standard.  
 
 
 LLOQ plasma 
(pg on column) 
LOD standard 
(fg on column) 
2-AG 878 14 
2-AG ether 647 73 
AEA 64 4 
DEA 22 36 
DLE 22 6 
NADA 60 10 
NAGly 320 633 
O-AEA 59 21 
OLDA 111 13 
OEA 22 2 
PEA 22 2 
SEA 11 1 
 
Table 2.3: Lower limit of quantification (LLOQ) and limit of detection (LOD) values. The 
lowest point from the calibration curve that allowed back-calculation of the determined 
concentration within 20% deviation from the actual concentration was accepted as LLOQ. 
LODs were calculated from detector responses obtained from direct injection of 
endocannabinoid standard. 
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Accuracy and precision 
The results in Table 2.2 show that the method provides good accuracy and 
precision for the specified endocannabinoids when using a calibration curve 
prepared in plasma. The initial validation criteria for accuracy and precision were 
not met in some occasions. However, deviations were only minor and in addition, 
the correction for background endocannabinoids in the reference plasma may 
have introduced an additional source of variation which is dominant especially at 
low concentrations. This effect was most prominent for AEA and 2-AG. The 
accuracies were much higher than 100% but consistent, which makes correction 
for the observed deviation in accuracy justified.  
Due to the endogenous presence of some endocannabinoids it is difficult to 
prepare a calibration curve in plasma with the correct concentration range for 
unknown samples. The best option is to prepare a calibration curve in 
‘endocannabinoid-free’ plasma, however this ‘blanc’ plasma is unavailable. The 
second best option is to use a calibration curve prepared in acetonitrile. It must be 
noted that calculating the accuracies using a calibration curve prepared in 
acetonitrile will result in higher deviations with respect to calculations using the 
calibration curve in plasma (see Table 2.2). It is therefore necessary to correct the 
endocannabinoids concentration calculated with the calibration curve in 
acetonitrile for this matrix effect using QC samples.  
 
Ion suppression 
Ion suppression was calculated by dividing the peak area of the deuterated 
standard in blanc plasma sample after clean up and reconstitution in acetonitrile 
containing deuterated standards by the area of deuterated standard in standard 
solution in acetonitrile. The ion suppression was 64.8%, for AEA-d8, 45.9% for 
NADA-d8, 65.4% for NAGly-d8, and 61.3% for PEA-d4. For 2-AG-d8, ion 
enhancement was observed and was quantified at 77.7%. It is clear from these 
results that matrix effects are significant, thus providing a good argument for 
preparing calibration curves in plasma.  
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 Pre- preparative (n=3) Post-preparative (n=3) 
    Day 1 1 week 2 months 1 week 
2-AG -6.9 20.1 43.2 -8.9 
2-AG-ether -3.7 -2.2 -12.2 5.4 
AEA 62.8 54.3 21.6 -2.4 
DEA 3.9 -0.1 11.8 13.2 
DLE 4.2 1.5 7.6 -6.8 
NADA -10.2 3.4 - 8.8 
NaGly 1.2 8.4 -0.4 -0.1 
O-AEA -15.8 -15.9 22.6 2.7 
OEA 2.4 1.0 38.4 8.9 
OLDA -1.3 12.0 - -7.5 
PEA 2.6 3.1 51.2 12.9 
SEA -0.5 6.7 48.9 3.9 
 
Table 2.4: Pre- and post-preparative stability of endocannabinoids in human plasma. 
Deviations (%) of endocannabinoid levels in stored plasma (1 day, 1 week and 2 months) at 
-80 °C with respect to actual concentration from freshly prepared samples. - = not 
detectable. 
 
 
Stability 
Storage of plasma samples for one day and one week revealed only slight 
deviations in recovery except for AEA; see Table 2.4. Short term storage of spiked 
plasma showed higher deviations compared to freshly prepared samples. 
Especially for 2-AG, PEA, and SEA the concentrations deviated more than 20% 
from the actual concentration. Therefore, it is recommended to process the 
plasma samples as soon as possible. Moreover, PMSF was added to plasma to 
prevent enzymatic breakdown by FAAH. It is recommended to immediately 
separate plasma from blood after venipuncture since endocannabinoids are 
released ex vivo [24], add PMSF to 100 µM in plasma and store at -80 °C or extract 
immediately. 
Post-preparative stability of reconstituted extracts showed only minor deviations 
between first and second injection of the samples. Therefore it is concluded that 
endocannabinoids in reconstituted plasma extracts are stable for at least one 
week when stored at 4 °C.  
Analytical method development 
 
56 
 
Freeze-thaw cycle analysis revealed that 2 cycles results in deviations larger than 
20% for almost all endocannabinoids (data not shown). It is therefore 
recommended to avoid freeze-thaw cycles. 
 
Human plasma samples 
The presented method was used to determine endocannabinoid levels in plasma 
from 23 healthy female volunteers using a calibration curve prepared in 
acetonitrile. Plasma (1 mL) was extracted, evaporated and reconstituted in 100 µL 
acetonitrile which was analyzed on the LC-MS/MS system according to the final 
protocol. Concentrations were corrected for each sample using its corresponding 
QC which was prepared and analyzed on the same day.  
AEA, 2-AG, DLE, OEA, PEA and SEA were detected in all samples but no 2-AG 
ether, O-AEA, DEA, NAGly, NADA, or OLDA was observed. Mean plasma 
concentrations were 0.24 ± 0.11 ng/mL for AEA, 7.09 ± 12.39 ng/mL for 2-AG, 1.39 
± 0.36 ng/mL for PEA, 0.04 ± 0.02 ng/mL for DLE, 1.37 ± 0.43 ng/mL for OEA, and 
0.52 ± 0.18 ng/mL for SEA. The mean plasma AEA concentration reported here is 
in the same order of magnitude compared to observations by other authors [21, 
23, 32, 33]. However, it must be noted that it is difficult to compare 
concentrations in real life samples reported in literature due to differences in 
subjects, intervention and sample pre-treatment.  
 
Conclusion 
A method for the simultaneous detection of twelve endocannabinoids and related 
compounds in human plasma has been developed and validated. The method was 
shown to be linear, accurate, and precise. However, some validation criteria were 
mildly exceeded, most likely due to the endogenous presence of some 
endocannabinoids in plasma. To our knowledge no validation criteria have been 
defined for the analysis of endogenous compounds using methods as described in 
this paper. It is difficult to validate this method at low concentrations due to the 
lack of ‘blank’ sample materials and therefore it is difficult to determine an 
accurate LLOQ. 
Since sample clean-up and chromatographic separation were optimized to 
recover structurally different compounds, the quantitative analysis of other 
endocannabinoids or related compounds can easily be integrated in this method. 
Moreover, this method has been modified and successfully used to quantify the 
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level of endocannabinoids in other matrices, such as adipose tissue, brain tissue, 
cell culture media and cell homogenates. This supports the conclusion that the 
method presented here is also able to detect components which have not been 
found in human plasma so far. A detailed discussion about the physiological 
significance of a plasma concentration for each specific compound falls beyond 
the scope of this paper. Due to their tissue-specific production and instability, 
some compounds may not appear in plasma in significant amounts under normal 
conditions but could be present under other circumstances. Indeed, NADA was 
not found in the real samples analyzed so far. On the other hand the flexibility of 
the method has been shown to allow detection of other fatty acid amides that 
may be formed, for example those of n-3 polyunsaturated fatty acids after their 
intake.  
To the best of our knowledge, no other validated method has been published that 
offers quantification of this broad range of endocannabinoids and related acyl-
amides in human plasma. 
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Abstract  
 
n-3 PUFAs have beneficial health effects which are believed to be partly related to 
their anti-inflammatory properties, however the exact mechanisms behind this 
are unknown. One possible explanation could be via their conversion to N-acyl 
ethanolamines (NAEs), which are known to possess anti-inflammatory properties. 
Using fatty acid precursors we showed that 3T3-L1 adipocytes are indeed able to 
convert docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to their NAE 
derivatives docosahexaenoyl ethanolamine (DHEA) and eicosapentaenoyl 
ethanolamine (EPEA), respectively. This synthesis took place on top of an 
apparent background formation of these NAEs in standard culture medium. In 
addition we were able to demonstrate the presence of DHEA, but not of EPEA, in 
human plasma. DHEA and EPEA were found to decrease LPS induced adipocyte 
IL-6 and MCP-1 levels. Results of combined incubations with PPAR-γ and CB2 
antagonists suggest a role of these receptors in mediating the reduction of IL-6 by 
DHEA. Our results are in line with the hypothesis that in addition to other 
pathways, formation of N-acyl ethanolamines may contribute to the biological 
activity of n-3 PUFAs. Different targets, including the endocannabinoid system, 
may be involved in the immune-modulating activity of these “fish oil-derived 
NAEs”. 
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Introduction 
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) such as docosahexaenoic acid 
(DHA; C22:6; n-3 ) and eicosapentaenoic acid (EPA;  C20:5; n-3) have been linked 
to several positive health effects, such as a reduced risk for cardiovascular 
diseases,  potentially cancer and certain mental illnesses [1]. Moreover, 
consumption of DHA, EPA or fatty fish containing high levels of n-3 PUFAs has 
been shown to reduce the inflammatory component and improve other 
characteristics of the metabolic syndrome [2, 3]. The exact mechanisms behind 
these effects are unknown, but evidence suggests that DHA and EPA can be 
converted to anti-inflammatory eicosanoids known as resolvins [3, 4]. Fatty acids 
can also be directly converted to N-acyl ethanolamines (NAEs). Several members 
of this class possess anti-inflammatory properties [5-8]. NAEs can be rapidly 
synthesized in membranes, released on demand and broken down again by the 
enzyme fatty acid amide hydrolase (FAAH) [9-11]. Therefore, the local availability 
of a specific type of fatty acid precursor may determine product formation and 
hence bio-activity. This suggests a link with dietary intake, since it is well known 
that incorporation of fatty acids into membranes can be modulated by their 
proportional abundance in the diet [4]. Recently, Artmann et al. demonstrated a 
correlation between NAE patterns in various organs and tissues of rats and fatty 
acid composition of their diets [12].  Such a shift in balance can also explain the 
reported decrease in the levels of the endocannabinoids anandamide 
(arachidonoyl ethanolamine; AEA) and 2-arachidonoylglycerol (2-AG) following 
exposure to DHA or EPA [13, 14]. 
 
 
 
Figure 3.1: Structures of the N-acyl ethanolamines from DHA and EPA, DHEA and EPEA 
respectively. 
 
Obesity is characterized by low-grade systemic inflammation and increased 
infiltration of activated macrophages in the adipose tissue [15]. Interestingly, the 
adipocytes themselves can also produce pro-inflammatory cytokines such as 
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interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1), which are 
delivered to the blood stream to act on distant organs such as liver and skeletal 
muscle [16-20]. Although it is not clear what initiates this inflammation, current 
evidence suggests that these inflammatory processes in the adipose tissue are the 
link to co-pathologies observed with the metabolic syndrome, such as 
hypertension, decreased insulin sensitivity and artherosclerosis [19]. Therefore, 
attenuating the inflammatory process in adipose tissue is now considered as a 
promising target to reduce complications of obesity.  
The present study addresses the question whether NAEs formed from DHA and 
EPA, docosahexaenoylethanolamine and eicosapentaenoylethanolamine (DHEA 
and EPEA, Figure 3.1) could be involved in suppressing an inflammatory response 
in 3T3-L1 adipocytes. Formation of NAEs was studied at different precursor 
concentrations and time points and deuterated substrates were used to follow 
product formation.  We also demonstrated the presence of DHEA in human 
plasma. Effects of DHEA and EPEA on the release of the pro-inflammatory 
cytokines IL-6 and MCP-1 were studied after stimulating the adipocytes with 
lipopolysaccharide (LPS).  
 
Material and methods 
Chemicals and materials 
AEA-d8, DHEA, DHA, DHA-d5, EPA, EPA-d5, GW9662 (PPAR-γ antagonist) and 
SR144528 (CB2 antagonist) were from Cayman Chemical (Ann Arbor, MI, USA). 
Acetonitrile (ACN) was from Biosolve (Valkenswaard, The Netherlands). 
Isopropanol (IPA) and ethanol were from JT Baker (Deventer, The Netherlands). 
Trifluoro acetic acid (TFA) and thiazolyl blue tetrazolium bromide (MTT) were 
from Sigma (Steinheim, Germany). Phenylmethylsulfonyl fluoride (PMSF) was 
from Fluka (Steinheim, Germany) and was diluted to 100 mM in IPA and stored at 
4 °C. Bond Elut SPE C8 columns (200 mg, 6 mL) were from Varian Inc (Lake Forest, 
CA, USA). Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
GlutaMAX I, penicillin-streptomycin (pen-strep), Newborn Calf Serum (NCS), and 
Fetal Calf Serum (FCS) were from Gibco (Auckland, New Zealand). Insulin, isobutyl-
1-methylxanthine (IBMX), dexamethasone and LPS (O111:B4) were from Sigma. 
ELISA kits for IL-6 and MCP-1 were purchased from R&D Systems (Minneapolis, 
MN, USA). 
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Enzymatic synthesis of EPEA 
Since EPEA is not commercially available yet, it was synthesized using our method 
described earlier [21]. In short, EPA was coupled to ethanolamine using Candida 
antarctica lipase and purified with preparative HPLC to yield highly concentrated 
EPEA extracts. To confirm the identity of the product EPEA, the purified extract 
(> 98% pure) was subjected to high-resolution MS/MS analysis on a Thermo-
Finnigan LTQ linear ion trap mass spectrometer coupled to a high-resolution 
Thermo-Finnigan Orbitrap mass spectrometer. Mass Frontier 5.0 software 
(HighChem, Slovak Republic) was used to predict the fragmentation pattern for 
the NAE structure from EPA.  
 
 
 
Figure 3.2: High resolution MS/MS spectrum of EPEA. Compound was subjected to MS-MS 
analysis at 20% collision energy. Peaks were observed at m/z 346.27 (intact EPEA+H), 
328.26 (-18, loss of H2O, see structure) and 285.22 (-61, loss of ethanolamine, see 
structure), which are consistent with the EPEA structure and not its esterified isomer, 
which should reveal loss of the ammonium terminus but not loss of water. The m/z 328.26 
and 285.22 peaks were also predicted by Mass Frontier. The m/z 267.21 peak is consistent 
with loss of ethanolamine and water from EPEA.  
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As shown in Figure 3.2, the high resolution MS/MS dissociation analysis of EPEA 
(m/z 346.27) yielded fragments at m/z 328.26 (-18; loss of H2O) and 285.22 (-61; 
loss of ethanolamine), which were also predicted by Mass Frontier. An additional 
peak at m/z 267.21 was found and is consistent with loss of H2O and 
ethanolamine from the parent compound. The peaks which were consistent with 
loss of water and ethanolamine confirmed that the synthesis product is the NAE 
structure of EPA.  
 
LC-MS/MS analysis of NAE levels in human plasma and cell culture medium 
To determine whether the NAEs DHEA and EPEA are detectable in human plasma, 
blood samples were taken from 3 healthy volunteers after obtaining informed 
consent. Blood was collected in EDTA containing tubes (Beckton Dickinson). 
Plasma was immediately separated, processed and analyzed using LC-MS/MS as 
described earlier [22] with inclusion of scan events for DHEA (m/z 372.3  62.2) 
and EPEA (m/z 346.3  62.2). In short, 1 mL plasma was extracted with 4 mL ACN 
containing AEA-d8 as an internal standard. After centrifugation, the supernatants 
were diluted with 15 mL MQ water containing 0.13% TFA, loaded on activated SPE 
C8 columns (Bond Elut C8, Varian Inc, Lake Forest, CA, USA), washed with 2 mL 
20% v/v ACN in MQ containing 0.1% TFA. NAEs were finally eluted with 2 mL 80% 
v/v ACN in MQ containing 0.1% TFA, evaporated to dryness using a vacuum 
concentrator (MAXI Dry Plus, Heto-Holten, Denmark) and stored at -80°C until 
further analysis. Before LC-MS/MS analysis, dried extracts were reconstituted in 
100 µL ACN containing 0.1% TFA and 5 µL was injected on column for 
quantification. NAE levels were determined on a Thermo Finnigan Surveyor 
autosampler coupled to a Thermo Finnigan TSQ Quantum triple quadrupole mass 
spectrometer (San José, CA, USA) operated in selective reaction mode (SRM). The 
interface between LC and MS consisted of an electrospray ionization source 
operating in positive ion mode. Peaks were indentified using LCquan version 2.5.5 
software (Thermo). Concentrations NAEs were calculated using an external 
calibration curve of each NAE individually using the peak ratio of the compound 
divided by the internal standard (AEA-d8). 
Cell culture medium was transferred to a 2 mL eppendorf tube and PMSF was 
added to a final concentration of 100 µM. Ten µL internal standard solution 
containing AEA-d8 was added and the tubes were vortexed. Subsequently, TFA 
was added to a final concentration of 0.1%, samples were vortexed and 
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centrifuged for 5 minutes at 14k rpm. Supernatants were subsequently extracted 
and analyzed using the solid phase extraction (SPE) procedure and LC-MS/MS 
method mentioned earlier with additional wash steps using 2 mL 10% v/v ACN in 
MQ with 0.1% TFA and 2 mL 40% v/v ACN in MQ containing 0.1% TFA in the SPE 
procedure. Dried extracts were stored at -80 °C prior to analysis or immediately 
analyzed for AEA, DHEA, EPEA, oleoyl ethanolamine (OEA), palmitoyl 
ethanolamine (PEA), and stearoyl ethanolamine (SEA) with the LC-MS/MS method 
described above. 
 
Cell culture 
3T3-L1 pre-adipocytes (kind gift from Dr. E. Kalkhoven, University Medical Center 
Utrecht, The Netherlands) were cultured in DMEM supplemented with 10% NCS 
and 1% pen-strep at 37 °C and 5% CO2 and were split every 2-3 days. Cells were 
not allowed to grow to confluence prior to the differentiation step. 
 
Differentiation of 3T3-L1 adipocytes 
3T3-L1 pre-adipocytes were seeded in 6-wells plates (8*103 cells/mL; 2 mL/well) 
and grown to confluence in five days at 37 °C and 5% CO2 with the medium being 
refreshed every 2-3 days. At three days post confluency, differentiation was 
initiated with 1 µM insulin, 0.5 mM IBMX and 1 µM dexamethasone in DMEM 
supplemented with 10% FCS and 1% pen-strep (DMEM-FCS) for 3 days followed 
by fresh insulin medium (1 µM insulin in DMEM-FCS) every 2-3 days, which was 
continued during experiments. Differentiation was confirmed with light 
microscopy at eight days after initiation of differentiation, revealing cells with the 
typical adipocyte phenotype characterized by increased cell volume, round 
morphology, and the presence of lipid droplets. Experiments were conducted with 
fully differentiated cells at 8-10 days post induction of differentiation. 
 
Biosynthesis of DHEA and EPEA from DHA and EPA by 3T3-L1 adipocytes 
Differentiated adipocytes were exposed to 10, 30 and 50 µM of DHA or EPA in 
insulin medium for 24 or 48 hrs. Insulin medium and solvent vehicle in insulin 
medium were used as controls. DHA stock solution was prepared in IPA, EPA was 
prepared in ethanol. After incubation, medium content of DHEA and EPEA was 
determined as described above. Cytotoxicity assays based on LDH release showed 
that the used concentrations and solvents are not cytoxic (data not shown).  
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Effects of DHEA and EPEA on LPS- induced cytokine production  
Differentiated adipocytes potentially synthesize pro-inflammatory cytokines, e.g. 
after stimulation with LPS.  To investigate the immune-modulating properties of 
DHEA and EPEA, differentiated 3T3-L1 adipocytes were pre-incubated for 1 hr 
with 1 nM – 10 µM of DHEA or EPEA in insulin medium. Subsequently, cells were 
exposed for 8 hr to medium containing DHEA and EPEA to which 50 ng/mL of LPS 
had been added. To investigate the possible roles of the CB2 or PPAR-γ receptors 
in these effects, GW9662 (PPAR-γ antagonist) and/or SR144528 (CB2 antagonist) 
were used in a final concentration of 100 nM. Medium aliquots of 100 µL were 
collected and immediately stored at -20 °C until analysis. Medium levels of IL-6 
and MCP-1 were analyzed using ELISA according to the manufacturer’s 
instructions. Cytotoxicity assays based on LDH release and MTT conversion 
showed that the used concentrations and solvents are not cytoxic (data not 
shown). 
 
Statistical analysis  
Data are presented as mean ± standard deviation where appropriate. 
Comparisons between groups were made with one-way analysis of variance 
(ANOVA) followed by Dunnett’s t test using SPSS Statistics 17.0 software. P < 0.05 
was considered as significant level of difference. 
 
Results 
DHEA, but not EPEA, is detectable in human plasma  
Plasma from three healthy volunteers after an overnight fast was analyzed for 
DHEA and EPEA (see Figure 3.3 for SRM chromatogram). DHEA levels were on 
average 0.17 +/- 0.16 ng/mL. EPEA was below detection limits in human plasma.  
 
Exposure of 3T3-L1 adipocytes to DHA and EPA leads to increased levels of DHEA 
and EPEA in cell culture medium 
Exposure of 3T3-L1 cells for 24 hr to 10 µM DHA resulted in increased DHEA levels 
up to 42 pg/mL whereas in vehicle control medium (insulin medium with solvent) 
21 pg/mL was found (P = 0.069). Following incubation with 30 and 50 µM DHA, 90 
and 143 pg/mL DHEA, respectively was found (P < 0.001 for both concentrations; 
see Figure 3.4a for bar graph and Figure 3.5 for chromatograms). Similar values 
were found when the cells were incubated for 48 hours.  
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Figure 3.3: SRM chromatogram of DHEA in human plasma. Extraction and LC-MSMS 
analysis was performed as described in section ‘material and methods’. Human plasma 
contained DHEA, but EPEA was not detectable.  
 
EPEA levels were increased significantly from 509 pg/mL in vehicle control 
medium to 1796 pg/mL after 24 hr of exposure to 10 µM EPA (P < 0.01), whereas 
30 and 50 µM EPA increased EPEA levels to 4027 pg/mL and 5556  pg/mL, 
respectively (both P < 0.001; see Figure  3.4b). Again, similar results were 
obtained after 48 hrs of incubation. 
To ensure that the solvent did not affect NAE synthesis, insulin medium without 
solvent or PUFA was also included as a blanc control. Concentrations of DHEA and 
EPEA in vehicle control incubations did not significantly deviate from these 
incubations. In addition, to rule out the possibility of spontaneous condensation 
of the fatty acids with ethanolamine in the medium without the cells being 
involved, the same incubations were repeated in used medium in the absence of 
cells. Both DHA and EPA did not increase DHEA or EPEA levels in these controls, 
indicating that the adipocytes were needed for the increases in DHEA and EPEA as 
described above (data not shown). Medium levels of AEA, PEA, OEA, and SEA 
were not affected with 48 hr exposure to DHA, whereas EPA resulted in a small 
increase for only OEA and PEA (Figure 3.4c and 3.4d). 
Adipocytes, NAEs, and inflammation 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4a, b: Medium levels of DHEA (a) EPEA (b) after exposure of 3T3 L1 adipocytes to 
DHA and EPA (n=3). Both DHEA and EPEA levels were increased after exposure to DHA or 
EPA, respectively. Legend: * P<0.05; ** P<0.01; *** P<0.001. 
 
In summary, 3T3-L1 adipocytes synthesize and release DHEA and EPEA in standard 
media, which can be further enhanced by adding their precursors DHA and EPA. 
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Figure 3.4c, d: Medium levels of other NAEs (c and d) after exposure of 3T3 L1 adipocytes 
to DHA and EPA, respectively (n=3). Legend: * P<0.05; ** P<0.01. 
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Figure 3.5: SRM chromatogram for DHEA and EPEA in cell culture medium after 24 hr 
exposure to 50 µM DHA or EPA, respectively. Medium (2 mL) was extracted and analyzed 
for DHEA and EPEA levels as described in section ‘material and methods’.  
 
 
Chapter 3 
73 
 
The increase in DHEA and EPEA levels is directly related to conversion of fatty acids 
added to the medium 
Exposure to DHA and EPA increases biosynthesis of DHEA and EPEA, but it is not 
known if this was mediated by direct conversion of the fatty acids added to the 
medium or if this was caused indirectly by mobilization of intracellular fatty acids 
which were subsequently converted. Therefore, adipocytes were exposed to the 
deuterium labelled DHA-d5 and EPA-d5 fatty acids, which are 5 Da heavier than 
the normally occurring structures. Therefore, this allows (semi-quantitative) 
tracking of these structures through metabolism using LC-MS/MS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Production of DHEA-d5 (a) and EPEA-d5 (b) in medium after exposure of  3T3-L1 
adipocytes for 48 hr to DHA-d5 and EPAd-5, respectively (n=3). Exposure to DHA-d5 and 
EPA-d5 resulted in a dose-dependent increase in DHEA-d5 and EPEA-d5, respectively, 
whereas both ethanolamides were not detected in the blanc control incubation. 
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Exposing differentiated 3T3-L1 adipocytes to 2-10 µM DHA-d5 and EPA-d5 for 48 
hr resulted in a dose-dependent increase in both DHEA-d5 and EPEA-d5 levels 
(Figure 3.6a and 3.6b, respectively), whereas no DHEA-d5 or EPEA-d5 was 
observed in blanc control incubations. Therefore, it can be concluded that the 
increased levels of DHEA and EPEA after exposure to DHA and EPA are at least 
partly explained by direct conversion of these fatty acids from the medium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 a, b: Effect of DHEA (a) and EPEA (b) on IL-6 levels in medium of 3T3-L1 
adipocytes after LPS stimulation (n=4). Both DHEA and EPEA reduced IL-6 levels in response 
to LPS stimulation at all concentrations tested. Legend: * P<0.05; *** P<0.001.  
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Figure 3.7 c, d: Co-incubations of DHEA and EPEA with GW9662 (100 nM, PPAR-γ 
antagonist) and SR144528 (100 nM, CB2 antagonist) both restored IL-6 levels with a 
maximum and significant effect when GW9662 and SR144528 were simultaneously added 
at 50 nM. Legend: * P<0.05; ** P<0.01. 
 
 
DHEA and EPEA reduce adipocyte IL-6 and MCP-1 levels after LPS-stimulation  
To investigate the possible interactions of DHEA and EPEA with an inflammatory 
response, differentiated 3T3-L1 cells were pre-incubated for 1 hr with 1 nM - 10 
µM of DHEA or EPEA and subsequently stimulated with 50 ng/mL LPS while 
maintaining the same concentrations of DHEA or EPEA. Results are depicted in 
Figures 3.7 (IL-6) and 3.8 (MCP-1). Both DHEA and EPEA significantly reduced IL-6 
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levels at all concentrations tested (see Figure 3.7a and 3.7b for significance levels) 
compared to the vehicle control. The strongest reduction was approximately 50% 
and was found for 10 nM for DHEA and 100 nM for EPEA. Between the 
experiments (4 repetitions) there was a variation in the dose-response relation. 
Interestingly, this reduction became less when DHEA and EPEA were added in the 
micromolar range. The inhibitory effect of DHEA and EPEA almost completely 
disappeared in the presence of GW9662 or SR144528 (Figure 3.7c and 3.7d). 
Antagonizing effects of the combination of GW9662 and SR144528 (50 nM each) 
were more pronounced than those of the individual compounds at 100 nM. 
In addition to IL-6, MCP-1 levels were also significantly reduced by DHEA and EPEA 
for all concentrations tested (see Figure 3.8 for significance levels) compared to 
the vehicle control. Similar to IL-6, MCP-1 levels were also less reduced when 
DHEA and EPEA were added in the micromolar range compared to the nanomolar 
range. DHEA and EPEA produced the strongest reduction of MCP-1 at 10 nM, 
corresponding to approximately 50% of the control value. Co-incubation with 
GW9662 and SR144528 did not affect MCP-1 levels for both DHEA and EPEA. 
To confirm that the observed effects are mediated by NAEs and not by the fatty 
acids DHA and EPA that could be re-formed by hydrolysis, the experiments were 
repeated with the fatty acids mentioned above. DHA and EPA did not lower IL-6 
and MCP-1 levels (data not shown).  
 
Discussion 
“Fish oil” fatty acids DHA and EPA are associated with several positive health 
effects, including a lower risk for fatal heart disease, improvement of parameters 
associated with obesity and the metabolic syndrome, and anti-inflammatory 
properties [1-3]. Several mechanisms have been proposed  to explain these 
effects, including conversion to anti-inflammatory eicosanoids and resolvins [3]. 
Interestingly, PUFAs also serve as precursors for NAEs, with some of them 
possessing anti-inflammatory properties or  metabolic effects mediated through 
CB1, CB2, and PPAR receptors [8, 9, 11]. However, the contribution of PUFA-
derived NAEs to the beneficial effects of PUFAs is not known. Here, we show for 
the first time that 3T3-L1 adipocytes can directly synthesize DHEA and EPEA from 
their corresponding n-3 fatty acid precursors.  
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Figure 3.8: Effect of DHEA (a) and EPEA (b) on MCP-1 levels in medium of 3T3-L1 
adipocytes after LPS stimulation (n=4). Both DHEA and EPEA reduced MCP-1 levels in 
reponse to LPS stimulation at all tested concentrations. Legend: * P<0.05; ** P<0.01; *** 
P<0.001. 
 
As the endocannabinoid system is involved in many physiological and pathological 
processes, it is regarded as an important target for intervention by drugs or 
nutrients.  Although only few studies show direct formation of NAEs from long-
chain PUFA precursors, several other studies demonstrated that dietary 
intervention with n-3 fatty acids also indirectly affects the endocannabinoid 
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balance. In the study of Artmann et al., decreased levels of all NAEs measured 
were found in livers of rats fed with LCPUFAs for 1 week, except for DHEA and 
EPEA [12]. Batetta et al. recently showed that diets rich in long-chain PUFAs 
decreased AEA and 2-AG levels in visceral fat of obese Zucker rats [13]. Together, 
these data suggest that NAE patterns tend to follow the relative abundance of the 
corresponding precursor lipids in the diet. Batetta et al. also showed that feeding 
n-3 PUFAs to Zucker rats leads to a reduction in ectopic fat deposition, lower liver 
triglycerides and LDL plasma levels, and a decreased tumor necrosis factor-α 
(TNF-α) secretion by macrophages [13]. The authors link these observations to the 
observed decrease of AEA and 2-AG concentrations in visceral adipose tissue, 
suggesting that this might be due to reduced stimulation of CB1, which is 
associated with increased adipogenesis and lipogenesis and negative crosstalk 
between adipose tissue and muscle [11, 23, 24]. In a study reported by Matias et 
al. [14], incubation of 3T3-F442A adipocytes with 100 µM of DHA for 72 h resulted 
in reduced intracellular AEA and 2-AG levels. However, no data on the formation 
of DHEA or EPEA were given in their paper. In our study levels of the other NAEs, 
AEA, OEA, PEA and SEA in the medium were not significantly changed upon 
exposure to DHA whereas EPA only increased OEA and PEA slightly. This may be 
due to the differences in experimental conditions. In addition, our data 
correspond to extracellular (medium) NAE levels, which might be different to the 
intracellular values measured by Matias et al [14]. Since NAEs act on adjacent 
cells, with their receptors being at least (CB1, CB2, TRPV1) located on cell 
membranes, levels of excreted NAE will be of biological relevance. The 
observation that values of NAEs other than DHEA and EPEA were not affected can 
also be due to the relatively slow incorporation of fatty acids in the cell 
membranes or a low conversion efficiency. Certainly, the formation of DHEA and 
EPEA, compared to the level of precursor added to the cells, is relatively low. 
When 30 µM DHA is added, only 90 pg/mL DHEA (= 0.24 nM) is found in the 
medium. The overall metabolic fate of most of the DHA and EPA added to the 
adipocytes is not known as yet, but could also be esterified to triglycerides or 
phospholipids in membranes or reside in the medium. Finally, they may be further 
metabolized by COX-2, which is also present in adipocytes [25, 26]. 
Remarkably, EPEA levels were higher than those of DHEA. This may be explained 
by differences between levels of esterified EPA compared to DHA in 3T3-L1 
adipocytes, which is reported to exist for 3T3-F442A adipocytes [14]. To the best 
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of our knowledge, there is no data available concerning DHA and EPA background 
levels in the 3T3-L1 cells used in the work presented here.  
Adipocytes communicate with distant tissues and cells to regulate metabolism 
through so-called adipokines, including IL-6, MCP-1, adiponectin, leptin and TNF-
α [17-20]. Obesity is associated with increased serum levels of IL-6 and MCP-1, 
which are considered to contribute to the increase of insulin resistance and 
thereby to the further development of the metabolic syndrome. Previous work 
demonstrated that DHA and EPA have anti-inflammatory properties in 
macrophages and this was also reported for DHA in 3T3-L1 adipocytes, but at 
higher doses and longer exposures than tested in this study for their respective 
NAEs [27, 28].  Data from the present study show that both DHEA and EPEA 
decrease adipocyte IL-6 and MCP-1 levels after stimulation with LPS and suggest 
that both PPAR-γ and CB2 receptors are involved in the inhibition of IL-6. In 
another paper, we also demonstrated that DHEA has anti-inflammatory 
properties in macrophages which are mediated through an interaction with the 
CB2 receptor [29]. Furthermore, CB2 receptor mRNA expression was reported in 
human adipocytes [30]. Previously performed studies suggested that the n-pentyl 
chain in anandamide is necessary for optimal binding to cannabinoid receptors 
[31], but other work demonstrated that both DHEA and EPEA have affinity for 
CB1, although less than AEA [32]. It remains to be established whether increasing 
the ethyl chain to a pentyl chain will increase affinity for CB2. 
In addition to CB2, DHEA also binds to other receptors including PPARs [12], 
underlining the complexity of NAE signaling. This may explain that the reduction 
of IL-6 and MCP-1 was strongest when NAEs were applied in the nanomolar range. 
Remarkably, no effects on MCP-1 levels were found using GW9662 and SR144528. 
More studies are needed to reveal the mechanism of inhibition of MCP-1 release.  
Human plasma was shown to contain DHEA with no detectable levels of EPEA, 
which is similar to what was reported previously by others [33]. In line with 
previous observations, DHEA could potentially be a mediator of the beneficial 
effects of dietary n-3 PUFA in humans.  
In conclusion, cultured adipocytes secrete increased amounts of DHEA and EPEA 
to the medium after exposure to DHA and EPA, and these ethanolamines have 
anti-inflammatory properties on adipocytes. The beneficial health effects of n-3 
PUFAs could potentially be mediated by conversion to their ethanolamines. 
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Abstract 
 
N-acylethanolamines (NAEs), such as anandamide (AEA), are a group of 
endogenous lipids derived from a fatty acid linked to ethanolamine and have a 
wide range of biological activities, including regulation of metabolism and food 
intake. We hypothesized that i) NAE plasma levels are associated with levels of 
total free fatty acids (FFAs) and their precursor fatty acid in fasting and non-
fasting conditions and ii) moderate alcohol consumption alters non-fasting NAE 
levels. In a fasting and non-fasting study we sampled blood for measurements of 
specific NAEs and FFAs. In the fasting study blood was drawn after an overnight 
fast in 22 postmenopausal women. In the non-fasting study blood was sampled 
before and frequently after a standardized lunch with beer or alcohol-free beer in 
19 premenopausal women. Fasting AEA levels correlated with total FFAs (r=0.84; 
p<0.001) and arachidonic acid levels (r=0.42; p<0.05). Similar results were 
observed for other NAEs with both total FFAs and their corresponding fatty acid 
precursors. In addition, AEA (r=0.66; p<0.01) and OEA levels (r=0.49; p<0.02) 
positively related with BMI. Changes over time in non-fasting AEA levels were 
correlated with changes in total FFA levels, both after a lunch with beer (r=0.80; 
95% confidence interval: 0.54-0.92) and alcohol-free beer (r=0.73; 0.41-0.89). 
Comparable correlations were found for other NAEs, without differences in 
correlations of each NAE between beer and alcohol free beer with lunch. In 
conclusion, i) in fasting and non-fasting states circulating anandamide and other 
N-acylethanolamines were associated with free fatty acid levels and ii) moderate 
alcohol consumption does not affect non-fasting NAE levels. This suggests that 
similar physiological stimuli cause the release of plasma N-acylethanolamines and 
free fatty acids in blood. 
 
Trial registration: ClinicalTrials.gov ID no: NCT00524550 and NCT00652405 
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Introduction 
N-acylethanolamines (NAEs) are a group of lipid mediators, derived from a fatty 
acid precursor linked to an ethanolamine moiety. The best studied NAE is the 
endocannabinoid arachidonoylethanolamide (anandamide; AEA). In addition to 
AEA, NAEs also comprise of other non-endocannabinoids such as 
palmitoylethanolamide (PEA), oleoylethanolamide (OEA) and 
stearoylethanolamide (SEA), for which palmitic acid, oleic acid and stearic acid 
serve as their respective precursor fatty acids (see Figure 4.1 for structures). NAEs 
have several biological effects, including regulation of food intake and energy 
metabolism [1, 2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Structures of the N-acylethanolamines AEA, OEA, PEA and SEA.  
 
 
Several studies have shown that dietary fatty acids determine levels of 
corresponding NAEs in different tissues, suggesting a link between availability of 
precursor fatty acids and NAEs formation [3-5]. In obesity, a state characterized by 
elevated circulating free fatty acids (FFAs), levels of AEA are also increased [6, 7]. 
Conversely, when FFA levels decline after a meal, non-fasting levels of AEA are 
concomitantly decreased in normal-weight subjects [8]. This made us hypothesize 
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that their release into plasma is regulated by similar physiological stimuli and that 
plasma NAE levels parallel those of total FFAs and their precursor fatty acids.  
Secondly, since AEA and OEA are involved in the regulation of appetite [9], we 
also wanted to study whether the well-known appetite-inducing effects of acute 
alcohol consumption [10] might be related to changes in NAEs. Therefore, we 
investigated the correlation of different NAEs with FFAs in both fasting and non-
fasting conditions and the effect of moderate alcohol consumption on non-fasting 
NAE levels. 
 
Subjects and Methods 
Samples were analyzed from two studies (fasting and non-fasting) conducted at 
TNO Quality of Life, Zeist, the Netherlands. An independent centralized ethics 
committee (METOPP; Tilburg, the Netherlands) approved both protocols. Studies 
are registered at Clinical trials.gov: NCT00524550 and NCT00652405. Eligible 
women consumed between 5 and 21 units of alcohol per week, were apparently 
healthy, non-smokers and had no family history of alcoholism. They gave written 
informed consent.  
For the fasting study we used samples from an intervention study completed 
earlier [11]. At the first day of the intervention subjects arrived at the premises 
after an overnight fast when blood was drawn.  
The non-fasting study was part of a randomized, open label, crossover trial in 
which subjects consumed two cans of beer (~13g alcohol each) or two cans of 
alcohol-free beer (<0.1 g alcohol) (both: Amstel, Amsterdam, the Netherlands) 
daily for three weeks during dinner. Each three-week intervention period was 
preceded by a one-week wash-out. At the last day of each treatment, subjects 
came to the premises for a standardized lunch (1978 kJ; 16.1% protein, 21.0% fat 
and 62.9% carbohydrate). The two lunches were consumed around noon under 
similar conditions, 28 days apart. Treatment order (beer vs. alcohol-free beer with 
lunch) was randomized according to the intervention trial. A first can of study 
substance was consumed one hour before the start of the lunch, a second can 
during the lunch. Both cans were consumed within 15 minutes. Blood was 
sampled before and at several time points after lunch. 
In both studies, venous blood was drawn in tubes containing silica as clot activator 
for serum (FFA analysis) or Potassium Ethylene Diamine Tetra Acid for plasma 
(NAE analysis). To inactivate fatty acid amide hydrolase (FAAH), 
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phenylmethanesulphonyl fluoride (final concentration: 100 µM) was added to the 
plasma samples. Total FFA determinations in blood were performed using 
Olympus analytical equipment and reagents. Plasma levels of NAEs were 
determined using a LC-MS/MS technique [12]. Specific serum FFA were measured 
using a high-resolution UHPLC-MS technique [13]. 
 
Variable  
Glucose (mmol/L) 5.45 ± 0.11 
Insulin (pmol/L) 51.9 ± 5.8 
Triglycerides (mmol/L) 1.47 ± 0.13 
Free fatty acids (mmol/L) 0.59 ± 0.06 
Anadamide (nmol/L) 6.8 ± 0.70 
Oleoylethanolamide (nmol/L) 43.8 ± 3.3 
Palmitoylethanolamide (nmol/L) 40.0 ± 3.7 
Stearoylethanolamide (nmol/L) 16.3 ± 1.9 
 
Table 4.1. Fasting characteristics of the twenty-two postmenopausal women.  
 
 
Pearson’s coefficient of correlation was calculated to assess correlations between 
fasting FFA and NAE. In the non-fasting study variables at baseline (t=-60 min 
before lunch) were compared between treatments with a mixed analysis of 
variance model. For the correlation between changes over time (non-fasting 
study), a Fisher’s z transformation was applied on individual correlations to 
correct for deviations from the normal distribution and 95% confidence interval 
(CI) for each correlation coefficient were calculated [14]. SAS statistical software 
package (SAS version 9, SAS Institute, Cary, NC) was used to perform statistical 
analyses. Statistical significance was defined as p<0.05. 
 
Results 
The 22 postmenopausal women enrolled in the fasting study had a mean BMI of 
26.3 kg/m2 (range: 19.4-34.1) and a mean age of 55.8 years (range: 51-61). See 
Table 4.1 for fasting characteristics. Fasting AEA levels correlated positively with 
total FFA (r=0.84, p<0.001) and with arachidonic acid levels (r = 0.42; p<0.05). 
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 Alcohol-free beer Beer P value 
Glucose (mmol/L) 
 
4.97 ± 0.07 5.09 ± 0.07 0.18 
Insulin (pmol/L) 44.0 ± 9.2 37.1 ± 9.2 0.55 
Triglycerides (mmol/L) 1.17 ± 0.07 1.08 ± 0.07 0.17 
Free fatty acids (mmol/L) 0.39 ± 0.04 0.44 ± 0.04 0.18 
Anadamide (nmol/L) 5.90 ± 0.39 5.98 ± 0.39 0.86 
Oleoylethanolamide (nmol/L) 52.7 ± 6.5 54.4 ± 6.5 0.74 
Palmitoylethanolamide (nmol/L) 53.9 ± 4.1 57.8 ± 4.1 0.23 
Stearoylethanolamide (nmol/L) 15.1 ± 0.9 15.2 ± 0.9 0.98 
 
Table 4.2. Fasting characteristics of the nineteen premenopausal women at baseline (t=-60 
min before lunch) after the three weeks of consuming beer or alcohol-free beer. 
 
 
OEA, PEA and SEA levels also positively correlated with serum fasting total FFA 
levels (All r>0.44; p<0.05). Comparable correlations were observed between oleic 
acid and OEA (r=0.71; p<0.001), palmitic acid and PEA (r=0.54; p<0.01) and stearic 
acid and SEA (r=0.77; p<0.0001) (Figure 4.2). Furthermore, AEA (r=0.66; p<0.01) 
and OEA levels (r=0.49; p<0.02) were also positively related with BMI. 
All 19 premenopausal (mean age 23.1 years; range 20-32) women in the non-
fasting study had a normal weight (mean BMI: 22.2 kg/m2; range: 19.8-24.7). No 
differences in FFA or NAE levels at baseline were observed between treatments 
after the three week intervention periods (see Table 4.2 for fasting 
characteristics). Curves for AEA, OEA, PEA and total FFA after both meals are 
shown in Figure 4.3. Non-fasting changes in total FFA were positively associated 
with changes in NAEs: (r=0.73; 95% confidence interval: 0.41-0.89) and (r=0.80; 
0.54-0.92) for AEA; (r=0.89; 0.73-0.96) and (r=0.91; 0.78-0.97) for OEA and 
(r=0.77; 0.49-0.91) and (r=0.76; 0.47-0.90) for PEA after a meal either with 
nonalcoholic beer or beer respectively. Correlations over time of each NAE with 
total FFAs did not differ between lunches with or without alcohol consumption. In 
a subgroup of six women, comparable coefficients with NAEs and their specific 
fatty acids were found for both lunches (data not shown). 
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Figure 4.2: Pearson correlations between plasma levels of several N-acylethanolamines 
and their corresponding serum levels of fatty acid in twenty-two postmenopausal women 
after an overnight fast. 
 
Discussion 
The primary findings of this study are i) all fasting and non-fasting plasma NAEs 
investigated are positively associated with both serum total FFAs and their specific 
fatty acid precursor and ii) prolonged and acute moderate alcohol consumption 
does not alter non-fasting NAE levels. These findings imply that circulating NAEs 
are a reflection of plasma FFA levels. This suggests AEA levels to be altered in 
general under conditions characterized by changes in circulating FFAs. Indeed, 
increased levels of AEA are observed in obesity, diabetes, and eating disorders 
such as anorexia and binge-eating disorder [6, 8, 15]. Furthermore, increased 
levels of circulating AEA, OEA and PEA were found in patients with liver cirrhosis 
[16]. Besides the correlation with fasting FFAs, we also observed a strong 
correlation between AEA and OEA with BMI in postmenopausal women. This is in 
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line with previous work which observed higher levels of AEA among obese 
postmenopausal women compared with normal-weight counterparts [6]. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Means (±SEM) of serum free fatty acid (FFA) concentrations and plasma 
concentrations of anandamide (AEA), palmitoylethanolamide (PEA) and 
oleoylethanolamide (OEA) before and during three hours after a lunch with beer (●) or 
alcohol-free beer consumption (○) in 19 normal-weight premenopausal women. 
 
 
Although the release of NAEs into plasma may still be biologically relevant, it 
remains to be determined of the observed relation between FFA and NAE levels is 
also causal. Perhaps, the increase in FFA levels is paralleled by increased 
membrane phospholipid cleavage. The increased levels of AEA and 2-
arachidonoylglycerol (2-AG), another arachidonic acid-derived endocannabinoid, 
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have led to the concept of the ‘overactivated’ endocannabinoid system in obesity 
in which FAAH expression is reduced [6, 7, 17]. However, our data suggest that 
increased levels of endocannabinoids and other NAEs in obesity could take place 
in parallel with increased FFA concentrations and does not necessarily reflect a 
functional change of the endocannabinoid system alone. 
Only one other study investigated non-fasting AEA concentrations in humans, 
without reporting results on FFAs [8]. They found decreased AEA levels one hour 
after a lunch. Possibly the physiological stimuli involved in the decrease of FFA 
levels after consumption of a meal also contribute to a reduced release of NAEs 
from membrane phospholipids. However, a decreased activity of enzymes 
involved in NAE synthesis such as N-acylphosphatidylethanolamine hydrolyzing 
phospholipase (NAPE-PLD) or increased FAAH activity can not be excluded.  
To our best knowledge, this is the first human study in which NAEs are reported 
after both prolonged and acute moderate alcohol consumption. Acute alcohol 
consumption is generally known to stimulate appetite [10]. In our study, 
circulating non-fasting NAEs did not differ between a lunch with or without 
alcohol consumption. It thus seems unlikely that the acute appetite-inducing 
effects of alcohol are caused by alterations in circulating NAEs. 
The observed correlations between NAEs and FFAs are persistent for several NAEs 
in various populations (pre- and postmenopausal women) and under different 
conditions (fasting and non-fasting). However, some limitations warrant 
consideration. It remains to be established whether changes in plasma NAEs will 
also modify NAEs in target tissues such as adipose tissue, brain, liver and 
intestines as seen in animal studies [3] and to which extend these changes affect 
physiology. The exact site of NAE synthesis is unknown, but the liver, adipose 
tissue or blood cells could contribute to the changes in NAE levels. Furthermore, 
other regulators such as insulin may affect NAE levels [18]. Finally, we did not 
measure 2-AG, another important endocannabinoid, or other NAEs. 
In conclusion, we provide evidence that in humans fasting peripheral NAEs are 
positively correlated with both serum total fasting FFA and their specific fatty acid 
precursor. Furthermore, we showed that non-fasting changes over time in AEA 
and related NAEs are positively correlated with non-fasting changes in free fatty 
acids, independent of alcohol consumption. This suggests that circulating N-
acylethanolamines might be a reflection of free fatty acids in blood. The biological 
significance of these findings is still unknown and requires further investigation.  
Plasma NAE levels are correlated with free fatty acid levels 
 
92 
 
 
Acknowledgements 
We gratefully acknowledge the volunteers for participation; H. Fick, D. 
Rouwendaal, A. Speulman, J. Jansen, I. Klöpping, I. van den Assum, J. Jacobs, E. 
Busink, and C. Hoeflaken for practical work during the studies; J. Catsburg, M. 
Rondhuis, L. Coulier, J. Bezemer, R. Ramaker and M. Hekman for laboratory 
analyses; and E. Dutman for data management; These studies were partially 
supported by the Dutch Foundation for Alcohol Research (SAR).  
 
References 
 
 [1]  Lambert, DM, Muccioli, GG. Endocannabinoids and related N-acylethanolamines in the 
control of appetite and energy metabolism: emergence of new molecular players. Current 
Opinion in Clinical Nutrition & Metabolic Care 2007; 10:735-744. 
 [2]  O'Sullivan, SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-
activated receptors. Br J Pharmacol 2007; 152:576-582. 
 [3]  Artmann, A, Petersen, G, Hellgren, LI et al. Influence of dietary fatty acids on 
endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. 
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2008; 1781:200-
212. 
 [4]  Berger, A, Crozier, G, Bisogno, T et al. Anandamide and diet: Inclusion of dietary 
arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-
acylethanolamines in piglets. Proceedings of the National Academy of Sciences of the United 
States of America 2001; 98:6402-6406. 
 [5]  Matias, I, Carta, G, Murru, E et al. Effect of polyunsaturated fatty acids on endocannabinoid 
and N-acyl-ethanolamine levels in mouse adipocytes. Biochimica et Biophysica Acta (BBA) - 
Molecular and Cell Biology of Lipids 2008; 1781:52-60. 
 [6]  Engeli, S, Böhnke, J, Feldpausch, M et al. Activation of the Peripheral Endocannabinoid 
System in Human Obesity. Diabetes 2005; 54:2838-2843. 
 [7]  Engeli, S, Jordan, J. The endocannabinoid system: Body weight and metabolic regulation. 
Clinical Cornerstone 2006; 8:S24-S35. 
 [8]  Matias, I, Gonthier, MP, Orlando, P et al. Regulation, Function, and Dysregulation of 
Endocannabinoids in Models of Adipose and b-Pancreatic Cells and in Obesity and 
Hyperglycemia. J Clin Endocrinol Metab 2006; 91:3171-3180. 
Chapter 4 
93 
 
 [9]  Hansen, HS, Diep, TA. N-acylethanolamines, anandamide and food intake. Biochemical 
Pharmacology 2009; 78:553-560. 
 [10]  Caton, SJ, Ball, M, Ahern, A, Hetherington, MM. Dose-dependent effects of alcohol on 
appetite and food intake. Physiology & Behavior 2004; 81:51-58. 
 [11]  Joosten, M, De Graaf, C, Rietman, A, Witkamp, R, Hendriks, H. Short-term oral exposure to 
white wine transiently lowers serum free fatty acids. Appetite 2010;  
 [12]  Balvers, MGJ, Verhoeckx, KCM, Witkamp, RF. Development and validation of a quantitative 
method for the determination of 12 endocannabinoids and related compounds in human 
plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography 
B 2009; 877:1583-1590. 
 [13]  Kleemann, R, van Erk, M, Verschuren, L et al. Time-Resolved and Tissue-Specific Systems 
Analysis of the Pathogenesis of Insulin Resistance. PLoS ONE 2010; 5:e8817- 
 [14]  Blom, WA, Lluch, A, Stafleu, A et al. Effect of a high-protein breakfast on the postprandial 
ghrelin response. Am J Clin Nutr 2006; 83:211-220. 
 [15]  Monteleone, P, Matias, I, Martiadis, V et al. Blood Levels of the Endocannabinoid 
Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in 
Bulimia Nervosa. Neuropsychopharmacology 2005; 30:1216-1221. 
 [16]  Caraceni, P, Antonella, V, Piscitelli, F et al. Circulating and hepatic endocannabinoids and 
endocannabinoid-related molecules in patients with cirrhosis. Liver International 2009; 1-10. 
 [17]  Blüher, M, Engeli, S, Klöting, N et al. Dysregulation of the Peripheral and Adipose Tissue 
Endocannabinoid System in Human Abdominal Obesity. Diabetes 2006; 55:3053-3060. 
 [18]  Di Marzo, V, Verrijken, A, Hakkarainen, A et al. Role of insulin as a negative regulator of 
plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009; 
161:715-722. 
 
 
 
 
 
Plasma NAE levels are correlated with free fatty acid levels 
 
94 
 
  
 Chapter 5 
 
Time-dependent effect of in vivo inflammation on 
eicosanoid and endocannabinoid levels in plasma, liver, 
ileum an adipose tissue in C57BL/6 mice fed a fish oil 
diet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Michiel G.J. Balvers*, Kitty C.M. Verhoeckx*, Jocelijn Meijerink, Sabina 
Bijlsma, Carina M. Rubingh, Heleen M. Wortelboer, and Renger F. Witkamp 
*Both authors contributed equally 
 
Accepted for publication (International Immunopharmacology) 
Effect of inflammation on plasma and tissue eicosanoids and endocannabinoids 
 
96 
 
Abstract 
 
Eicosanoids and endocannabinoids/N-acyl ethanolamines (NAEs) are fatty acid 
derived compounds with a regulatory role in inflammation. Considering their 
complex metabolism, it is likely that inflammation affects multiple compounds at 
the same time, but how lipid profiles change in plasma and other tissues after an 
inflammatory stimulus has not been described in detail. In addition, dietary fish oil 
increases levels of several n-3 fatty acid derived eicosanoids and 
endocannabinoids, and this may lead to a broader change in the profiles of 
bioactive lipids.  
In the present study mice were fed a diet containing 3 % w/w fish oil for 6 weeks 
before receiving i.p. saline or 3 mg/kg lipopolysaccharide (LPS) to induce an 
inflammatory response. Eicosanoid and endocannabinoid/NAE levels (in total 61 
metabolites) in plasma, liver, ileum, and adipose tissue were quantified using 
targeted lipidomics after 2, 4, 8, and 24 hrs, respectively.  
Tissue- and time-dependent effects of LPS on bioactive lipids profiles were 
observed. For example, levels of CYP derived eicosanoids in the ileum were 
markedly affected by LPS, whereas this was less pronounced in plasma and 
adipose tissue. For some compounds, such as 9,10-DiHOME, opposing effects of 
LPS were seen in the plasma compared to the other tissues, suggesting differential 
regulation of bioactive lipid levels after an inflammatory stimulus.  
Taken together, our results show that plasma levels do not always correlate with 
the effects found in tissues, which underlines the need to measure profiles and 
pathways of mediators involved in inflammation, including endocannabinoid-like 
structures, in both plasma and tissues. 
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Introduction 
The initiation, amplification and resolution of inflammation is controlled by a 
variety of molecules, including eicosanoids [1]. The synthesis of eicosanoids starts 
in the cell membrane, were fatty acids are released from membrane 
phospholipids and subsequently shuttled into one or more metabolic pathways, 
involving enzymes like cyclooxygenase (COX), inducible cyclooxygenase (COX-2), 
cytochrome P450 (CYP), or lipooxygenases (LOX)-5, -12 or -15 [1-4]. These 
pathways result in  distinct eicosanoids, yielding prostaglandins (PGs), 
thromboxanes (TBXs), epoxyeicosatrienoic acids (EETs), hydroxyeicosatetraenoic 
acids (HETEs), and leukotrienes (LTs) (see Figure 5.1a for an overview of 
eicosanoids). Their effects depend on target tissue, concentration, nature of 
stimulus, timing and presence of other mediators [1]. Arachidonic acid (ARA) is 
the best studied substrate in eicosanoid biosynthesis, partly because of its high 
abundancy in cell membranes of immune cells [5]. However, other fatty acids, 
such as the n-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA) are also substrates for the above-mentioned 
enzymes, yielding compounds like PGD3, PGE3, TBXB3, and 5-HEPE [1, 6, 7] (Figure 
5.1b). The n-3 derived eicosanoids are in general less potent pro-inflammatory 
mediators compared to their ARA counterparts, and this could contribute to the 
anti-inflammatory properties which are associated with dietary intake of n-3 
PUFAs [8-10]. In addition to this, n-3 PUFAs are also converted into resolvins, a 
class of compounds with active anti-inflammatory and inflammation resolving 
properties [11, 12].  
The N-acyl ethanolamines (NAEs) represent another class of lipid-derived 
mediators with a role in inflammation. Anti-inflammatory properties have been 
described for several NAEs, including endocannabinoid arachidonoyl 
ethanolamide (AEA; also known as anandamide) and palmitoyl ethanolamide 
(PEA) [13, 14]. Anti-inflammatory properties have been described for  the n-3 fatty 
acid derived NAEs docosahexaenoyl ethanolamide (DHEA) and eicosapentaenoyl 
ethanolamide (EPEA) (see Figure 1a-b), and these compounds were more potent 
than AEA in inhibiting nitric oxide release from macrophages [15, 16]. Increased 
levels of NAEs during inflammation have been described in several in vitro and 
animals models [17-19], and are observed in parallel with decreased expression of 
the primary NAE degrading enzyme fatty acid amide hydrolase (FAAH) [18]. 
Furthermore, pharmacological inhibition of FAAH or monoacyl glycerol lipase 
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(MAGL) reduced disease symptoms in several models of inflammation [20, 21], 
suggesting that NAEs/endocannabinoids are part of a protective response against 
inflammatory stress.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1a: Overview of enzymatic pathways involved in eicosanoid and NAE synthesis. 
Arachidonic acid (ARA) is the best studied precursor for eicosanoid synthesis, but linoleic 
acid (LA) can also serve as substrates for different enzymes, including COX, CYP and the 
LOX isoenzymes, yielding distinct eicosanoids and intermediates.  
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It is likely that multiple bioactive lipids are affected by inflammation considering 
their complex metabolism, but most studies only report effects on a limited 
number of (established) compounds, such as PGE2 and AEA. In addition, studies on  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1b: Overview of enzymatic pathways involved in eicosanoid and NAE synthesis. 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can also serve as substrates 
for different enzymes, including COX, CYP and the LOX isoenzymes, yielding distinct 
eicosanoids, intermediates, and NAEs.  
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time-dependent effects of e.g. LPS on bioactive lipid levels in plasma and 
peripheral tissues are scarce, and the formation of n-3 fatty acid derived bioactive 
lipids after various diets in these tissues needs further exploration. To better 
understand the role of bioactive lipids in the various phases of inflammation, it is 
important to know how they react to an inflammatory stimulus, specifically how 
their levels change over time and to what extent effects are comparable between 
plasma and peripheral tissues. In the present study, we investigated in detail the 
time-dependent effect of i.p. LPS on the levels of bioactive lipids 
(endocannabinoids/NAEs and eicosanoids) in plasma, liver, ileum and adipose 
tissue in mice fed with a diet rich in fish oil by using a targeted lipidomics 
approach. The results showed time- and tissue dependent effects of LPS on 
bioactive lipid profiles, and more importantly effects on plasma were not always a 
reflection of bioactive lipid levels in tissues. 
 
Materials and methods 
Chemicals 
Lipopolysaccharide (0111:B4; LPS), indomethacin, paraoxon, butylated 
hydroxytoluene (BHT), and trifluoro acetic acid (TFA) were from Sigma (Steinheim, 
Germany) and phenylmethylsulfonyl fluoride (PMSF) was from Fluka (Steinheim, 
Germany). Milli-Q water (Milli-Q Advantage unit, Millipore, Amsterdam, The 
Netherlands) was used in all analyses. ULC-grade acetonitrile (ACN) and formic 
acid (FA) were obtained from Biosolve (Valkenswaard, The Netherlands). LC-MS 
grade methanol was from Riedel-de-Häen (Steinheim, Germany). Isopropanol and 
ethanol were from JT Baker (Deventer, The Netherlands). 12-
[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid (AUDA) and 
all analytical and internal standards were from Cayman (Ann Arbor, MI, USA). 
Standard stock solutions were prepared in ethanol (eicosanoids) or acetonitrile 
(endocannabinoids/NAEs), aliquoted and stored at -80 °C until analysis. HLB SPE 
columns (Oasis, 60 mg, 3 mL) were obtained from Waters (Etten-Leur, The 
Netherlands). C8 SPE columns (Bond Elut; 200 mg, 3 mL) were from Varian Inc 
(Lake Forest, CA, USA). ELISA kits were from R&D Systems (Minneapolis, MN, 
USA). 
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Animal experiment 
Wild type male C57BL/6 mice were obtained from Harlan (Horst, The Netherlands) 
and housed two or three mice per cage in a temperature controlled environment 
with a 12 hour light-dark cycle (light at 6.00-18.00). The mice, 4 weeks old at 
arrival, had free access to a standard run-in diet (AIN93-M, with a 4% w/w fat as 
soy bean oil) for two weeks, after which all animals switched to a fish oil diet (AIN-
93-M, containing 1% soy bean oil and 3% Marinol®). The diets were obtained from 
Research Diet Services (Wijk bij Duurstede, The Netherlands) and the Marinol® 
was a kind gift from Lipid Nutrition (Wormerveer, The Netherlands). Diets were 
stored in air-tight bags at -20 °C until just before feeding, and fresh food was 
provided two times per week to minimize oxidation of the fatty acids in the diet. 
GC-MS based analysis of the diets confirmed that the correct amounts of DHA and 
EPA were present, and that the DHA and EPA levels were stable for at least 4 
weeks under the described conditions. Food consumption and animal weight 
were measured two times per week. 
After six weeks, animals were divided into two groups and received either i.p. 
saline or 3 mg/kg LPS. At t=0, and after 2, 4, 8, and 24 hrs respectively, four 
animals from both the saline and the LPS groups were anesthetized (only four 
saline treated animals at t=0), blood was collected from the orbital sinus, 
captured in 1.3 mL EDTA coated tubes (Sarstedt; Etten-Leur, The Netherlands) and 
put on ice until centrifugation (10’, 10,000 rpm at 4 °C). After centrifugation, 
plasma was aliquoted. For eicosanoid analysis, 200 µL plasma was stored in 1 mL 
methanol containing paraoxon, BHT, AUDA, indomethacin, and PMSF to prevent 
eicosanoid oxidation and breakdown. For endocannabinoid/NAE analysis, 100 µL 
plasma was stored in the presence of 100 µM PMSF and 100 µM URB602 
(inhibitor of 2-AG hydrolysis). Subsequently, the animals were sacrificed by 
cervical dislocation after which liver, ileum and epididymal adipose tissue was 
collected and immediately snap-frozen in liquid nitrogen. All plasma and tissue 
samples were stored at -80 °C until further analysis. Analysis of plasma 
interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) levels confirmed 
that LPS had triggered an inflammatory response by showing strongly increased 
IL-6 and MCP-1 levels in LPS-treated mice (data not shown). From the 24 hr LPS 
group, one animal died just before the end of the experiment; not enough plasma 
could be obtained from two other animals in the 24 hr LPS group to perform 
endocannabinoid analysis.  
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The study was conducted according to the Netherlands Law on Animal 
Experiments, and approved by the local Animal Experiments Committee of 
Wageningen University. 
 
Extraction of endocannabinoids/NAEs from plasma 
Plasma (100 µL) was thawed and 400 µL extraction mixture containing 100 µM 
PMSF and internal standards (AEA-d8, 2-AG-d8 and OEA-d4) in ACN was added 
while the sample was gently vortexed. After subsequent centrifugation (5’ at 
13,000 rpm and RT), the supernatant was transferred to a clean eppendorf tube 
and evaporated to dryness in a vacuum concentrator (Scanvac; Lynge, Denmark). 
The dried extracts were reconstituted in 100 µL ACN containing 0.1% TFA and 
used for LC-MS/MS analysis. 
 
Extraction of endocannabinoids/NAEs from tissues 
Endocannabinoid/NAE were extracted from freeze-dried liver and ileum using a 
method adapted from a previously published protocol for plasma [22]. 
Approximately 50 mg freeze-dried liver or 10 mg freeze-dried ileum were 
extracted by adding 1 mL extraction mixture (ACN) and sonication. The samples 
were centrifuged (5’ at 14,000 rpm), the supernatant was transferred to a clean 
15 mL tube, and this was repeated once. The pooled ACN fractions were diluted 
with MQ water containing 0.13% TFA until the final ACN concentration was 20% 
prior to SPE clean-up as described before [22]. In short, columns were washed 
with 20% v/v ACN in MQ water containing 0.1% TFA, eluted with 80% v/v ACN in 
MQ water containing 0.1% TFA and evaporated to dryness using vacuum 
centrifugation. The dried extracts were reconstituted in 100 µL ACN containing 
0.1% TFA and used for LC-MS/MS analysis. 
For adipose tissue, approximately 100 mg ‘wet’ tissue was extracted with 1 mL 
extraction solution (ACN) by sonication. The samples were centrifuged for 5’ at 
14,000 rpm and RT, the supernatant was transferred to a clean 2.0 mL eppendorf 
tube, and the ACN extraction was repeated once. The 2 mL ACN extract was 
subsequently evaporated to dryness, reconstituted in 100 µL ACN containing 0.1% 
TFA and used for LC-MS/MS analysis. 
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LC-MS/MS analysis of endocannabinoids/NAEs 
Two LC-MS/MS systems were used for endocannabinoid/NAE analysis. Plasma 
extracts were analyzed by UPLC coupled to a Xevo TQ-S mass spectrometer 
(Waters; Etten-Leur, The Netherlands) because high sensitivity was essential for 
adequate quantification in extracts obtained from 100 µL plasma samples. Liver, 
ileum and adipose tissue were analyzed on a Surveyor HPLC coupled to a TSQ 
Quantum Discovery mass spectrometer (Thermo Finnigan; Breda, The 
Netherlands) using a method adapted from a previous publication [22]. 
For the UPLC-Xevo system, 3 µL plasma extract was injected on a Acquity C8 BEH 
UPLC column (2.1 x 100 mm, 1.7 µm) and was separated using gradient elution 
with a stable flow of  500 µL/min. The gradient started with 100% A (40:40:20 
v/v/v of MQ water : methanol : ACN with 0,1% FA) which was maintained until 
0.35 minutes, followed by a linear increase to 100% B (7:3 v/v methanol : ACN 
with 0.1% FA) which was achieved at 7.0 minutes and was maintained until 9.0 
minutes. Finally, the column equilibrated for 3 minutes at 100% A. The column 
was maintained at 60 °C during analysis, and the samples were kept at 10 °C. The 
MS was operating in selective reaction mode using electrospray ionization in 
positive ion mode, with a capillary voltage of 1.5 kV, a source temperature of 150 
°C and a desolvation temperature of 500 °C. Cone voltage and collision energy 
were optimized for each compound individually (see Table 5.1a for parent and 
product m/z values). Peak identification and quantification was performed using 
MassLynx software version 4.1. Calibration curves were run in duplicate from 
which one regression equation was generated.  
For the analysis of liver, ileum and adipose tissue, a TSQ Quantum Discovery was 
used as described before [22]. Five µL extract was separated on an Xterra C8 MS 
column (2.1 x 150 mm, 3.5 µm) using gradient elution with a constant flow of 150 
µL/min. The same solutions were used as with the Xevo system, but now 1 g/L 
ammonium acetate was added (the most dominant parent for 2-AG in this MS is 
the ammonium adduct). The gradient started with 100% A which was maintained 
until 2.0 minutes, followed by a linear increase to 100% B which was achieved at 
8.00 minutes and maintained until 16.0 minutes, and the column was left to 
equilibrate for 5 minutes at 100% A. The column was maintained at 40 °C during 
analysis and the samples were cooled at 4 °C. The MS was operating in selective 
reaction mode using electrospray ionization in positive ion mode, with a capillary 
voltage of 4.5 kV and a capillary temperature of 350 °C. Cone voltage and collision  
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energy were optimized for each compound individually. Peak identification and 
quantification was performed using LCquan software version 2.5.5. Calibration 
curves were run in duplicate from which one regression equation was generated. 
 
Compounds Parent (m/z) Product (m/z) 
 
AEA 348 62 
2-AG (NH4 adduct) 379 (396) 287 
DHEA 372 62 
EPEA 346 62 
DLE 350 62 
OEA 326 62 
PEA 300 62 
SEA 328 62 
   
Internal standards 
AEA-d8 356 63 
OEA-d4 330 66 
2-AG-d8 (NH4 adduct) 387 (404) 294 
 
Table 5.1a: m/z Values of parent and product ions of endocannabinoids/NAEs used in the 
LC-MS/MS method. For tissue, 2-AG analyses (performed on TSQ Quantum MS), the 
ammonium adduct was the most dominant parent ion. For plasma 2-AG analyses 
(performed on Xevo TQ-S MS), the molecular ion (M+H) was the most dominant parent.  
 
Extraction of eicosanoids from plasma 
Internal standards were added to the plasma samples which were already 
precipitated with methanol (see section ‘animal experiment’), and the samples 
were put on ice for 30 minutes. Samples were subsequently centrifuged (5’, 3000g 
and 4 °C) and the supernatant was transferred to a glass tube. Just before loading 
on activated HLB columns, 4.75 mL MQ water containing 0.1% v/v FA was added 
to the methanol extract, diluting the extract to 20% methanol. After loading, the 
columns were washed with 2 mL 20% methanol in MQ water containing 0.1% FA, 
and the columns were allowed to dry for 15 minutes. The SPE columns were 
eluted with 2 mL methanol and the samples were captured in tubes already 
containing 20 µL of 10% glycerol and 500 µM BHT in ethanol. The tubes were 
placed in a water bath at 40 °C and the methanol was evaporated under a gentle 
stream of nitrogen, after which the samples were reconstituted in 100 µL ethanol 
containing another internal standard (CUDA) and immediately used for LC-MS/MS 
analysis. 
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Extraction of eicosanoids from tissues 
The extraction of eicosanoids from liver, ileum and adipose tissue was similar to 
plasma eicosanoid extraction. Approximately 100 mg liver and adipose tissue, and 
50 mg ileum was extracted with 1 mL methanol containing internal standards and 
sonication. After centrifugation (5’, 3000g and 4 °C), the supernatants were 
transferred to clean tubes and the methanol extraction was repeated once. Just 
before loading on HLB SPE columns, 8 mL MQ water containing 0.1% FA was 
added to the methanol extracts. For the SPE procedure and further, see section 
‘Plasma extraction of eicosanoids’.  
 
LC-MS/MS analysis of eicosanoids 
All eicosanoid analyses were performed on a UPLC coupled to a Xevo TQ-S mass 
spectrometer (Waters). Five µL extract was injected on a Acquity C18 BEH UPLC 
column (2.1 x 100 mm, 1.7 µm) and was separated using gradient elution with a 
stable flow of  600 µL/min. The gradient started with 95% A (MQ water with 0.1% 
FA) and 5% B (ACN with 0.1% FA) followed by a linear increase to 70% A and 30% 
B which was achieved at 5.0 minutes. This was followed by a linear increase 
towards 50% B which was achieved at 11.25 minutes and maintained until 13.25 
minutes. The system was subsequently switched to 100% B, which was achieved 
at 15.75 minutes and maintained until 16.75 minutes, after which the column was 
left to equilibrate at 5% B for approximately 3 minutes. The column was 
maintained at 50 °C during analysis, and the samples were kept at 10 °C. The MS 
was operating in selective reaction mode using electrospray ionization in negative 
ion mode, with a capillary voltage of 3.3 kV, a source temperature of 150 °C and a 
desolvation temperature of 600 °C. Cone voltage and collision energy were 
optimized for each compound individually (see Table 5.1b for parent and product 
m/z values). Peak identification and quantification was performed using MassLynx 
software version 4.1. Calibration curves were run in duplicate from which one 
regression equation was generated. During data analysis, 5 peaks of unknown 
identity were found to be influenced by diet or LPS treatment, and these 
compounds are listed UK1 to UK5. These peaks were visible in the transitions m/z 
295.2 > 195.2 and m/z 295.2 > 171.1. ARA, DHA and EPA were also determined 
using this method. 
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Compounds Parent (m/z) Product (m/z) 
 
12-HHTrE 279.0 179.3 
13-HODE  295.1 195.0 
9-HODE 295.1 171.0 
EPA 301.1 257.2 
ARA 303.1 259.2 
12,13-DiHOME 313.2 183.0 
9,10-DiHOME 313.2 201.0 
15-deoxy-d-12,14-PGJ2 315.0 271.1 
12-HEPE 317.2 179.0 
5-HEPE 317.2 115.0 
11,12-EET 319.1 167.0 
12-HETE 319.1 179.2 
5-HETE 319.1 203.1 
14,15-EET 319.1 219.2 
5,6-EET 319.1 191.3 
11-HETE 319.1 167.0 
8,9-EET 319.1 167.0 
15-HETE 319.2 219.1 
20-HETE 319.2 275.3 
2,3-dinor-8-iso-PGF2α 325.1 237.2 
DHA 327.1 283.1 
9,10,13-TriHOME  329.2 171.1 
9,12,13-TriHOME  329.2 211.1 
PGB2 333.2 174.9 
LTB4 335.1 194.8 
14,15-DiHETrE 337.1 207.0 
11,12-DiHETrE 337.1 166.9 
5,6-DiHETrE 337.1 144.8 
8,9-DiHETrE 337.1 127.0 
17-keto-4(z),7(z),10(z),13(z),15(e),19(z) DHA 341.5 111.0 
17-HDoHE 343.1 281.4 
PGE3 349.0 269.1 
PGD3 349.1 269.1 
PGD2 351.1 271.1 
Lipoxin A4 351.1 114.9 
13,14-dihydro-15-keto-PGD2 351.1 175.0 
13,14-dihydro-15-keto-PGE2 351.1 175.1 
PGE2 351.1 271.2 
13,14-dihydro-15-keto-PGF2α 353.1 113.1 
8-iso-PGF2α 353.1 193.0 
11β-PGF2α 353.1 193.0 
PGF2α 353.1 193.0 
PGF2β 353.2 193.1 
10,17-DiHDoHE 359.1 152.9 
Maresin 359.6 177.1 
19,20-DiHDoPE 361.1 272.7 
TBXB3 367.1 168.9 
TBXB2 369.1 169.0 
Resolvin D2 375.1 175.0 
Resolvin D1 375.1 140.8 
LTE4 438.0 351.0 
n-acetyl LTE4 480.0 351.1 
LTD4 495.1 142.9 
Table 5.1b: m/z Values of parent and product ions of eicosanoids used in the LC-MS/MS 
analysis. Compounds are ranked based on their parent m/z value. 
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Internal standards Parent (m/z) Product (m/z) 
   
13-HODE-d4 299.2 198.2 
ARA-d8 311.2 267.2 
20-HETE-d6 325.1 281.3 
15-HETE-d8 327.2 226.1 
14,15-EET-d11 330.2 268.3 
PGB2-d4 337.1 178.9 
CUDA 339.1 214.1 
LTB4-d4 339.1 197.1 
8,9-DiHETrE-d11 348.2 127.0 
PGE2-d4 355.1 275.1 
13-14-dihydro-15-keto-PGF2α-d4 357.1 187.0 
8-iso-PGF2α-d4 357.1 196.9 
11β-PGF2α-d4 357.1 313.4 
PGF2α-d4 357.1 313.4 
PGD2-d9 360.3 280.1 
TBXB2-d4 373.1 173.0 
LTD4-d5 500.0 142.9 
 
Table 5.1b (cont.): m/z Values of parent and product ions of eicosanoids used in the LC-
MS/MS analysis. Compounds are ranked based on their parent m/z value. 
 
 
Data analysis 
Univariate analysis was performed with SAS version 9.1 (2002-2003 by SAS 
Institute Inc, Cary, NC, USA). Time-dependent effects of inflammation were 
analyzed using ANOVA. ANOVA assumptions were checked for each variable. If 
these assumptions were not met, rank transformation was applied for that 
particular variable. Partial tests were performed using Tukey-Kramer multiple 
comparison correction. Benjamini and Hochberg false discovery rate correction 
was applied to correct for false positives. In all statistical tests performed, the null 
hypothesis (no effect) was rejected at the 0.05 level of probability (α = 5%).  
Only data from animals from which all analyses were completed were included in 
the univariate model. From one of the animals in the 8 hr saline group, the liver 
endocannabinoid analysis was not completed. The data from the t=0 saline 
treated animals was duplicated to make a t=0 LPS treated group to be analyzed in 
the univariate model. The animal experiment also contained 48 hr groups, but LPS 
treatment resulted in high mortality in these groups, for which the data from 
these groups is not presented in this paper.  
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Results 
The metabolism of eicosanoids and endocannabinoids is complex, and only few 
studies have explored the effect of inflammation on their formation in detail. In 
this study, mice fed a fish oil diet were treated i.p. with saline or LPS, and the 
change in levels of 61 eicosanoids and endocannabinoids in plasma, liver, ileum 
and adipose tissue was followed during a 24 hrs time course. 
The eicosanoids and endocannabinoids which were significantly altered by LPS 
treatment are listed in Table 5.2, with time curves presented in Figures 5.2-5 to 
illustrate the effect of LPS. Univariate data analysis was used to evaluate 
significant differences of LPS, and if necessary rank transformation was applied 
prior to ANOVA. 
 
LPS treatment affected the plasma profiles of both eicosanoids and 
endocannabinoids 
Treatment of mice with LPS had a time-dependent effect on the profile of 
eicosanoids in plasma (Table 5.2 and Figure 5.2). In general, LPS increased the 
levels of 16 eicosanoids, but different patterns were observed. For example; some 
compounds displayed a relatively delayed effect of LPS (e.g. 5,6-DiHETrE and LTE4) 
with only significant effects after 24 hrs LPS, whereas others showed a relatively 
early increase followed by normalization (e.g. PGE2). The n-3 fatty acid 
counterpart of PGE2, PGE3, however, was increased by LPS at all time points, 
which was most pronounced at 24 hrs after LPS injection. Furthermore, the time 
curves for PGE2 and its metabolite 13,14-dihydro-15-keto-PGE2 showed 
considerable overlap. The eicosanoids formed by the CYP pathway, such as 14,15-
DiHETrE, 12,13-DiHOME and 11,12-DiHETrE were still increasing in the LPS treated 
mice at 24 hrs. In addition, also the fatty acids ARA and EPA were significantly 
increased by LPS after 4 hrs (ARA) and 8 hrs (ARA & EPA) respectively. TBXB2 and 
12-HHTrE were decreased bij LPS at all time points.  
Plasma levels of the NAEs DHEA, EPEA, OEA, PEA and SEA were increased by LPS, 
typically from 4 hrs after LPS with a sustained or even stronger effect until 24 hrs 
for DHEA. 
 
 
 
 
Fatty acids & n-3 
derived metabolites 2 hr 4 hr 8 hr 24 hr 
 
 2 hr 4 hr 8 hr 24 hr 
  
ARA 
plasma - ↑ ↑ - 
DHA 
plasma - - - - 
liver - - - - liver - - - - 
ileum ↑ ↑ ↑ - ileum ↑ ↑ ↑ ↑ 
adi. tiss. - ↑ ↑ ↑ adi. tiss. - - - - 
EPA 
plasma - - ↑ - 
12-HEPE 
plasma - - - - 
liver - - - - liver - - - - 
ileum ↑ ↑ ↑ - ileum - - - - 
adi. tiss. - - - - adi. tiss. ↑ ↑ ↑ ↑ 
PGE3 
plasma ↑ ↑ ↑ ↑ 
TBXB3 
plasma - - - - 
liver - - - - liver - - - - 
ileum - - - - ileum ↑ ↑ ↑ ↑ 
adi. tiss. - - - - adi. tiss. ↑ ↑ ↑ ↑ 
10,17-
DiHDoHE 
plasma ND ND ND ND 
19,20-
DiHoPE 
plasma ↑ ↑ ↑ ↑ 
liver ND ND ND ND liver - - - - 
ileum - - - - ileum - ↑ ↑ - 
adi. tiss. ↑ ↑ ↑ ↑ adi. tiss. - ↑ ↑ ↑ 
17 keto-
DHA 
plasma ↓ ↓ ↓ ↓ 
 
liver ↓ ↓ ↓ ↓ 
ileum - - - - 
adi. tiss. ↑ ↑ ↑ ↑ 
Table 5.2 (1/5): Effect of LPS treatment on in vivo eicosanoid and endocannabinoid levels in mice. Only statistically significant 
effects are listed, with ↑ representing an increase and ↓ a decrease by LPS, respectively. ND indicates that the compound was 
not detected in the particular matrix, and ‘-‘ indicates that no statistical differences were observed. Adi. tiss.= adipose tissue. 
  
  
CYP metabolites 2 hr 4 hr 8 hr 24 hr 
 
 2 hr 4 hr 8 hr 24 hr 
5,6-EET 
plasma ND ND ND ND 
5,6-
DiHETrE 
plasma - - - ↑ 
liver ND ND ND ND liver - - - - 
ileum ND ND ↑ - ileum ↑ - ↑ - 
adi. tiss. ↑ ↑ ↑ ↑ adi. tiss. - - - - 
  
8,9-EET 
plasma ND ND ND ND 
8,9-
DiHETrE 
plasma - - - - 
liver - - - - liver - - - - 
ileum ↑ ↑ ↑ ↑ ileum ↑ ↑ ↑ ↑ 
adi. tiss. ND ND ND ND adi. tiss. ↑ ↑ ↑ ↑ 
  
11,12-
DiHETrE 
plasma ↑ ↑ ↑ ↑ 
14,15-
DiHETrE 
plasma - ↑ - ↑ 
liver - - - - liver - - - - 
ileum ↑ ↑ ↑ ↑ ileum ↑ ↑ ↑ ↑ 
adi. tiss. - - - - adi. tiss. - - - - 
  
9,10-
DiHOME 
plasma - - ↑ ↑ 
12,13-
DiHOME 
plasma - - ↑ ↑ 
liver ↓ ↓ ↓ ↓ liver - - - - 
ileum - - - - ileum - - - - 
adi. tiss. - - - - adi. tiss. - - - - 
Table 5.2 (2/5): Effect of LPS treatment on in vivo eicosanoid and endocannabinoid levels in mice. Only statistically significant 
effects are listed, with ↑ representing an increase and ↓ a decrease by LPS, respectively. ND indicates that the compound was 
not detected in the particular matrix, and ‘-‘ indicates that no statistical differences were observed. Adi. tiss.= adipose tissue. 
  
 
 
 
COX metabolites 2 hr 4 hr 8 hr 24 hr 
 
 2 hr 4 hr 8 hr 24 hr 
  
 PGE2 
plasma ↑ ↑ - - 
12-HHTrE 
plasma ↓ ↓ ↓ ↓ 
liver - - - - liver - - - - 
ileum - - - - ileum - - - - 
adi. tiss. ↑ ↑ ↑ ↑ adi. tiss. ↑ - - - 
  
13,14-
dihydro-
15-
keto-
PGE2 
plasma ↑ ↑ ↑ ↑ 
13,14-
dihydro-
15-keto-
PGF2a 
plasma - - - - 
liver ND ND ND ND liver ↑ ↑ ↑ ↑ 
ileum - - - - ileum - - - - 
adi. tiss. - - - - adi. tiss. - - - - 
 
 
TBXB2 
plasma ↓ ↓ ↓ ↓ 
liver - - - - 
ileum - - - - 
adi. tiss. - - - - 
 
Table 5.2 (3/5): Effect of LPS treatment on in vivo eicosanoid and endocannabinoid levels in mice. Only statistically significant 
effects are listed, with ↑ representing an increase and ↓ a decrease by LPS, respectively. ND indicates that the compound was 
not detected in the particular matrix, and ‘-‘ indicates that no statistical differences were observed. Adi. tiss.= adipose tissue. 
  
  
LOX metabolites 2 hr 4 hr 8 hr 24 hr 
 
 2 hr 4 hr 8 hr 24 hr 
  
13-
HODE 
plasma ↑ ↑ ↑ ↑ 
LTE4 
plasma ND ND ND ↑ 
liver - - - - liver ND ND ND ND 
ileum - - - - ileum ND ND ND ND 
adi. tiss. ↑ ↑ ↑ ↑ adi. tiss. ↑ ↑ ↑ ↑ 
  
Lipoxin 
A4 
plasma - - - - 
5-HETE 
plasma ND ND ND ND 
liver - - - - liver - - - - 
ileum - - - - ileum ↑ ↑ ↑ ↑ 
adi. tiss. - - ↑ - adi. tiss. ↑ ↑ ↑ ↑ 
 
 
9,12,13-
TriHOME 
plasma - - - - 
liver - - - - 
ileum - - - - 
adi. tiss. ↑ ↑ ↑ ↑ 
 
Table 5.2 (4/5): Effect of LPS treatment on in vivo eicosanoid and endocannabinoid levels in mice. Only statistically significant 
effects are listed, with ↑ representing an increase and ↓ a decrease by LPS, respectively. ND indicates that the compound was 
not detected in the particular matrix, and ‘-‘ indicates that no statistical differences were observed. Adi. tiss.= adipose tissue. 
  
 
 
 
NAEs 2 hr 4 hr 8 hr 24 hr 
 
 2 hr 4 hr 8 hr 24 hr 
  
AEA 
plasma - - - - 
DHEA 
plasma ↑ ↑ ↑ ↑ 
liver ↑ ↑ ↑ ↑ liver ↑ ↑ ↑ ↑ 
ileum ↑ ↑ ↑ ↑ ileum - - - - 
adi. tiss. - - - - adi. tiss. - - - - 
  
EPEA 
plasma - ↑ ↑ - 
OEA 
plasma - ↑ ↑ ↑ 
liver - ↑ ↑ - liver ↑ ↑ ↑ ↑ 
ileum ↑ ↑ ↑ ↑ ileum ↑ ↑ - - 
adi. tiss. - - - - adi. tiss. - - ↑ ↑ 
  
PEA 
plasma - ↑ ↑ ↑ 
SEA 
plasma - ↑ ↑ ↑ 
liver - - - - liver - - - - 
ileum ↑ ↑ ↑ ↑ ileum ↑ ↑ ↑ ↑ 
adi. tiss. - - - - adi. tiss. - - - - 
 
Table 5.2 (5/5): Effect of LPS treatment on in vivo eicosanoid and endocannabinoid levels in mice. Only statistically significant 
effects are listed, with ↑ representing an increase and ↓ a decrease by LPS, respectively. ND indicates that the compound was 
not detected in the particular matrix, and ‘-‘ indicates that no statistical differences were observed. Adi. tiss.= adipose tissue. 
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LPS treatment had minor effects on liver eicosanoid levels 
In contrast to plasma, only minimal effects of LPS treatment on liver eicosanoid 
levels were observed, with only 3 compounds significantly altered (Table 5.2 and 
Figure 5.3). Levels of 13,14-dihydro-15-keto-PGF2α were significantly increased by 
LPS over all time points. Levels of 17-keto-DHA and 9,10-DiHOME were decreased 
by LPS at all time points.  
Liver levels of AEA, DHEA and OEA were increased by LPS at all time points, 
whereas EPEA was only increased after 4 and 8 hrs followed by normalization at 
24 hr.  
 
LPS treatment affected CYP-derived eicosanoids and NAE levels in ileum  
Out of all components quantified, 12 eicosanoids were significantly increased by 
LPS (Table 5.2 and Figure 5.4) in the ileum. Most of the eicosanoids were 
increased at  all time points, including three DiHETrE compounds, 8,9-EET, TBXB3, 
5-HETE, and the fatty acids (ARA, DHA and EPA). Interestingly, 5,6-EET was 
increased after 8 hrs in the LPS group and its metabolite 5,6-DiHETrE was 
increased after 2 and 8 hrs, whereas the other EETs and DiHETrEs were increased 
over a broader time range.  
Levels of AEA, EPEA, OEA, PEA and SEA were increased 2 hrs after LPS stimulation 
and remained high at least until 4 hrs (OEA), but in general until 24 hrs after LPS 
stimulation.  
 
Adipose tissue eicosanoid levels were differentially affected by LPS 
In adipose tissue, 15 eicosanoids were significantly increased after LPS treatment, 
all belonging to several branches of the eicosanoid pathway (Table 5.2 and Figure 
5.5). Higher levels of PGE2, TBXB3, 5-HETE, 5,6-EET, 8,9-DiHETrE, and the n-3 fatty 
acid derived compounds, 12-HEPE and 10,17-DiHDoHE, were observed at all time 
points. Levels of 19,20-DiHoDE, another n-3 derived compound, were also 
increased by LPS, but only from 4 hr and further. Other eicosanoids showed also 
different time effects, for example; 12-HHTrE only increased after 2 hrs of LPS, 
10,17-DiHDoHE showed peak levels at 8 hrs, and ARA levels were still increasing at 
24 hrs after LPS treatment. Adipose tissue levels of DHA and EPA were not 
affected by LPS. 
From the NAEs, only OEA levels were increased at 8 and 24 hrs after LPS 
treatment.  
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Figure 5.2: Time curves of mean plasma eicosanoid and endocannabinoid concentration levels in mice after treatment with either saline or LPS. 
Data indicate mean ± standard deviation (n=1 for 24 hr LPS plasma endocannabinoid analysis; n=3 for 24 hr LPS eicosanoid analysis; n=4 for all 
other analyses). Time points with a significant LPS effect are marked (* P < 0.05; ** P < 0.01; *** P < 0.001).  
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Figure 5.3: Time curves of mean liver eicosanoid and endocannabinoid concentration levels in mice after treatment with either saline or 
LPS. Data indicate mean ± standard deviation (n=3 for 8 hr saline liver endocannabinoid analysis; n=3 for all 24 hr LPS analyses; n=4 for all 
other analyses). Time points with a significant LPS effect are marked (* P < 0.05; ** P < 0.01; *** P < 0.001). 
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Figure 5.4: Time curves of mean ileum eicosanoid and endocannabinoid concentration levels in mice after treatment with either saline or 
LPS. Data indicate mean ± standard deviation (n=3 for all 24 hr LPS analyses; n=4 for all other analyses). Time points with a significant LPS 
effect are marked (* P < 0.05; ** P < 0.01; *** P < 0.001). 
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Figure 5.5: Time curves of mean adipose tissue eicosanoid and 
endocannabinoid concentration levels in mice after treatment with either saline 
or LPS. Data indicate mean ± standard deviation (n=3 for all 24 hr LPS analyses; 
n=4 for all other analyses). Time points with a significant LPS effect are marked 
(* P < 0.05; ** P < 0.01; *** P < 0.001).  
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Discussion 
Eicosanoids and endocannabinoids are important regulators of inflammation, with 
highly dynamic concentrations. Considering the complexity of eicosanoid and 
endocannabinoid metabolism, it is likely that inflammation affects multiple 
compounds at the same time, and that differential effects between plasma and 
tissues exist. However, so far most studies have only focused on a limited number 
of (established) compounds in a restricted number of tissues or plasma instead of 
evaluating profiles of compounds. In addition, little is known about the effect of 
inflammation on (more recently discovered) n-3 fatty acid derived metabolites. 
The purpose of this study was to systematically evaluate the profiles of bioactive 
lipids using a multi-compartment targeted lipidomics approach in plasma and 
tissues following an inflammatory stimulus in mice fed a fish oil diet. The data 
show time- and tissue-dependent effects in all compartments, with the highest 
number of eicosanoids altered in ileum and adipose tissue.  
Due to technical advances in the field of mass spectrometry, the capability to 
adequately measure more compounds at lower concentration levels in biological 
matrices has increased. Tandem MS methods capable of measuring > 80 
compounds or more in a single analytical run are not unusual [23-25]. When 
considering all pathways and substrates in the fatty acid metabolome, this 
number of compounds is easily met. Their simultaneous quantification could 
potentially give new insights in associations between bioactive lipids after e.g. 
inflammatory stimulus or dietary intervention. Despite the advances in analytical 
chemistry, adequate bioactive lipid quantification is challenging due to their broad 
concentration range and different physiological characteristics. However , it is of 
high relevance to understand which bioactive lipids are formed and present at 
what time point after e.g. an inflammatory stimulus or dietary intervention, 
because regulation of their synthesis can depend on e.g. enzyme activity, time 
and availability of parent compounds.  
Al already mentioned above, it can be concluded from our study that LPS 
treatment changed the profile of many bioactive lipids, which differed in time and 
were tissue specific, and with the most pronounced effects in ileum and adipose 
tissue. In the discussion, we will mainly focus on contrastive effects of LPS on 
eicosanoids across plasma and tissues, differential effects of LPS on eicosanoids 
derived from CYP enzymes, n-3 fatty acid derived eicosanoids, and finally effects 
on NAEs. 
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Interestingly, some contrastive effects of LPS on eicosanoids were seen. LPS 
treatment decreased the levels of 12-HHTrE, a PGH2 metabolite [26] in plasma, 
whereas adipose tissue levels were increased. However, at the same time, plasma 
and adipose tissue levels of PGE2, another PGH2 metabolite [27], were increased 
by LPS. This could indicate selective synthesis towards PGE2 at the expense of 12-
HHTrE in plasma, or specific breakdown or uptake in e.g. adipose tissue of plasma 
12-HHTrE. Similar opposite effects were observed for 9,10-DiHOME, which was 
increased in plasma, but decreased in liver after LPS. The significance and origin of 
this is not understood and requires further investigation.  
LPS treatment affected eicosanoids derived from different enzymes, including 
COX- and LOX metabolites, and several differential effects were observed for CYP 
metabolites. Interestingly, we observed little effects in liver although it contains 
considerable levels of CYP. Theken and cowokers recently demonstrated that 
intrahepatic LPS reduced liver expression of several CYP enzymes after 24 hrs in 
mice, paralleled by decreased EET and HETE levels [28]. In our study, LPS 
treatment altered only few eicosanoids in liver, with only 13,14-dihydro-15-keto-
PGF2α increased and no effects on EETs or DiHETrEs were observed, but this 
discrepancy might relate to the fish oil diet which was used in the present study or 
the administration route of LPS. However, other work demonstrated that 
chemically induced colitis can reduce liver CYP enzyme expression [29], indicating 
that hepatic CYP expression can also be decreased when the site of inflammation 
is the intestine, such as the i.p. route in our work. Levels of 9,10-DiHOME, another 
compound related to the CYP pathway, was reduced in our work, which is in line 
with the effects on CYP enzymes published by Theken and coworkers.  
In contrast to liver, we have observed numerous effects of LPS treatment on CYP 
metabolites in plasma and ileum. Levels of 11,12-EET, 5,6- DiHETrE, 11,12- 
DiHETrE and 14,15-DiHETrE in plasma, and 5,6-DiHETrE and 14,15-DiHETrE in 
ileum were increased by LPS. So far, most research on EETs focuses on effects on 
the vascular bed, cardiovascular health and ion channels, with few reports on 
intestinal effects. Their increase after LPS in the intestine might point to a new 
role for these compounds in gut inflammation, as these compounds are also 
known for their anti-inflammatory properties [3]. Ileum shows highest levels of 
5,6-EET and 8,9-EET at 8 hrs after LPS, whereas in adipose tissue 5,6-EET levels 
peaked already after 2 hrs LPS, suggesting differential regulation of EET levels 
across different tissues.   
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The metabolism of n-3 fatty acids to e.g. eicosanoids and resolvins has received 
much attention due to their proposed anti-inflammatory properties. The effect of 
LPS treatment on n-3 fatty acid derived mediators could also be investigated as 
the mice received a fish oil diet for 6 weeks prior to the LPS treatment. Therefore, 
we hypothesized that these metabolites would be liberated by an inflammatory 
stimulus after consuming a fish oil diet. Levels of 10,17-DiHDoHE, 19,20-DiHoPE, 
and 17-keto-DHA were increased by LPS in certain instances. In contrast to our 
expectations, no resolvins were detected in any tissue at any time after LPS 
injection. The class of resolvins has attracted much attention over the last years 
due to their active inflammation resolving properties in relation to n-3 fatty acids 
[12, 30]. Possibly, resolvins are not released until 24 hrs after initiation of 
inflammation, or their levels remained below the detection limit of the LC-MS/MS 
method. Despite this, 10,17-DiHDoHE, also known as Protectin DX, and 
structurally related to 17-HDoHE, which is a marker for resolving synthesis [30, 
31], was increased in adipose tissue after LPS challenge. The role of this 
compound in adipose tissue inflammation has not been explored yet, but is 
potentially relevant for metabolic diseases such as the metabolic syndrome which 
is characterized by adipose tissue inflammation. In contrast to effects on 10,17-
DiHDoHE, no effects of LPS treatment on 17-HDoHE levels were found in the 
present study.  
Next tot the resolvins and related compounds, n-3 fatty acids can also be 
converted to certain prostaglandins, such as PGE3. LPS treatment triggered the 
increase of PGE3 in plasma and TBXB3 in ileum and adipose tissue. Ileal TBXB3 
levels peaked after 2 hrs, whereas in adipose tissue the increase was more 
gradual. These compounds have pro-inflammatory and pro-aggregatory 
properties, but are less potent than their ARA-derived counterparts and may thus 
be involved in the anti-inflammatory properties associated with dietary intake of 
n-3 fatty acids. PGE2 and PGE3 were not detected in plasma after saline, but were 
visible after LPS treatment. In plasma however, PGE2 showed early peak levels and 
no significant increase after 24 hrs of LPS, whereas PGE3 levels gradually increased 
over time with the strongest increase after 24 hrs. PGE2 is a commonly studied 
plasma marker of an inflammatory response. Our data demonstrate again that 
studying markers like PGE2 in isolation from other markers may lead to the wrong 
conclusion that the inflammatory response might have already turned down. 
Although it is accepted that both PGE2 and PGE3 are synthesized via the same 
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pathway, clearly different factors are involved in determining their ultimate levels. 
A comparable pattern is seen for the EETs/DiHETrEs in ileum, where 5,6-EET and 
its metabolite 5,6-DiHETrE were only increased after 8 hr, whereas other EETs and 
DiHETrEs were increased over a broader time range, although with peak levels 
after 8 hrs. It has been described that different CYP enzymes synthesize distinct 
proportions of the different EETs, with e.g. CYP2C8 and CYP2C9 producing specific 
ratios of 11,12-EET and 14,15-EET [32]. Inflammation is known to have different 
effects on CYP enzymes [33], thereby potentially affecting the EET profile. Specific 
regulation of CYP enzymes by LPS in the ileum might explain this difference, but 
further research should elucidate this. 
TBXB2, the inactive metabolite from TBXA2, was decreased in plasma after LPS at 
all time points. TBXA2 is normally involved in platelet aggregation and 
vasoconstriction. Previous work demonstrated that during endotoxemic shock 
TBXA2 levels would first increase, followed by a subsequent decrease [34]. 
Interestingly, in the present study, 24 hrs after LPS administration, the mice 
showed severe signs of systemic inflammation, including shock, which might 
relate to the decrease in TBXA2 levels, but this remains speculative at this point. 
Moreover, it is likely that the shock symptoms were caused by alterations in the 
eicosanoid and endocannabinoid metabolomes as a whole, rather than by 
individual compounds.  
LPS clearly increased NAE levels in ileal tissue, resulting in increased levels of most 
NAEs from 2 hrs after LPS treatment, with enhanced levels still present after 8 or 
24 hrs. Increases in plasma or adipose tissue NAE levels were usually at later time 
points, if present. These findings are in line with a previously hypothesized role of 
the endocannabinoid system in protecting against inflammatory stress in the gut 
[17, 20] or elsewhere [18, 21]. Interestingly, although levels of EPEA were affected 
by LPS in both plasma and ileum, DHEA levels were barely affected. In addition, in 
contrast to previous reports suggesting increased levels of systemic AEA during 
inflammation [19], we did not find significant effects on plasma AEA levels after 
LPS treatment. This might relate to the differences in diets between the studies, 
as dietary n-3 fatty acids are known to decrease levels of AEA in at least peripheral 
tissues [35-37]. The dietary fish oil might have decreased baseline plasma AEA 
levels, and this might translate into a poor response of plasma AEA to 
inflammatory stress. 
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In contrast to limited effects on hepatic eicosanoid levels, hepatic levels of the 
endocannabinoids AEA, DHEA, EPEA and OEA were affected by LPS. Other work, 
investigating effects of hepatic reperfusion injury on liver endocannabinoids, also 
observed increased levels of AEA and OEA [38]. Interestingly, the latter study also 
showed that AEA and 2-AG levels correlated with markers of inflammation and 
tissue damage, and that targeting CB2 receptors resulted in decreased 
inflammatory responses after reperfusion stress. Considering the anti-
inflammatory properties of DHEA and EPEA [15, 16] and binding to CB2 [39], their 
levels might also be involved in limiting hepatic tissue damage during 
inflammatory or reperfusion stress. 
Despite pronounced effect on eicosanoids in adipose tissue, only OEA levels were 
affected by LPS here. Obesity, also characterized by induction of inflammation in 
the adipose tissue compartment [40], is known to result in changes in 
endocannabinoid levels. Epididymal fat of diet-induced obese mice or visceral fat 
from obese humans contained more 2-AG than their controls, but also effects of 
obesity on AEA were found [41]. Unfortunately, the authors did not report any 
effects on OEA or other NAEs in these studies. Interestingly, in subcutaneous 
adipose tissue, a high fat diet reduced AEA and 2-AG levels [42]. This shows that 
different adipose tissue compartments can react differently to different types of 
inflammatory stress, and more work is needed to understand this.  
In summary, we demonstrated that treatment of mice with LPS when fed a fish oil 
diet changed the profile of eicosanoids and endocannabinoids in plasma, liver, 
ileum and adipose tissue. Effects were observed during a 24 hr time course, with 
tissue and compound specific differences. Feeding mice with a fish oil diet yielded 
detectable levels of n-3 derived eicosanoids and endocannabinoids. Markers of 
resolvin synthesis were detected, but the resolvins themselves were not 
detectable 24 hrs after induction of inflammation. The data indicate that changes 
in plasma profiles do not reflect effects in tissues, thus meaning that extrapolating 
effects in plasma to biological effects in tissues is not valid without further 
investigation. Nevertheless, it is clear that during in vivo inflammation the levels 
of eicosanoids and endocannabinoids are highly dynamic. Therefore, if we want to 
better understand the role of eicosanoids in endocannabinoids in (patho)-
physiology, it is important to determine the profile of these metabolomes rather 
than quantifying individual compounds.  
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Abstract 
 
It is well established that dietary intake of n-3 fatty acids is associated with anti-
inflammatory effects, and this has been linked to modulation of the eicosanoid 
and endocannabinoid metabolomes. However, the amount of data on specific 
tissue effects is limited, and it is not known how inflammation affects this relation.  
In the present study we systematically explored the combined effects of n-3 fatty 
acid diets and inflammation on the in vivo endocannabinoid and eicosanoid 
metabolomes using a multicompartment, detailed targeted lipidomics approach. 
Male C57BL/6 mice received diets containing 0%, 1%, or 3% w/w fish oil (FO) for 6 
weeks, after which 2 mg/kg LPS or saline was administered i.p. Levels of 
endocannabinoids/N-acylethanolamines (NAEs) and eicosanoids, covering n-3 and 
n-6 fatty acid derived compounds, were determined in plasma, liver, ileum and 
adipose tissue using LC-MS/MS. FO generally increased ‘n-3’ NAEs and eicosanoids 
at the expense of compounds derived from other fatty acids, affecting all 
branches of the eicosanoid metabolome. LPS generally increased levels of 
endocannabinoids/NAEs and eicosanoids, with opposing effects across plasma 
and tissues. Multivariate data analysis revealed that separation between diet 
groups in the saline treated groups was primarily explained by decreases in other 
than n-3 derived compounds. In the LPS treated groups, the separation was 
primarily explained by increases in n-3 derived compounds. In conclusion, FO 
caused marked changes in the n-3 to n-6 balance of the endocannabinoid and 
eicosanoid metabolomes, with specific effects depending on inflammatory status. 
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Introduction 
Dietary intake of long-chain n-3 polyunsaturated fatty acids (PUFAs), like 
docosahexaenoic acid (DHA; 22:6 n-3) and eicosapentaenoic acid (EPA; 20:5 n-3), 
is known to have beneficial health effects in both humans and animals, which are 
partly explained by a reduction of inflammatory processes [1-4]. The mechanisms 
behind this are not completely understood, but involve binding of n-3 PUFAs to 
GPR120 [5], their conversion to resolvins [6], and the alteration of the eicosanoid 
balance [1]. Increased dietary intake of n-3 PUFAs leads to enhanced 
incorporation of DHA and EPA in cell membranes, at the expense of incorporation 
of the n-6 PUFA arachidonic acid (ARA; 20:4 n-6). This results in decreased 
synthesis of ARA-derived eicosanoids,  for example prostaglandin E2 (PGE2), after 
e.g. an inflammatory stimulus [7]. At the same time, increased levels of n-3 fatty 
acid derived eicosanoids are observed. These n-3 fatty acid derived metabolites 
are often referred to as ‘3-series’ or ‘5-series’ eicosanoids, comprising structures 
like prostaglandin D3 (PGD3), PGE3, thromboxane B3 (TBXB3), and 5-
hydroxyeicosapentaenoic acid (5-HEPE), or leukotriene B5 (LTB5), respectively (see 
Figure 6.1a and 6.1b for an overview of eicosanoids and their origin). These 
compounds are in general also pro-inflammatory, but considered less potent than 
the ARA-derived metabolites under certain circumstances, thereby contributing to 
a reduction of the general inflammatory status and specific inflammatory 
processes associated with fish oil consumption [1, 3, 4].  
Over the last decades, several endocannabinoids and related N-acyl 
ethanolamines (NAEs) have emerged as important regulators of metabolism and 
inflammation [8-11]. Like the eicosanoids, these compounds are also derived from 
fatty acids following incorporation in cell membranes [12, 13]. Arachidonoyl 
ethanolamide (anandamide, AEA) and 2-arachidonoyl glycerol (2-AG) are two 
endocannabinoids which are derived from arachidonic acid, but combinations 
derived with other fatty acids also exist, such as palmitoyl ethanolamide (PEA) and 
the n-3 fatty acid derived NAEs docosahexaenoyl ethanolamide (DHEA), 
eicosapentaenoyl ethanolamide (EPEA). Both AEA and PEA are known for their 
anti-inflammatory properties [14, 15].  
Several in vitro and animal studies have demonstrated a link between availability 
of specific fatty acids in the diet and the presence of endocannabinoids and 
related NAEs. Berger and coworkers reported enhanced levels of anandamide and 
2-AG in piglet brain after feeding milk supplemented with ARA, with a diet rich in  
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DHA showing even higher levels of its NAE metabolite, DHEA [16]. Wood and 
coworkers showed that a two-week diet rich in DHA elevated plasma and brain 
levels of DHEA in mice, while decreasing plasma 2-AG [17]. Artmann and 
coworkers demonstrated that feeding rats a fish oil (FO) diet, by nature rich in n-3 
PUFAs, decreased jejunal levels of AEA and PEA, but increased the levels of n-3 
NAEs DHEA and EPEA [18]. Fish oil also decreased adipose tissue levels of AEA and 
2-AG in a rat model of obesity [19]. It thus seems that the profile of NAEs  
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Figure 6.1a: Overview of enzymatic pathways involved in 
eicosanoid and NAE synthesis. Arachinoic acid is the best 
studied precursor for eicosanoid synthesis, but linoleic 
acid can also serve as substrates for different enzymes, 
including COX, CYP and the LOX isoenzymes, yielding 
distinct eicosanoids and intermediates.  
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Figure 6.1b: Overview of enzymatic pathways involved in eicosanoid and NAE synthesis. 
EPA and DHA can also serve as substrates for different enzymes, including COX, CYP and 
the LOX isoenzymes, yielding distinct eicosanoids, intermediates, and NAEs.  
 
represents the relative abundance of fatty acids in the diet.  Recently, is was 
shown that DHEA and EPEA display anti-inflammatory properties in macrophages 
and adipocytes [20, 21], indicating that these compounds might be involved in the 
anti-inflammatory effects which are related to dietary n-3 PUFA intake.  
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In addition to diet, inflammation is also known to affect the synthesis and/or 
release of both eicosanoids and NAEs [22], but it is not known how inflammation 
itself affects e.g. DHEA and EPEA tissue levels in vivo. Moreover, it is not known if 
changes induced by dietary fatty acids also persist under inflammatory conditions, 
or if the effect of diet is different under inflammatory conditions. 
In the present study, we systematically explored in detail the (combined) effect of 
dietary fish oil and inflammation on levels of endocannabinoids/NAEs and 
eicosanoids in plasma, liver, ileum and adipose tissue of wild type C57BL/6 mice 
using a targeted lipidomic approach. In total, levels on 61 compounds were 
analyzed, including levels of PGE3, PGD3, TBX-B3, 5-HEPE, resolvin D1, DHEA and 
EPEA. Both univariate and multivariate data analysis tools were used to assess 
differences in metabolite patterns between the intervention groups. Our data 
show in detail that dietary intake of fish oil shifted the n-3 to n-6 balance in the 
endocannabinoid and eicosanoid metabolomes in all tissues examined. In 
addition, the direction of this shift appeared to be affected by inflammation, and 
was different between the examined tissues. 
 
Materials and methods 
Chemicals and reagents 
Lipopolysaccharide (0111:B4; LPS), indomethacin, paraoxon and butylated 
hydroxytoluene (BHT) were from Sigma (Steinheim, Germany). 
Phenylmethylsulfonyl fluoride (PMSF) was from Fluka (Steinheim, Germany). 12-
[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid (AUDA) and 
URB602 was purchased from Cayman (Ann Arbor, MI, USA). Milli-Q water (Milli-Q 
Advantage unit, Millipore, Amsterdam, The Netherlands) was used in all analyses. 
ULC-grade acetonitrile (ACN), formic acid (FA) and trifluoro acetic acid (TFA) were 
obtained from Biosolve (Valkenswaard, The Netherlands). LC-MS grade methanol 
was from Riedel-de-Häen (Steinheim, Germany). Isopropanol and ethanol were 
from JT Baker (Deventer, The Netherlands). All analytical and internal standards, 
except EPEA, were purchased from Cayman. EPEA was synthesized as described 
earlier [23]. For eicosanoids, stock solutions were prepared in ethanol, aliquoted 
and stored at -80 °C until analysis. For endocannabinoids/NAEs, stocks were 
prepared in ACN, aliquoted and stored at -80 °C until analysis. C8 SPE columns 
(Bond Elut; 200 mg, 3 mL) were from Varian Inc (Lake Forest, CA, USA). HLB SPE 
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columns (Oasis, 60 mg, 3 mL) were from Waters (Etten-Leur, The Netherlands). 
ELISA kits were from R&D Systems (Minneapolis, MN, USA). 
 
Animal experiment 
Wild type male C57BL/6 mice were obtained from Harlan (Horst, The Netherlands) 
and housed two or three per cage in a temperature controlled environment with a 
12 hour light-dark cycle (light at 6.00-18.00). The mice, 4 weeks old at arrival, had 
free access to a standard run-in diet (AIN93-M, with a 4% w/w fat content 
whereof 1% soy bean oil and 3% high-oleic acid sunflower oil (HOSF)) for two 
weeks. At the age of 6 weeks the mice were divided in to three groups of 16 mice; 
group 1 was kept on the standard diet, group 2 received a diet containing AIN93-
M with 1% fish oil (1% FO) (Marinol®), 2% HOSF, and 1 % soy bean oil. The third 
group had access to a diet containing AIN93-M with 1% soy bean oil and 3% fish 
oil (3% FO). The diets and water were available ad libitum. Diets were prepared by 
Research Diet Services (Wijk bij Duurstede, The Netherlands) and the Marinol® 
was a kind gift from Lipid Nutrition (Wormerveer, The Netherlands). Diets were 
stored in air-tight bags at -20 °C until just before feeding, and fresh food was 
provided two times per week to minimize oxidation of the fatty acids in the diet. 
GC-MS based analysis of the diets confirmed that the correct amounts of DHA and 
EPA were present, and re-analysis after 4 weeks revealed that its amounts were 
stable under the described conditions (data not shown). Food consumption and 
animal weight were measured two times per week, revealing no differences in 
food intake or body weight between the diet groups. 
The diets were continued for six weeks, after which the animals received either 
i.p. saline (8 mice per diet group) or 2 mg/kg LPS (8 mice per diet group). After 24 
hrs, the animals were anesthetized, blood was collected from the orbital sinus and 
captured in 1.3 mL EDTA coated tubes (Sarstedt; Etten-Leur, The Netherlands) and 
put on ice until centrifugation (10’, 10,000 rpm at 4 °C). After centrifugation, 
plasma was aliquoted. For eicosanoid analysis, 200 µL plasma was stored in 1 mL 
methanol containing paraoxon, BHT, AUDA, indomethacin, and PMSF to prevent 
eicosanoid oxidation and breakdown. For endocannabinoid/NAE analysis, 100 µL 
plasma was stored in the presence of PMSF and URB602. Subsequently, the 
animals were sacrificed by cervical dislocation after which liver, ileum and adipose 
tissue were collected and immediately snap-frozen in liquid nitrogen. All plasma 
and tissue samples were stored at -80 °C until further analysis. Analysis of plasma 
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interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) levels confirmed 
that LPS had triggered an inflammatory response by showing strongly increased 
IL-6 and MCP-1 levels in LPS-treated mice (data not shown).  
The study was conducted according to the Netherlands Law on Animal 
Experiments, and approved by the local Animal Experiments Committee of 
Wageningen University. 
 
Extraction of endocannabinoids/NAEs from plasma 
Plasma (100 µL) was thawed and 400 µL extraction mixture containing 100 µM 
PMSF and internal standards (AEA-d8, 2-AG-d8 and OEA-d4) in ACN was added 
while the sample was gently vortexed. After subsequent centrifugation (5’ at 
13,000 rpm and RT), the supernatant was transferred to a clean eppendorf tube 
and evaporated to dryness in a vacuum concentrator (Scanvac; Lynge, Denmark). 
The dried extracts were reconstituted in 100 µL ACN containing 0.1% TFA and 
used for LC-MS/MS analysis. 
 
Extraction of endocannabinoids/NAEs from tissues 
Endocannabinoid/NAE were extracted from freeze-dried liver and ileum using a 
method adapted from a previously published protocol for plasma [24]. 
Approximately 50 mg freeze-dried liver or 10 mg freeze-dried ileum were 
extracted by adding 1 mL extraction mixture (ACN) and sonication. The samples 
were centrifuged (5’ at 14,000 rpm), the supernatant was transferred to a clean 
15 mL tube, and this was repeated once. The pooled ACN fractions were diluted 
with MQ water containing 0.13% TFA until the final ACN concentration was 20% 
prior to SPE clean-up as described before [24]. In short, columns were washed 
with 20% v/v ACN in MQ water containing 0.1% TFA, eluted with 80% v/v ACN in 
MQ water containing 0.1% TFA and evaporated to dryness using vacuum 
centrifugation. The dried extracts were reconstituted in 100 µL ACN containing 
0.1% TFA and used for LC-MS/MS analysis. 
For adipose tissue, approximately 100 mg ‘wet’ tissue was extracted with 1 mL 
extraction solution (ACN) by sonication. The samples were centrifuged for 5’ at 
14,000 rpm and RT, the supernatant was transferred to a clean 2.0 mL eppendorf 
tube, and the ACN extraction was repeated once. The 2 mL ACN extract was 
subsequently evaporated to dryness, reconstituted in 100 µL ACN containing 0.1% 
TFA and used for LC-MS/MS analysis. 
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Compounds Parent (m/z) Product (m/z) 
 
AEA 348 62 
2-AG (NH4 adduct) 379 (396) 287 
DHEA 372 62 
EPEA 346 62 
DLE 350 62 
OEA 326 62 
PEA 300 62 
SEA 328 62 
   
Internal standards 
AEA-d8 356 63 
OEA-d4 330 66 
2-AG-d8 (NH4 adduct) 387 (404) 294 
Table 6.1a: m/z Values of parent and product ions of endocannabinoids/NAEs used in the 
LC-MS/MS method. For tissue, 2-AG analyses (performed on TSQ Quantum MS), the 
ammonium adduct was the most dominant parent ion. For plasma 2-AG analyses 
(performed on Xevo TQ-S MS), the molecular ion (M+H) was the most dominant parent.  
 
LC-MS/MS analysis of endocannabinoids/NAEs 
Two LC-MS/MS systems were used for endocannabinoid/NAE analysis. Plasma 
extracts were analyzed by UPLC coupled to a Xevo TQ-S mass spectrometer 
(Waters; Etten-Leur, The Netherlands) because high sensitivity was essential for 
adequate quantification in extracts obtained from 100 µL plasma samples. Liver, 
ileum and adipose tissue were analyzed on a Surveyor HPLC coupled to a TSQ 
Quantum Discovery mass spectrometer (Thermo Finnigan; Breda, The 
Netherlands). 
For the UPLC-Xevo system, 3 µL plasma extract was injected on a Acquity C8 BEH 
UPLC column (2.1 x 100 mm, 1.7 µm) and was separated using gradient elution 
with a stable flow of  500 µL/min. The gradient started with 100% A (40:40:20 
v/v/v of MQ water : methanol : ACN with 0,1% FA) which was maintained until 
0.35 minutes, followed by a linear increase to 100% B (7:3 v/v methanol : ACN 
with 0.1% FA) which was achieved at 7.0 minutes and was maintained until 9.0 
minutes. Finally, the column equilibrated for 3 minutes at 100% A. The column 
was maintained at 60 °C during analysis, and the samples were kept at 10 °C. The 
MS was operating in selective reaction mode using electrospray ionization in 
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Compounds Parent (m/z) Product (m/z) 
 
12-HHTrE 279.0 179.3 
13-HODE  295.1 195.0 
9-HODE 295.1 171.0 
EPA 301.1 257.2 
ARA 303.1 259.2 
12,13-DiHOME 313.2 183.0 
9,10-DiHOME 313.2 201.0 
15-deoxy-d-12,14-PGJ2 315.0 271.1 
12-HEPE 317.2 179.0 
5-HEPE 317.2 115.0 
11,12-EET 319.1 167.0 
12-HETE 319.1 179.2 
5-HETE 319.1 203.1 
14,15-EET 319.1 219.2 
5,6-EET 319.1 191.3 
11-HETE 319.1 167.0 
8,9-EET 319.1 167.0 
15-HETE 319.2 219.1 
20-HETE 319.2 275.3 
2,3-dinor-8-iso-PGF2α 325.1 237.2 
DHA 327.1 283.1 
9,10,13-TriHOME  329.2 171.1 
9,12,13-TriHOME  329.2 211.1 
PGB2 333.2 174.9 
LTB4 335.1 194.8 
14,15-DiHETrE 337.1 207.0 
11,12-DiHETrE 337.1 166.9 
5,6-DiHETrE 337.1 144.8 
8,9-DiHETrE 337.1 127.0 
17-keto-4(z),7(z),10(z),13(z),15(e),19(z) DHA 341.5 111.0 
17-HDoHE 343.1 281.4 
PGE3 349.0 269.1 
PGD3 349.1 269.1 
PGD2 351.1 271.1 
Lipoxin A4 351.1 114.9 
13,14-dihydro-15-keto-PGD2 351.1 175.0 
13,14-dihydro-15-keto-PGE2 351.1 175.1 
PGE2 351.1 271.2 
13,14-dihydro-15-keto-PGF2α 353.1 113.1 
8-iso-PGF2α 353.1 193.0 
11β-PGF2α 353.1 193.0 
PGF2α 353.1 193.0 
PGF2β 353.2 193.1 
10,17-DiHDoHE 359.1 152.9 
Maresin 359.6 177.1 
19,20-DiHDoPE 361.1 272.7 
TBXB3 367.1 168.9 
TBXB2 369.1 169.0 
Resolvin D2 375.1 175.0 
Resolvin D1 375.1 140.8 
LTE4 438.0 351.0 
n-acetyl LTE4 480.0 351.1 
LTD4 495.1 142.9 
Table 6.1b: m/z Values of parent and product ions of eicosanoids used in the LC-MS/MS 
analysis. Compounds are ranked based on their parent m/z value. 
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Internal standards Parent (m/z) Product (m/z) 
   
13-HODE-d4 299.2 198.2 
ARA-d8 311.2 267.2 
20-HETE-d6 325.1 281.3 
15-HETE-d8 327.2 226.1 
14,15-EET-d11 330.2 268.3 
PGB2-d4 337.1 178.9 
CUDA 339.1 214.1 
LTB4-d4 339.1 197.1 
8,9-DiHETrE-d11 348.2 127.0 
PGE2-d4 355.1 275.1 
13-14-dihydro-15-keto-PGF2α-d4 357.1 187.0 
8-iso-PGF2α-d4 357.1 196.9 
11β-PGF2α-d4 357.1 313.4 
PGF2α-d4 357.1 313.4 
PGD2-d9 360.3 280.1 
TBXB2-d4 373.1 173.0 
LTD4-d5 500.0 142.9 
Table 6.1b (cont.): m/z Values of parent and product ions of eicosanoids used in the LC-
MS/MS analysis. Compounds are ranked based on their parent m/z value. 
 
positive ion mode, with a capillary voltage of 1.5 kV, a source temperature of 
150 °C and a desolvation temperature of 500 °C. Cone voltage and collision energy 
were optimized for each compound individually (see Table 6.1a for parent and 
product m/z values). Peak identification and quantification was performed using 
MassLynx software version 4.1. Calibration curves were run in duplicate from 
which one regression equation was generated.  
For the analysis of liver, ileum and adipose tissue, a TSQ Quantum Discovery was 
used as described before [24]. Five µL extract was separated on an Xterra C8 MS 
column (2.1 x 150 mm, 3.5 µm) using gradient elution with a constant flow of 
150 µl/min. The same solutions were used as in the Xevo system, but now 1 g/L 
ammonium acetate was added (the most dominant parent for 2-AG in this MS is 
the ammonium adduct). The gradient started with 100% A which was maintained 
until 2.0 minutes, followed by a linear increase to 100% B which was achieved at 
8.00 minutes and maintained until 16.0 minutes, and the column was left to 
equilibrate for 5 minutes at 100% A. The column was maintained at 40 °C during 
analysis and the samples were cooled at 4 °C. The MS was operating in selective 
reaction mode using electrospray ionization in positive ion mode, with a capillary 
voltage of 4.5 kV and a capillary temperature of 350 °C. Cone voltage and collision 
energy were optimized for each compound individually. Peak identification and 
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quantification was performed using LCquan software version 2.5.5. Calibration 
curves were run in duplicate from which one regression equation was generated. 
 
Extraction of eicosanoids from plasma 
Internal standards were added to the plasma samples which were already 
precipitated with methanol (see section ‘animal experiment’), and the samples 
were put on ice for 30 minutes. Samples were subsequently centrifuged (5’ at 
3000 x g and 4 °C) and the supernatant was transferred to a glass tube. Just 
before loading on activated HLB columns, 4.75 mL MQ water containing 0.1% v/v 
FA was added to the methanol extract, diluting the extract to 20% methanol. After 
loading, the columns were washed with 2 mL 20% methanol in MQ water 
containing 0.1% FA, and the columns were allowed to dry for 15 minutes. The SPE 
columns were eluted with 2 mL methanol and the samples were captured in tubes 
already containing 20 µL of 10% glycerol and 500 µM BHT in ethanol. The tubes 
were placed in a water bath at 40 °C and the methanol was evaporated under a 
gentle stream of nitrogen, after which the samples were reconstituted in 100 µL 
ethanol containing another internal standard (CUDA) and immediately used for 
LC-MS/MS analysis. 
 
Extraction of eicosanoids from tissues 
The extraction of eicosanoids from liver, ileum and adipose tissue was similar to 
plasma eicosanoid extraction. Approximately 100 mg liver and adipose tissue, and 
50 mg ileum was extracted with 1 mL methanol containing internal standards and 
sonication. After centrifugation (5’ at 3000 x g and 4°C), the supernatants were 
transferred to clean tubes and the methanol extraction was repeated once. Just 
before loading on HLB SPE columns, 8 mL MQ water containing 0.1% formic acid 
was added to the methanol extracts. For the SPE procedure and further, see 
section ‘Plasma extraction of eicosanoids’.  
 
LC-MS/MS analysis of eicosanoids 
All eicosanoid analyses were performed on a UPLC coupled to a Xevo TQ-S mass 
spectrometer (Waters). Five µL extract was injected on a Acquity C18 BEH UPLC 
column (2.1 x 100 mm, 1.7 µm) and was separated using gradient elution with a 
stable flow of  600 µL/min. The gradient started with 95% A (MQ water with 0.1% 
FA) and 5% B (ACN with 0.1% FA) followed by a linear increase to 70% A and 30% 
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B which was achieved at 5.0 minutes. This was followed by a linear increase 
towards  50% B which was achieved at 11.25 minutes and maintained until 13.25 
minutes. The system was subsequently switched to 100% B, which was achieved 
at 15.75 minutes and maintained until 16.75 minutes, after which the column was 
left to equilibrate at 5% B for approximately 3 minutes. The column was 
maintained at 50 °C during analysis, and the samples were kept at 10 °C. The MS 
was operating in selective reaction mode using electrospray ionization in negative 
ion mode, with a capillary voltage of 3.3 kV, a source temperature of 150 °C and a 
desolvation temperature of 600 °C. Cone voltage and collision energy were 
optimized for each compound individually (see Table 6.1b for parent and product 
m/z values). Peak identification and quantification was performed using MassLynx 
software version 4.1. Calibration curves were run in duplicate from which one 
regression equation was generated. During data analysis, 5 peaks of unknown 
identity were found to be influenced by diet or LPS treatment, and these 
compounds are listed UK1 to UK5. These peaks were visible in the transitions m/z 
295.2 > 195.2 and m/z 295.2 > 171.1. ARA, DHA and EPA were also determined 
using this method. 
 
Data analysis 
Univariate analysis was performed with SAS version 9.1 (2002-2003 by SAS 
Institute Inc, Cary, NC, USA). ANOVA assumptions were checked for each variable. 
If these assumptions were not met, rank transformation was applied for that 
particular variable. Partial tests were performed using Tukey-Kramer multiple 
comparison correction. Benjamini and Hochberg false discovery rate correction 
was applied to correct for false positives. In all statistical tests that were 
performed, the null hypothesis (no effect) was rejected at the 0.05 level of 
probability (α = 5%). 
The added value of multivariate data analysis in addition to univariate statistics is 
that correlations between variables are taken into account, so combinations of 
variables which are associated with differences between treatment groups. 
Multivariate data analysis summarizes all the variables into one variable by means 
of a linear combination, now called the ‘principal component’, which accounts for 
a significant amount of variance in the data. Using principal component analysis 
(PCA), we screened for group separation, outliers, (undesired) patterns and this 
was further analyzed with principal component discriminant analysis (PCDA). 
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PCDA includes the original group designation of the animals in the model and is 
therefore called a supervised classification technique. PCA and PCDA were 
performed in the Matlab environment (R2008b, 1984-2008, The Mathworks Inc, 
Natick, MA, USA) using the PLS toolbox for Matlab version 5.0.3 (r 6466, 1995-
2008, Eigenvector Research Inc, Wenatchee, WA, USA). PCA and PCDA are 
described in more detail elsewhere [25, 26]. For all multivariate models data were 
autoscaled to mean zero and variance 1 for each variable. For PCDA, stability of 
the model was evaluated by 10-fold cross-validation, revealing correct 
classification rates of typically 80-100%. PCA and PCDA were performed on the 
combined data (‘fused data’), containing data on both endocannabinoids/NAEs 
and eicosanoids from plasma, liver ileum and adipose tissue combined in one data 
set. 
 
Results 
Fish oil diet and inflammation alter the endocannabinoid/NAE balance 
To investigate the effect of dietary n-3 fatty acids and inflammation on 
endocannabinoid/NAE and eicosanoid levels, wild-type male C57BL/6 mice 
received a diet containing either no, 1% w/w or 3% w/w FO followed by either 
saline or 2 mg/kg LPS i.p. injection. Endocannabinoid/NAE levels were determined 
in plasma, liver, ileum and adipose tissue.  
Significant differences between diet groups and LPS treatment were obtained 
with the ANOVA test and are summarized in tables 6.2a-b for 
endocannabinoids/NAEs and 6.3a-b for eicosanoids. A diet effect is here defined 
as an effect of the diet which (in magnitude and direction) was the same for saline 
and LPS-treated mice. The term LPS effect refers to situations in which LPS 
induced a change in a concentration of a compound, which was similar for all diet 
groups. An interaction effect indicates that only certain (combinations of) diets 
with saline or LPS resulted in significant differences, and therefore separate 
comparisons (‘partial tests’) should be interpreted rather than main effects. Table 
2a shows diet effects on NAEs/endocannabinoids, and 2b LPS effects. Compounds 
with an interaction effect are highlighted with * in the tables. 
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 plasma liver ileum adi. tiss. 
Ctrl vs 1% 
FO 
n-3 derived 
EPEA ↑ * ↑ ↑ 
DHEA ↑ ↑ ↑ ↑ 
other 
AEA * ↓ ↓ ↓ 
2-AG ↓ ↓ ↓ ↓ 
DLE ↓ - ↓ ↓ 
OEA ↓ ↓ - * 
Ctrl vs 3% 
FO 
n-3 derived 
EPEA ↑ * ↑ ↑ 
DHEA ↑ ↑ ↑ ↑ 
other 
AEA * - ↓ ↓ 
2-AG ↓ ↓ ↓ ↓ 
DLE ↓ - ↓ ↓ 
OEA ↓ ↓ - * 
SEA ↓ - - ↑ 
1% FO vs 
3% FO 
n-3 derived 
EPEA - * ↑ ↑ 
DHEA - ↑ ↑ ↑ 
other 
2-AG - ↓ - ↑ 
OEA ↓ - - * 
SEA ↓ - - ↑ 
 
Table 6.2a: Effect of the fish oil diets on endocannabinoid/NAE levels in plasma, liver,  
ileum and adipose tissue (diet effect). Only statistically significant effects are listed, with ↑ 
representing an increase by the FO diet, and ↓ a decrease. ND indicates that the 
compound was not detected in the particular matrix, and ‘-‘ indicates that no statistical 
significant differences were observed. * indicates an interaction effect. Adi. tiss.= adipose 
tissue. 
 
The fish oil diets altered endocannabinoid levels with different effects in plasma, 
liver, ileum and adipose tissue (Table 6.2a). DHEA was increased by both fish oil 
diets in all compartments compared to control diet. For EPEA, an interaction 
effect was observed in liver, but the compound was increased by the fish oil diets 
in plasma, ileum and adipose tissue. The endocannabinoids/NAEs derived from 
other fatty acids, such as AEA and 2-AG, were in general decreased by the fish oil 
diets, but some deviations were observed. For instance, 2-AG levels in adipose 
tissue and liver were decreased in both fish oil groups compared to the control 
diet. When comparing the 1% versus the 3% FO group, liver 2-AG was lower in the 
3% group, but higher in adipose tissue. DLE in liver was not influenced by the 
diets, but was decreased in plasma, ileum and adipose tissue in the fish oil groups. 
OEA was decreased in liver and plasma, but not in ileum. When comparing the 
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control diet group with the 3% FO group, SEA displayed opposite effects in 
adipose tissue and plasma; fish oil was found to decrease plasma levels, but 
increased adipose tissue levels of SEA. This was also observed when comparing 
the 1% versus the 3% FO groups.  
 
 
Table 6.2b: Effect of LPS on endocannabinoid/NAE levels in plasma, liver, ileum and  
adipose tissue (LPS effect). Only statistically significant effects are listed, with ↑ 
representing an increase by LPS and ↓ a decrease. ND indicates that the compound was 
not detected in the particular matrix, and ‘-‘ indicates that no statistical significant 
differences were observed. * indicates an interaction effect. Adi. tiss.= adipose tissue. 
 
The effect of LPS on endocannabinoids appeared to be both compound and tissue 
specific (Table 6.2b). LPS increased DHEA levels in all compartments, but for some 
compounds tissue-specific effects were seen. LPS decreased plasma 2-AG, 
whereas it increased adipose tissue 2-AG. A similar divergence is seen for SEA and 
PEA. LPS increased plasma and ileum SEA levels, but decreases liver and adipose 
tissue SEA levels. PEA levels were decreased in liver by LPS, but increased in ileum. 
In summary, both the fish oil diets and the LPS treatment affected plasma and 
tissue endocannabinoid/NAE levels. In general, DHEA and EPEA were increased by 
the fish oil diets, and compounds derived from other fatty acids were decreased, 
with different effects for 1% and 3% FO diets. LPS raised endocannabinoid/NAE 
levels in general, but opposing effects were seen for 2-AG, PEA and SEA across the 
tissues investigated.  
  
 plasma liver ileum adi.tiss. 
Saline vs 
LPS 
n-3 derived 
EPEA ↑ * - ↑ 
DHEA ↑ ↑ ↑ ↑ 
other 
AEA * ↑ ↑ - 
2-AG ↓ - - ↑ 
DLE ↑ ↑ ↑ - 
PEA * ↓ ↑ * 
OEA ↑ ↑ ↑ * 
SEA ↑ ↓ ↑ ↓ 
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 plasma liver ileum adi. ti. 
Ctrl vs 1% 
FO 
fatty acids 
ARA * ↓ - ↓ 
DHA ↑ - ↑ - 
EPA * ↑ ↑ ↑ 
n-3 
eicosanoids  
5-HEPE ↑ ↑ ↑ ↑ 
12-HEPE * ↑ ↑ ↑ 
PGD3 ND ND ↑ ↑ 
PGE3 - ND ↑ ↑ 
17-HDoHE - - ↑ ↑ 
10-17-DiHDoHE ND ND ↑ ↑ 
19,20-DiHoPE ↑ ↑ ↑ ↑ 
TBXB3 * ND ↑ ↑ 
n-6 
eicosanoids 
5,6 EET - ↓ - - 
11,12 EET - ↓ ↓ ↓ 
14,15 EET ↓ ↓ ↓ ↓ 
LTB4 ND ↑ ↓ * 
LTD4 ND ND ↓ - 
5,6-DiHETrE - ↓ ↓ ↓ 
8,9-DiHETrE ↓ ↓ ↓ * 
11,12-DiHETrE ↓ ↓ ↓ ↓ 
14,15-DiHETrE ↓ ↓ ↓ * 
PGE2 - ↓ - - 
PGF2α - ↓ - - 
8-iso-PGF2α - - - ↓ 
13,14-dihydro-15-keto-PGD2 ND ND ↓ ND 
13,14-dihydro-15-keto-PGE2 ↓ ↓ ↓ ↓ 
13,14-dihydro-15-keto-PGF2α ND ↓ ↓ ↓ 
12-HHTrE - ↓ - ↓ 
5-HETE ↓ ↓ - ↓ 
11-HETE - ↓ - ↓ 
12-HETE - ↓ - - 
15-HETE - ↓ - ↓ 
20-HETE ND ↓ - ND 
TBXB2 - ↓ - - 
13-HODE - ↓ - - 
9,10,13-TriHOME - * - ↓ 
Table 6.3a (1/3): Effect of the fish oil diets on eicosanoid levels in plasma, liver,  
ileum and adipose tissue (diet effect). Only statistically significant effects are listed, with ↑ 
representing an increase by the FO diet, and ↓ a decrease. ND indicates that the 
compound was not detected in the particular matrix, and ‘-‘ indicates that no statistical 
significant differences were observed. * indicates an interaction effect. Adi. tiss.= adipose 
tissue. 
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Fish oil diet and inflammation alter the eicosanoid balance 
The results of the eicosanoid analyses in plasma, liver, ileum and adipose tissue 
are presented in Tables 6.3a-b, with 6.3a showing diet effects and 6.3b LPS 
effects. Compounds with an interaction effects are highlighted with an * in the 
tables. The fish oil diets decreased levels of ARA and increased DHA and EPA, 
confirming that the increased dietary intake of n-3 fatty acids was reflected in 
tissue fatty acid levels (Table 6.3a). Furthermore, n-3 derived eicosanoid levels 
were increased by the fish oil diets, with the most pronounced effects observed in 
ileum and adipose tissue. The eicosanoids derived from other fatty acids were in 
general decreased by the fish oil diets, with some exceptions, and effects were 
not always consistent over all tissues tested. Ileum levels of LTB4 were decreased 
in ileum and adipose tissue by the fish oil diets, but liver levels were increased. 
Lipoxin A4 levels were increased in the 3% FO group compared to the control and 
1% FO diet in liver, ileum and adipose tissue. When comparing the 1% and 3% FO 
diets, ileal 5-HETE levels were decreased in the 3% FO group, but its level was 
increased in adipose tissue. The fish oil diets decreased eicosanoids belonging to 
different branches of the fatty acid eicosanoid cascade, including the 
cyclooxygenase pathway (COX; PGD2, PGE2 and their metabolites 13,14-dihydro-
15-keto-PGD2 and –PGE2, PGF2α, TBXB2), the 15-lipo-oxygenase pathway (15-LOX; 
15-HETE), 12-LOX (11-HETE and 12-HETE), 5-LOX (5-HETE, LTB4 and LTD4) and the 
cytochrome P450 pathways (EETs and DiHETrEs) (see Figure 6.1 for an overview). 
Treatment with LPS generally resulted in increased levels of fatty acids, n-3 
derived eicosanoids and other eicosanoids, with the most compounds affected in 
plasma and adipose tissue, and the least number of compounds altered in ileum 
(Table 6.3b). Again, opposing effects were observed between compartments for 
some components. LPS decreased plasma levels of 11-HETE, but increased liver 
levels. TBXB2 was decreased by LPS in plasma, but increased in ileum and adipose 
tissue.  
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 plasma liver ileum adi. tiss. 
Ctrl vs 3% 
FO 
fatty acids 
ARA * ↓ - - 
DHA ↑ - ↑ - 
EPA * ↑ ↑ ↑ 
17-keto DHA ND - ↑ * 
n-3 derived 
eicosanoids 
5-HEPE ↑ ↑ ↑ ↑ 
12-HEPE * ↑ ↑ ↑ 
PGD3 ND ND ↑ ↑ 
PGE3 - ND ↑ ↑ 
17-HDoHE - ↑ ↑ ↑ 
10-17-DiHDoHE ND ND ↑ ↑ 
19,20-DiHoPE ↑ ↑ ↑ ↑ 
TBXB3 * ND ↑ ↑ 
other 
eicosanoids 
5,6 EET - ↓ - - 
8,9 EET ND ND ↓ - 
11,12 EET ↓ ↓ ↓ ↓ 
14,15 EET ↓ ↓ ↓ - 
LTB4 ND ↑ ↓ * 
LTD4 ND ND ↓ - 
n-acetyl-leukotriene E4 ND ↓ * ND 
5,6-DiHETrE ↓ - ↓ ↓ 
8,9-DiHETrE ↓ ↓ ↓ * 
11,12-DiHETrE ↓ ↓ ↓ ↓ 
14,15-DiHETrE ↓ ↓ ↓ * 
PGD2 ↓ * - - 
PGE2 ↓ ↓ - - 
PGF2α - ↓ - - 
8-iso-PGF2α - - - ↓ 
13,14-dihydro-15-keto-PGD2 ND ND ↓ ND 
13,14-dihydro-15-keto-PGE2 ↓ ↓ ↓ ↓ 
13,14-dihydro-15-keto-PGF2α ND ↓ ↓ ↓ 
12-HHTrE ↓ ↓ - ↓ 
5-HETE ↓ - - - 
11-HETE ↓ ↓ - - 
12-HETE ↓ ↓ - ↓ 
15-HETE ↓ ↓ - ↓ 
20-HETE ND ↓ - ND 
TBXB2 ↓ ↓ - - 
9-HODE - - - ↓ 
13-HODE ↓ ↓ - ↓ 
lipoxin A4 ND ↑ ↑ ↑ 
 
Table 6.3a (2/3): Effect of the fish oil diets on eicosanoid levels in plasma, liver,  
ileum and adipose tissue (diet effect). Adi. tiss.= adipose tissue. 
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plasma liver ileum adi. tiss. 
 
1% FO vs 
3% FO 
fatty acids 
DHA - - ↑ - 
EPA * - ↑ ↑ 
17 keto-DHA ND - ↑ * 
 
n-3 derived 
eicosanoids 
5-HEPE - ↑ ↑ ↑ 
12-HEPE * - ↑ ↑ 
PGD3 ND ND - ↑ 
PGE3 - ND - ↑ 
17-HDoHE - ↑ - - 
19,20-DiHoPE - ↑ - ↑ 
 
other 
eicosanoids 
5-HETE - - ↓ ↑ 
11-HETE ↓ - - - 
13-HODE ↓ - - - 
15-HETE ↓ - - - 
PGE2 ↓ - - - 
13,14-dihydro-15-keto-PGE2 - - ↓ - 
13,14-dihydro-15-keto-PGF2α ND ↓ - - 
lipoxin A4 ND ↑ ↑ ↑ 
TBXB2 ↓ - - - 
Table 6.3a (3/3): Effect of the fish oil diets on eicosanoid levels in plasma, liver, ileum and 
adipose tissue (diet effect). Adi. tiss.= adipose tissue. 
 
Multivariate data analysis shows separation between diet groups and LPS 
treatment 
The univariate data analysis approach revealed that both fish oil and LPS altered 
endocannabinoid/NAE and eicosanoid levels, and effects were seen in plasma, 
liver, ileum and adipose tissue. In total, 244 variables obtained in four 
compartments were evaluated, which were, due to complexity, further analyzed 
with multivariate data analysis to evaluate differences between treatment groups. 
Two methods were used, the unbiased Principal component analysis (PCA) and 
Principal component discriminant analysis (PCDA). In the PCA plot (Figure 6.2), a 
good separation of the 6 intervention groups can be seen. The first principal 
component (PC) explains the separation between the diet groups, and the second 
PC distinguishes between saline or LPS treatment. 
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 plasma liver ileum adi. tiss. 
Saline 
vs LPS 
fatty acids 
ARA * ↑ - ↑ 
DHA ↑ ↑ - - 
EPA * - - ↑ 
n-3 derived 
eicosanoids 
5-HEPE ↑ - - ↑ 
PGD3 ND ND - ↑ 
PGE3 - ND ↑ ↑ 
10(S)-17(S)-DiHDoHE ND ND - ↑ 
19,20-DiHoPE ↑ ↑ ↑ ↑ 
TBXB3 * ND ↑ ↑ 
other 
eicosanoids 
5,6 EET - - - ↑ 
11,12 EET - - - ↑ 
14,15 EET - ↑ - - 
LTB4 ND ↓ - * 
LTD4 ND ND - ↑ 
n-acetyl leukotriene E4 ND ↑ * ND 
5,6 DiHETrE - - - ↑ 
8,9-DiHETrE ↑ - - * 
11,12-DiHETrE ↑ - - - 
14,15-DiHETrE ↑ - - * 
PGE2 ↑ ↑ - ↑ 
PGF2 - - - ↑ 
8-iso-PGF2 - ↑ - - 
13,14-dihydro-15-keto-PGE2 ↑ - - ↑ 
13,14-dihydro-15-keto-PGF2α ND ↑ - - 
12-HHTrE ↓ - - ↑ 
5-HETE ↑ - - ↑ 
11-HETE ↓ ↑ - ↑ 
12-HETE - ↓ - - 
15-HETE ↓ - - - 
20-HETE ND ↑ - ND 
TBXB2 ↓ - ↑ ↑ 
9-HODE ↑ - ↑ ↑ 
13-HODE - - ↑ ↑ 
9,10,13-TriHOME ↑ * - - 
lipoxin A4 ND - - ↑ 
 
Table 6.3b: Effect of LPS on eicosanoid levels in plasma, liver, ileum and adipose tissue (LPS 
effect). Only statistically significant effects are listed, with ↑ representing an increase by 
LPS and ↓ a decrease. ND indicates that the compound was not detected in the particular 
matrix, and ‘-‘ indicates that no statistical significant differences were observed. * 
indicates an interaction effect. Adi. tiss.= adipose tissue. 
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Figure 6.2: PCA analysis on fused data. The PCA plot shows good separation of the three 
diet groups. PC1 describes mainly the diet effect, and PC2 mainly the LPS effect. 
 
The diet effect in the saline treated mice is explained by other variables than the 
diet effect in the LPS-treated mice 
To further explore differences between diet groups, PCDA was performed. The 
data was split for saline and LPS-treated mice, thus resulting in two separate PCDA 
plots. PCDA analyses showed that there is separation based on diet for both the 
saline and LPS-treated mice (Figure 6.3). The contribution of a variable in the 
PCDA model is expressed as its D-score, with a positive score meaning an increase 
by the FO diets, and a negative score indicating a decrease.  
Analysis of D-scores revealed that the diet groups are separated by increased 
levels of n-3 derived compounds in the fish oil groups, and compounds derived 
from other fatty acids were generally decreased by the fish oil diets (Table 6.4). In 
addition to this, both endocannabinoids/NAEs and eicosanoids show up in the top 
of the rank lists, indicating that both classes of compounds are important to 
describe the diet effect. The ranking, number and origin of n-3 derived 
metabolites in the models is different between the saline and LPS treated animals. 
Out of the 50 compounds ranking highest for the saline treated mice, only 12  
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Saline 
 
 
LPS 
 
 
Figure 6.3: PCDA analysis, split for saline (upper panel) and LPS treated (lower panel) mice. 
A separation of diet groups is observed in both saline and LPS treated mice, with a more 
prominent separation in the LPS treated mice. 
 
compounds are n-3 fatty acid derived metabolites, while for the LPS treated mice, 
the top-50 list contains 25 n-3 fatty acid derived metabolites. In addition to this, 
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the majority of n-3 derived compounds in the LPS treated mice from this list 
originated from adipose tissue.  
From these results, it can be concluded that the diet effect of fish oil in the saline 
treated animals is mainly explained by a decrease of compounds derived from 
other than n-3 fatty acids, and to a lesser extent by an increase of n-3 derived 
metabolites. However, for the LPS treated mice, the diet effect is principally 
explained by an increase of n-3 derived metabolites, and to a lesser extent by a 
decrease of metabolites derived from other than n-3 fatty acids. 
 
Discussion 
Our results support the general idea that increasing dietary n-3 fatty intake results 
in increased levels of n-3 derived -endocannabinoids/NAEs and eicosanoids. 
However, to the best of our knowledge, our study is the first one describing 
effects of dietary fish oil on the balance between the “endocannabinoid” and 
eicosanoid pathways in such detail, in different compartments simultaneously, 
and in relation with inflammation.  In addition, our study illustrates the risk of 
obtained potentially premature conclusions when only a few mediators are 
analysed in a limited number of matrices. Several studies,  focusing on for 
example AEA (anandamide) and 2-AG only, have concluded that dietary fish oil 
leads to an overall down regulation of the endocannabinoid system [19, 27]. 
However, as we show other (n-3 derived-) endocannabinoids might be affected in 
an opposite direction following fish oil intake. Although there are still several 
questions regarding their biological role, there are reports showing that n-3 
derived ethanolamides have affinity for CB1 and CB2 receptors [28, 29], and have 
anti-inflammatory properties [20, 21]. 
LPS was found to produce a general increase of in vivo endocannabinoid/NAE and 
eicosanoid levels, although there were some exceptions (see below). Multivariate 
data analysis showed that the diet effect was also present during inflammatory 
conditions. Without LPS, the effect of a fish oil diet was mainly explained by a 
reduction of mediators other than those derived from n-3 fatty acids, and to a 
lesser degree by increased levels of n-3 derived metabolites. However, after LPS, 
the balance was shifted in favor of an increase of n-3 derived mediators while 
lower associations were found with reductions of non n-3 derived metabolites.  
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 Saline                           d-score 
  
  
  
  
  
  
LPS                                        d-score                           
  P_AEA                                                   -4,6879  L_2-AG                                                  -4,3994 
 L 2-AG                                                  -4,5742  P AEA                                                   -4,2737 
 P DLE                                                   -4,5412 1 F_EPA                                                   4,2374 
 F_AEA                                                   -4,4914 2 F_12-HEPE                                            4,1634 
 P_ARA                                                    -4,4486 3 P_EPA                                                   4,1441 
 P_11,12-DiHETrE                                         -4,4257  P_2-AG                                                  -4,1053 
1 F_DHEA                                                  4,3978  P_AA                                                    -4,0854 
 P_14,15-DiHETrE                                         -4,3961 4 I_PGE3                                                  4,0450 
 L_ARA                                                    -4,3915 5 F_TBXB3                                                 4,0374 
 L_13,14-dihydro-15-keto-PGF2a                           -4,3025 6 F_PGE3                                                  3,9827 
 L_12-HETE                                            -4,2590  P_DLE                                                   -3,9498 
 F_8,9-DiHETrE                                           -4,2553  L_14,15-DiHETrE                                         -3,8977 
 L_15-HETE                                            -4,2343 7 F_DHEA                                                  3,8946 
2 L_5-HEPE                                             4,2162 8 I_EPA                                                   3,8541 
 L 11-HETE                                            -4,1548 9 L_EPEA                                                  3,7505 
3 L_EPA                                                   4,1323  L_11,12-DiHETrE                                         -3,7410 
4 P_EPA                                                   4,1269 10 L_DHEA                                                  3,7222 
 F_DLE                                                   -4,1166  L_ARA                                                    -3,6999 
 P_8,9-DiHETrE                                           -4,0892 11 L_EPA                                                   3,6953 
 I 13,14-dihydro-15-keto-PGE2                            -4,0783 12 I_DHA                                                   3,6912 
 P OEA                                                   -4,0592 13 I_12-HEPE                                            3,6874 
 F_11,12 EET                                             -4,0186  L_8,9-DiHETrE                                           -3,6672 
 F_OEA                                                   -4,0148 14 F_EPEA                                                  3,6327 
 L_8,9-DiHETrE                                           -4,0079  L 13,14-dihydro-15-keto-PGF2α                           -3,6261 
 I_2-AG                                                  -3,9897  I_2-AG                                                  -3,6231 
 F 9,10-DiHOME                                           -3,9147 15 P_DHA                                                   3,5903 
 P_9,10-DiHOME                                           -3,8645  F_AEA                                                   -3,5678 
 L_LTB4                                                  3,8175  L_PGD2                                                  -3,5455 
 F_11,12-DiHETrE                                         -3,7600 16 F_PGD3                                                  3,5197 
 F_14,15-DiHETrE                                         -3,7376 17 F_19,20-DiHoPE                                          3,5168 
 L_5,6 EET                                               -3,7094  L_AEA                                                   -3,5158 
 I 13,14-dihydro-15-keto-PGF2α                           -3,7008 18 I_19,20-DiHoPE                                          3,4924 
 P 12,13-DiHOME                                          -3,6962  L 14,15 EET                                             -3,4871 
 F_12,13-DiHOME                                          -3,6718 19 I_EPEA                                                  3,4515 
5 P_DHEA                                                  3,6677 20 I_5-HEPE                                             3,4391 
 P_UK4                                                   -3,6605  I_AEA                                                   -3,4310 
 L_14,15 EET                                             -3,6511  F_SEA                                                   3,4187 
6 F_EPA                                                   3,6069  L 20-HETE                                            -3,4104 
7 I_19,20-DiHoPE                                          3,5938  I 13,14-dihydro-15-keto-PGE2                            -3,3956 
 F_5,6-DiHETrE                                           -3,5357 21 P_5-HEPE                                             3,3787 
 P_2-AG                                                  -3,5155 22 L_5-HEPE                                             3,3617 
8 I_12-HEPE                                            3,4899  L_TBXB2                                                 -3,3200 
 L_11,12 EET                                             -3,4781  L_12-HHTrE                                           -3,3155 
9 F_EPEA                                                  3,4723  P 5,6-DiHETrE                                           -3,3080 
10 L_19,20-DiHoPE                                          3,4679 23 F_5-HEPE                                             3,3048 
 L_12-HHTrE                                           -3,4525 24 P_DHEA                                                  3,2978 
 P_UK2                                                   -3,4144  P_11,12-DiHETrE                                         -3,2966 
 L_PGE2                                                  -3,4143 25 F_17 keto-DHA 3,2931 
11 I_EPA                                                   3,3758  L_11-HETE                                            -3,2792 
12 P_5-HEPE                                             3,3581  P_15-HETE                                            -3,2618 
Table 6.4: Top lists of endocannabinoids/NAEs and eicosanoids changed in saline and LPS treated 
mice. Negative D-scores indicate that the compound is decreased in the fish oil groups; positive D-
scores mean that it is increased by fish oil. P = plasma; L=liver; I=ileum; F=adipose tissue. Decrease of 
other than n-3 derived compounds ranks relatively high in the saline diet effect, whereas an increase 
in n-3 derived compounds (printed in bold) ranks high for the diet effect in the LPS treated mice. 
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The relation between dietary fatty acid intake and the presence of 
endocannabinoids/NAEs and eicosanoids in plasma and tissues has been 
established before [30, 31], but not under conditions of inflammation. Previous 
work with rats demonstrated that patterns of organ levels of NAEs follow the 
relative abundance of fatty acids in the diet [18]. Other work, investigating the 
effect of DHA on murine levels of endocannabinoids/NAEs in brain and plasma, 
showed strongest changes in plasma [17]. Interestingly, plasma AEA levels were 
not significantly affected by DHA alone, whereas other NAEs were decreased by 
DHA. Other work, supplementing krill oil or menhaden oil to human subjects also 
did not show an effect on plasma AEA levels [27]. Our work shows that six weeks 
of a fish oil diet is capable of reducing plasma AEA and 2-AG levels. This 
discrepancy might originate from differences in n-3 fatty acids sources, or length 
of the period in which the n-3 fatty acids were supplemented. 
Many studies analyze plasma levels of endocannabinoids/NAEs or eicosanoids. 
The present work shows that plasma levels do not always reflect effects in liver, 
ileum or adipose tissue. For example, plasma 2-AG levels decreased after LPS, but 
were increased in adipose tissue, and similar divergences were also observed for 
PEA, SEA, several HETEs, and TBXB2. The origin and significance of these findings 
are not known yet, but this could be related to synthesis, release, uptake or 
breakdown which might be differentially regulated by LPS or other factors across 
different organs. Nevertheless, based on our results, extrapolating effects found 
in  plasma to effects on peripheral tissues is not always appropriate.  
The LPS treated mice had a lower food intake combined with a small loss of body 
weight (data not shown), whereas the saline treated animals displayed normal 
food consumption and stable body weight. Previous work showed that levels of 
endocannabinoids and related NAEs depend on fasting status [32-34]; their tissue 
levels being high during fasting, followed by a rapid postprandial decrease. 
Possibly, the effect of LPS on endocannabinoid levels might in part be mediated 
through such a ‘fasting’ effect. In addition, inflammation reduces FAAH 
expression, and inhibition of FAAH or monoacyl glycerol lipase (MGL) has been 
shown to reduce disease symptoms in several models of inflammation [22, 35, 
36]. Similarly, studies using CB2 knock-out models under induced inflammatory 
conditions showed that increased levels of NAEs likely contribute to suppress 
inflammation [37]. Together, this suggests that increased levels of 
endocannabinoids/NAEs are part of a normal response protecting against 
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inflammatory stress. Previous work identified DHEA and EPEA as having anti-
inflammatory properties in macrophages and adipocytes [20, 21], and these 
compounds could be another link between fish oil and its anti-inflammatory 
effects as n-3 derived NAEs were more effective than AEA in suppressing nitric 
oxide release from macrophages [21].  
The fish oil diets also influenced levels of eicosanoids, including metabolites from 
the COX, CYP450, and 5-LOX, 12-LOX and 15-LOX pathways (figure 1), and these 
effects were in general also seen during inflammatory conditions. Another 
strength of the present study is that we analyzed both n-6 and n-3 related 
eicosanoids simultaneously in different compartments. In general, levels of n-3 
fatty acid derived eicosanoids (e.g. PGD3, PGE3, 5-HEPE, 12-HEPE and TBXB3) were 
increased with fish oil at the expense of eicosanoids derived from other fatty acids 
(e.g. PGD2, PGE2, PGF2 , TBXB2 and members of the EET and HETE subclasses). A 
functional role in inflammation has been described for several of these 
compounds, and it is likely that the changes in profiles which are found in this 
study (and before) are causally related to the anti-inflammatory effects which are 
associated with n-3 fatty acid intake. For example, PGE3 is less potent than PGE2 in 
inducing COX-2 expression and IL-6 release [38]. A similar principle applies to the 
thromboxanes [39, 40] and for 5-HETE/5-HEPE [41], which were also altered by 
the fish oil diets. 
Interestingly, the fish oil diets increased liver LTB4 levels, whereas ileum LTB4 
levels were decreased. LTB4 has multiple pro-inflammatory functions in the 
immune system [42], but the different effect of fish oil on organ levels of LTB4  is 
not understood. Lipoxin A4, a compound with anti-inflammatory properties [43], 
was increased by the 3% FO diet. This indicates that at least for this compound, 
which is synthesized from ARA, its level is not directly related to dietary supply of 
precursor, but that other presently unknown factors are involved.  
Levels of several EETs were reduced by the FO diets, especially in the liver. EETs 
play regulatory roles in heart and vascular physiology with effects on blood 
pressure regulation, but also have anti-inflammatory effects [44]. It thus seems 
that EETs do not play a role in the anti-inflammatory properties of n-3 fatty acids. 
Another line of evidence suggests that EETs very specifically alter the release of 
either insulin or glucagon [45, 46], pointing to a potential link between n-3 fatty 
acids and glucose metabolism. EETs might therefore also be part in mediating 
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effects of dietary fatty acids on metabolism, but this relation has not been given 
much attention yet. 
In the present study we did not detect resolvins in any of the samples. It might be 
that these compounds are not formed in quantities high enough to be detected 
with our method during the first 24 hrs after the initiation of the inflammatory 
response, or the detection limit of the analytical method was not sufficient to 
detect these compounds. However, the presence of 17-HDoHE (also known as 17-
HDHA), a marker for resolvin synthesis [47] with anti-inflammatory properties 
[48], was increased by the fish oil diets. The fish oil diets as well as LPS increased 
levels of 10,17-DiHDoHE, (also known as protectin DX) which was previously 
shown to reduce inflammation and accelerate its resolution [49]. Altogether, the 
fish oil diets altered all branches in the eicosanoid metabolome in a way that is 
largely associated with suppression of inflammation. 
A major finding of this work is that the effects of fish oil were also persistent 
under inflammatory conditions. Multivariate data analysis revealed that both 
endocannabinoids and eicosanoids are responsible for separation between diet 
groups. Under non-inflammatory conditions, the diet groups could be primarily 
separated based on the reduction of other than n-3 derived endocannabinoids 
and eicosanoids. In contrast, with LPS treatment, the diet groups were primarily 
separated by increases in levels of n-3 fatty acid derived endocannabinoids and 
eicosanoids. The combined approach of comparing normal versus inflammatory 
conditions was thus useful in demonstrating that effects of diet on eicosanoids 
and endocannabinoids are depending on inflammatory status.  
Recent evidence suggested that relatively high intakes of fish oil impairs the host’s 
resistance to microbial infection [50-52]. In our study, the mice that had received 
3% FO showed relatively more severe signs of shock after LPS, and one mouse 
from the 3% FO + LPS group died shortly before the end of the experiment. This 
would be in line with the notion that high fish oil intake might impair the host’s 
resistance to inflammatory stress, or to suppress the capability to overcome the 
inflammatory stimulus. We observed that plasma TBXB2 levels, a compound 
related to TBXA2 which is involved in vasoconstriction [53], was decreased in the 
3% FO group compared to the 1% FO group, but also by LPS. The combination 3% 
FO and LPS treatment might have caused a decrease in TBXA2 levels below its 
physiological range, potentially increasing the risk of inducing excessive 
vasodilatation and shock. Alternatively, pre-treatment of rats with a CB1 blocker 
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was effective in reducing hypotension after LPS administration [54], suggesting 
that increases in endocannabinoids after LPS might also contribute to the shock 
observed for the 3% FO + LPS group. Future work should point out which 
(combination of) metabolites account for the impaired resistance in the 3% FO + 
LPS group. Furthermore, future work should clarify which intake levels of n-3 fatty 
acids are beneficial to reduce symptoms of inflammatory diseases and where the 
inhibition of inflammation starts to interfere with an efficient response to an 
inflammatory stimulus. 
In conclusion, dietary fish oil caused marked changes in the n-3 to n-6 balance of 
the endocannabinoid and eicosanoid metabolomes, with specific effects 
depending on inflammatory status. The effects on metabolites are in line with the 
anti-inflammatory effects associated with n-3 fatty acid intake. 
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Abstract 
 
The origin of plasma NAEs is not exactly known, and it is assumed that plasma 
levels are a reflection of system levels as plasma may act as a ‘spill-over’ sink. 
However, plasma contains numerous classes of lipids which could contain 
esterified NAEs, and blood cells might also synthesize these compounds. In the 
present study, we i) compared free to esterified plasma NAE levels in mice fed 
diets with different amount of n-3 fatty acids, and ii) investigated the presence of 
NAE in blood cells. For this purpose a LC-MS/MS method was developed and 
validated for the quantification of AEA, 2-AG, DHEA, DLE, EPEA, OEA, PEA and SEA 
in 100 µL plasma using a simple acetonitrile extraction step. Plasma extracts 
contained 20-60 fold higher levels of esterified NAEs than free NAEs. Moreover, 
the effect of dietary n-3 fatty acids on free plasma NAE profiles was similar for 
esterified NAEs. Finally, esterified NAEs were also present in blood cells, and their 
pattern followed the same diet effect as observed for free and esterified plasma 
NAEs. Together, these data point to the presence of previously ignored pools of 
esterified NAEs in plasma and blood cells, which correlated with free plasma NAE 
levels. 
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Introduction 
Over the last decades, the fatty acid N-acyl ethanolamines (NAEs) have emerged 
as important regulators of diverse biological processes, including food intake, 
energy metabolism, and inflammation [1-4]. The best studied NAE is the 
endocannabinoid arachidonoyl ethanolamide (AEA; anandamide), but NAEs 
synthesized from other fatty acids also exist, such as docosahexaenoyl 
ethanolamide (DHEA),  dihomo-γ-linolenoyl ethanolamide (DLE), eicosapentaenoyl 
ethanolamide (EPEA), oleoyl ethanolamide (OEA), palmitoyl ethanolamide (PEA), 
and stearoyl ethanolamide (SEA). These compounds are widely present 
throughout the body and several publications have reported on their levels in 
tissues, plasma, and other body fluids [5-12]. Several papers have described 
analytical methods for NAE quantification, typically using solvent extraction 
and/or solid phase extraction (SPE) protocols combined with liquid-
chromatography coupled to tandem mass spectrometry (LC-MS/MS) analysis [13-
21]. These procedures extract and quantify NAEs which are present in “free form”, 
meaning that these NAEs were not-covalently bound e.g. esterified to for example 
phospholipids. Usually large amounts (e.g. 1 mL) of plasma are needed, making 
such methods not practical for the use in e.g. mouse studies. NAEs are often 
quantified in (human) plasma, but it should be kept in mind that the plasma 
compartment may act as a ‘spill-over’ sink for e.g. liver or adipose tissue 
synthesis, and the exact origin of plasma NAEs is thus not known. Peripheral blood 
also contains cells which could potentially synthesize NAEs, and could thereby 
contribute to (changes in) plasma NAE levels. Unfortunately, this has not received 
much attention yet. In the present study, we i) compared plasma levels of free 
NAEs to esterified NAE levels, and ii) investigated whether blood cells, obtained 
from the same blood sample, contained esterified NAE levels. To this end, mice 
were fed with diets containing different fatty acid compositions and subsequently 
100 µl plasma was extracted with or without a saponification (hydrolyzation) step. 
The NAEs in red blood cells were measured after saponification. NAEs were 
quantified using a new and more sensitive developed LC-MS/MS method. Higher 
levels of NAEs were found in plasma extracts after saponification, and NAEs were 
also detected in red blood cells. Together, these results indicate that both plasma 
and blood cells contain a pool of esterified NAEs which is only revealed after 
hydrolyzation of samples. 
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Materials and methods 
Chemicals and reagents 
Lipopolysaccharide (0111:B4; LPS) was from Sigma (Steinheim, Germany). 
Phenylmethylsulfonyl fluoride (PMSF) was from Fluka (Steinheim, Germany). 
URB602 was from Cayman (Ann Arbor, MI, USA). Milli-Q water (Milli-Q Advantage 
unit, Millipore, Amsterdam, The Netherlands) was used in all analysis. ULC-grade 
acetonitrile (ACN), isopropanol (IPA) formic acid (FA) and trifluoro acetic acid 
(TFA) were obtained from Biosolve (Valkenswaard, The Netherlands). LC-MS grade 
methanol was from Riedel-de-Häen (Steinheim, Germany). Analytical grade IPA 
was from JT Baker (Deventer, The Netherlands). Potassium hydroxide (KOH) was 
from Merck (Darmstadt, Germany). All analytical and internal standards, except 
EPEA, were from Cayman. EPEA was synthesized as described earlier [22]. NAE 
stocks were prepared in ACN, aliquoted and stored at -80 °C until analysis. C8 SPE 
columns (Bond Elut; 200 mg, 3 mL) were from Varian Inc (Lake Forest, CA, USA).  
 
Animal experiment 
The plasma and blood cells were collected from an animal experiment described 
in more detail elsewhere [23]. In short, wild-type C57BL/6 mice were fed for six 
weeks with a control diet (ctrl), 1% fish oil (1% FO) or 3% fish oil (3% FO). After six 
weeks, blood was collected from the orbital sinus and captured in 1.3 mL EDTA 
coated tubes (Sarstedt; Etten-Leur, The Netherlands) and put on ice until 
centrifugation (10’, 10,000 rpm at 4 °C). After centrifugation, 100 µL plasma was 
stored in the presence of 100 µM PMSF and 100 µM URB602. The blood cells 
were reconstituted in phosphate-buffered saline to a 1:1 ratio. Both plasma and 
blood cells were stored at -80 °C until analysis, thereby ensuring blood cell lysis. 
 
Plasma extraction of free NAEs 
Plasma (100 µL) was thawed and 400 µL ACN containing 100 µM PMSF and AEA-
d8, 2-AG-d8 and OEA-d4 was added while the sample was gently vortexed. After 
subsequent centrifugation (5’ at 13,000 rpm, RT), the supernatant was transferred 
to a clean eppendorf tube and evaporated to dryness in a vacuum concentrator 
(Scanvac; Lynge, Denmark). Prior to LC-MS/MS analysis, the dried extracts were 
reconstituted in 100 µL ACN containing 0.1% TFA. 
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Hydrolyzation and extraction of NAEs from plasma or blood cells 
Plasma or blood cell lysate (100 µL) was thawed and 400 µL ULC-grade IPA 
containing 100 µM PMSF and AEA-d8, 2-AG-d8 and OEA-d4 was added while the 
sample was gently vortexed. IPA was used to ensure extraction of lipophilic 
structures, including phospholipids and lipoprotein complexes. After 
centrifugation (5’ at 13,000 rpm, RT), the supernatant was transferred to a clean 
glass tube. Hydrolysis was performed through saponification by adding 200 µL 0.5 
M KOH in methanol and placing the tube at 60 °C for 45’. Hereafter, 4 mL MQ 
water containing 0.13% v/v TFA was added, and the extract was loaded on an 
activated C8 SPE column. The column was washed with 2 mL of 20% ACN 
containing 0.1% TFA, and subsequently eluted with 2 mL of 80% ACN containing 
0.1% TFA. The extract was evaporated to dryness in a vacuum concentrator and 
finally reconstituted in 100 µL ACN containing 0.1% TFA prior to LC-MS/MS 
analysis. The saponification step should hydrolyze all ester bonds, and the 
absence of 2-AG-d8 in the final extract was used as an indicator of complete 
sample hydrolysis. 
 
LC-MS/MS analysis of NAEs 
Extracts were analyzed on a Waters UPLC-XEVO TQ-S system. Three µL extract 
was injected on a Acquity C8 BEH UPLC column (2.1 x 100 mm, 1.7 µm) and was 
separated using gradient elution with a stable flow of  500 µL/min. The gradient 
started with 100% A (40:40:20 v/v/v of MQ water : methanol : ACN with 0.1% FA) 
which was maintained until 0.35 minutes, followed by a linear increase to 100% B 
(7:3 v/v methanol : ACN with 0.1% FA) which was achieved at 7.0 minutes. This 
was maintained until 9.0 minutes, and at 9.10 minutes the gradient was returned 
to 100% A, which was maintained until 12.0 minutes. The column was kept at 
60 °C during analysis, and the samples at 10 °C. The MS was operated in selective 
reaction mode using electrospray ionization in positive ion mode, with a capillary 
voltage of 1.5 kV, a source temperature of 150 °C and a desolvation temperature 
of 500 °C. Cone voltage and collision energy were optimized for each compound 
individually. Peak identification and quantification was performed using MassLynx 
software version 4.1. Calibration curves were run in duplicate from which one 
regression equation was generated.  
 
 
Plasma and blood cells contain esterified NAEs 
168 
 
Validation of the analytical method 
The accuracy and precision of the analytical method was evaluated using quality 
control samples (QCs), which were prepared by spiking NAE and 2-arachidonoyl 
glycerol (2-AG) stock solutions to 100 µL human plasma obtained from an 
apparently healthy volunteer. The spike levels correspond to one, three, and six 
times the basal plasma concentrations.  
 
Statistical analysis 
Data are presented as mean ± standard deviation where appropriate. 
Comparisons between groups were made with one-way analysis of variance 
(ANOVA) followed by Dunnett’s t test using SPSS Statistics 17.0 software. P< 0.05 
was considered as significant level of difference. 
 
 
Results 
Accuracy and precision of the analytical method 
A new analytical method was developed which allowed quantification of NAEs and 
2-AG in 100 µL plasma. The accuracy of the method was evaluated by spiking 
NAEs and 2-AG at three concentration levels to human plasma prior to sample 
work-up (see Table 7.1 for accuracies and related information). In most cases, 
good values for accuracy (70-120%) and precision (< 20%) were obtained, with 
usually higher precision values at the lowest spike level. It must be noted that 
2-AG was not detected in the particular batch of human plasma used for the 
validation, but this compound has been quantified in 100 µL murine plasma 
(unpublished results). The new ULPC-based chromatography allowed separation 
of 2-AG from its isomer 1-AG (see Figure 7.1 for chromatograms). Matrix effect 
was determined using internal standard areas, showing ion suppression for AEA-
d8 (60.5%), 2-AG-d8 (52.8%) and OEA-d4 (80.9%), and ion enhancement for PEA-
d4 (178.4%).  
 
Hydrolyzed plasma extracts contain higher levels of NAEs than non-hydrolyzed 
extracts 
To investigate whether plasma contains a pool of esterified NAEs, murine plasma 
samples were hydrolyzed using KOH saponification and concentrations were 
compared to the same plasma sample without saponification. 
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Table 7.1: Validation results for the quantification of NAEs and 2-AG from 100 µL human 
plasma. 
 
Figure 7.2 shows the esterified and free plasma NAE levels from murine samples. 
From Figure 7.2 can be concluded that NAE values after hydrolysis are higher (20 
to 60 fold) compared to free plasma values. EPEA, an n-3 fatty acid derived NAE, is 
not detectable in free plasma from mice fed the control diet, but was quantifiable 
after hydrolysis. 
Compound Concentration 
spiked 
Accuracy  Precision  
(intra-
day) 
LLOQ Blanc 
human 
plasma 
levels 
Linear range 
ng/ml % % RSD ng/mL ng/mL ng/mL 
AEA 
0.21 107.3 18.2 
0.056 0.14 0.056-406.6 0.62 106.3 4.9 
1.23 117.7 6.9 
2-AG 
6.13 72.0 16.8 
0.771 - 0.771-5617.2 18.39 72.6 6.5 
36.77 79.2 6.1 
DHEA 
0.15 101.1 31.5 
0.064 0.18 0.064-140.4 0.45 103.8 8.4 
0.89 117.5 7.9 
DLE 
0.02 110.8 47.5 
0.019 0.04 0.019-140.4 0.07 110.8 18.1 
0.13 133.8 12.6 
EPEA 
1.58 75.3 8.6 
0.069 - 0.069-499.9 4.74 80.3 6.8 
9.47 82.1 5.9 
OEA 
1.18 95.1 4.0 
0.064 0.96 0.064-140.4 3.53 95.4 1.8 
7.05 96.4 2.8 
PEA 
1.03 97.4 18.8 
0.064 0.94 0.064-140.4 3.08 101.3 3.3 
6.16 110.9 4.7 
SEA 
0.38 68.9 26.5 
0.095 0.41 0.095-69.6 1.14 75.1 7.1 
2.28 82.3 6.4 
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Figure 7.1: Chromatograms from the injection of 1-AG (upper left), 2-AG (upper right) or a 
1:1 mix of 1-AG and 2-AG (lower left), showing that 2-AG and 1-AG are separated. As 2-AG 
is prone to isomerization to 1-AG, some 1-AG is present in the chromatogram from the 2-
AG injection.  
 
In addition, the effects of dietary FO on free plasma NAE levels are also observed 
in saponificated samples; e.g. the fish oil diets decreased free plasma AEA, and 
the same decrease is observed in the hydrolyzed samples. In general, the 
concentrations in the hydrolyzed samples were 20-60 fold higher compared to the 
free NAE levels. Hydrolyzed samples contained no detectable 2-AG-d8 levels, 
indicating that the hydrolysis was complete. AEA-d8 and OEA-d4 levels were not 
affected by the hydrolyzation (data not shown). 
To confirm whether human plasma also contains esterified NAEs, plasma from 10 
healthy volunteers was hydrolyzed and the NAE levels were compared to free NAE 
levels from the same samples. As shown in Table 7.2, the NAE levels in hydrolyzed 
extracts are higher compared to the free NAE levels, indicating that human 
plasma also contains pools of esterified NAEs. 
 
 
1-AG
min
3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60
%
0
100
379.351 > 287.243
min
3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80
%
0
100 379.351 > 287.243
1-AG
2-AG
min
3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60
%
0
100 379.351 > 287.243
1-AG
2-AG
1-AG 2-AG 
Mix 1-AG + 2-AG 
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Blood cells contain quantifiable NAE levels 
As can be seen from Figure 7.3, hydrolyzed blood cell extracts contain quantifiable 
levels of all NAEs. In addition, the effect of the diets which was observed in free 
plasma levels is also evident in blood cell NAE levels; the fish oil diets increased 
levels of DHEA and EPEA and in general reduced levels of other NAEs. However, 
some differences between free plasma levels and levels in blood cells were 
obvious (e.g. PEA and SEA). Non-hydrolyzed blood cell extract also contained  
NAEs, but their levels were lower compared to hydrolyzed extracts (data not 
shown). 
 
Discussion 
There are numerous reports in literature presenting plasma NAE levels, but the 
site of synthesis of these compounds remains speculative as the plasma 
compartment may act as a ‘spill-over’ sink for organs with established NAE 
biosynthesis, such as liver or adipose tissue. The possibility that plasma or blood 
cells contain pools of esterified NAEs has not been investigated before. The 
purpose of this study was to compare free plasma NAE levels to esterified plasma 
NAEs in groups of mice fed with diets containing different fatty acid compositions, 
and to investigate whether blood cells also contain esterified NAEs. 
NAEs are in general present at low concentrations in plasma, and their accurate 
quantification requires adequate sample volumes, e.g. 1 mL of plasma, depending 
on the sensitivity of the instruments used. We have developed and validated a 
new analytical method for the quantification of NAEs from 100 µL plasma, 
extending its applicability to animal studies. Another advantage of the present 
method is the relatively simple sample work-up procedure which does not require 
a solid phase extraction (SPE) step, thus speeding up analysis time and reducing 
costs. The plasma NAE concentrations found in the human control sample are in 
agreement with previously published values [13, 15, 24, 25]. As the present 
method does not use sample clean up, special attention was paid to ion 
suppression caused by matrix effect. No differences with respect to the ‘1 mL’ 
method were observed [13]. Although 2-AG was not detected in the human 
control sample, it was possible to quantify this compound in 100 µL murine 
plasma samples (unpublished data). The levels of NAEs in hydrolyzed plasma 
extracts were in general 20-to-60 fold higher compared to non-hydrolyzed 
extracts, indicating that plasma contains significant pool of esterified NAEs. In  
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Figure 7.2: Free plasma NAE levels (left) and free + esterified NAE levels (right) in mice fed 
a control diet, 1% FO or 3% FO diet.   The effects of the FO diets are comparable for free 
plasma and esterified NAE levels, but the saponificated extracts contain higher NAE levels. 
* P<0.05; ** P<0.01; *** P<0.001 compared to ctrl diet. 
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Figure 7.2 (cont.): Free plasma NAE levels (left) and free + esterified NAE levels (right) in 
mice fed a control diet, 1% FO or 3% FO diet. The effects of the FO diets are comparable for 
free plasma and esterified NAE levels, but the saponificated extracts contain higher NAE 
levels. * P<0.05; ** P<0.01; *** P<0.001 compared to ctrl diet. 
 
addition, dietary fatty acids had the same effect on both free and esterified NAE 
profiles, increasing DHEA and EPEA levels and in general decreasing other NAEs. A  
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Figure 7.3: NAEs in hydrolyzed blood cell extracts. * P<0.05; ** P<0.01; *** P<0.001 
compared to ctrl diet. 
 
similar relation between dietary fatty acids and in vivo levels of NAEs has been 
described before [5, 26-29]. This shows that esterified NAEs are an appropriate  
0.0
10.0
20.0
30.0
ctrl 1% FO 3%FO
ng
/m
L 
AEA in blood cells 
0.0
10.0
20.0
30.0
40.0
ctrl 1% FO 3%FO
ng
/m
L 
DHEA in blood cells 
0.0
20.0
40.0
60.0
80.0
ctrl 1% FO 3%FO
ng
/m
L 
EPEA in blood cells 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
ctrl 1% FO 3%FO
ng
/m
L 
DLE in blood cells 
0.0
20.0
40.0
60.0
80.0
ctrl 1% FO 3%FO
ng
/m
L 
OEA in blood cells 
0.0
50.0
100.0
150.0
ctrl 1% FO 3%FO
ng
/m
L 
PEA in blood cells 
0.0
20.0
40.0
60.0
ctrl 1% FO 3%FO
ng
/m
L 
SEA in blood cells 
*** 
*** 
*** 
*** 
*** 
*** 
*** 
*** 
*** *** 
** 
Chapter 7 
 
175 
 
marker for free NAE levels, and it could be hypothesized that free plasma NAE 
levels are directly released from the esterified plasma NAE pool. However, the 
biochemical relation between free and esterified NAEs is not clear yet, and several 
considerations should be kept in mind. First, the compounds to which the NAEs 
are coupled to are not known, but the nature of the saponification hydrolysis 
combined with the structure formulas of NAEs rule out triglycerides as the source. 
Therefore, esterification to phospholipids is more likely. Plasma is known to 
contain N-acylphosphatidylethanolamines (NAPEs) [30]. NAPEs are cell 
membrane-associated intermediates in NAE biosynthesis and contain NAEs in 
esterified form [31, 32], but their contribution to the effects observed in the 
present chapter remains speculative. Secondly, it is not known whether the free 
plasma NAEs are directly derived from the as yet unidentified esterified plasma 
pool, from blood cells, liver or adipose tissue, or a combination of these. The solid 
relation between free and esterified NAE profiles in plasma does not necessarily 
rule out involvement of peripheral organs, as potential sources for esterified NAEs 
might be ultimately synthesized in e.g. liver. In addition to this, it is not clear what 
stimulus would result in the liberation of esterified NAEs in plasma, if this would 
be the case. 
 
 Free NAE (ng/mL) Free + esterified NAE (ng/mL) 
AEA 0.37 ± 0.12 8.07 ± 1.45 
DHEA 0.41 ± 0.24 3.99 ± 1.73 
DLE 0.05 ± 0.03 0.73 ± 0.24 
OEA 1.98 ± 0.70 22.66 ± 4.21 
PEA 1.46 ± 0.38 50.92 ± 11.68 
SEA 0.62 ± 0.22 34.31 ± 8.90 
 
Table 7.2: Free NAE levels and free + esterified NAE levels in human plasma (n=10). 
 
 
Blood cells were also shown to demonstrate significant amounts of esterified 
NAEs. In general, NAEs are synthesized from cell membrane phospholipids, 
involving calcium ion signaling and the action of multiple enzymes [31, 32], but 
these pathways have not been extensively investigated in blood cells. Blood 
contains different cell types, like erythrocytes and lymphocytes, and platelets. The 
contribution of these different cell types to the total esterified blood cell NAE 
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levels is not known, nor the relation to free plasma NAEs, but it is clear that blood 
cells contain significant amounts of NAEs. This might be of biological relevance as 
different studies have described effects of NAEs on immune cells [33, 34].  
To summarize, we successfully developed and validated a new analytical method 
for the quantification of NAEs from 100 µL plasma samples, which was used to 
demonstrate that plasma contains levels of esterified NAEs which are 
approximately 20-to-60 fold higher than free NAE levels. In addition, blood cells 
also contain significant levels of esterified NAEs. Together, these data show that 
blood contains a previously ignored pool of NAEs which are esterified to both 
plasma and blood cell structures. The physiological relevance of these pools 
remains to be demonstrated.  
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It is well established that dietary n-3 fatty acid intake is associated with anti-
inflammatory effects. The mechanisms behind these effects have been shown to 
include binding to nuclear and G-protein coupled receptors, interactions with 
eicosanoid synthesis, and conversion to resolvins which display anti-inflammatory 
properties. Fatty acids are also precursors for N-acylethanolamines 
(NAEs)/endocannabinoids, but the anti-inflammatory effects of n-3 fatty acids 
have not been linked to the endocannabinoid system before. This thesis describes 
the link between (dietary) fatty acids, NAEs/endocannabinoids, and inflammation. 
 
 
Nature’s combinatorial chemistry: endocannabinoid levels depend 
on (dietary) supply of fatty acids 
According to the most common view, endocannabinoids and other NAEs are 
locally released and rapidly broken down by enzymes including fatty acid amide 
hydrolase (FAAH) and monoacyl glycerol lipase (MAGL). The patterns of molecules 
which are released are considered to reflect the local availability of their 
precursor molecules. This  can be  regarded as  a form of combinatorial chemistry: 
different end products are formed depending on the supply of precursors to a 
system. Using in vitro and in vivo studies, we demonstrated that the principle of 
combinatorial chemistry also applies for fish oil-derived endocannabinoids. The 
work showed that dietary fatty acids determine the profile of endocannabinoids 
rather than just individual compounds. 
Adipocytes are known for their capacity to synthesize endocannabinoids and were 
previously used to study conversion of dietary fatty acids to NAEs [1]. In chapter 3, 
we demonstrated that adipocytes can convert the n-3 fatty acids 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to their respective 
NAEs, namely docosahexaenoyl ethanolamide (DHEA) and eicosapentaenoyl 
ethanolamide (EPEA). When DHA and EPA were supplied to the adipocytes via the 
in medium, levels of other NAEs were barely affected. In contrast, when DHA and 
EPA were supplied in dietary fish oil to mice as described in chapter 6, the 
endocannabinoid and eicosanoid metabolomes were altered, with increased 
levels of DHEA, EPEA and n-3 derived eicosanoids such as the prostaglandins (PGs) 
PGD3, PGE3, thromboxane B3 (TBXB3), and 5-hydroxyeicosapentaenoic acid (5-
HEPE). This was paralleled by decreased levels of metabolites not derived from n-
3 fatty acids. This demonstrated that fish oil alters metabolite profiles rather than 
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individual compounds, and that the principle of combinatorial chemistry also 
applies for in vivo condition after dietary fish oil. In general, these n-3 derived 
compounds are known to be less potent inducers of inflammation than its 
arachidonic acid-derived analogues [2-7]. As such, increased levels of n-3 derived 
compounds are thus in line with anti-inflammatory properties associated with n-3 
fatty acid intake. Moreover, inflammation triggered the release of NAEs, including 
DHEA and EPEA.  
The authors of previous papers have concluded that fish oil leads to a ‘reduction’ 
or ‘inhibition’ of the endocannabinoid system [8, 9], but such statements seem to 
be incorrect as our studies show that dietary fish oil changes the endocannabinoid 
profile towards increased levels of DHEA and EPEA, and reduced levels of other 
endocannabinoids.  
Taken together, the in vitro and in vivo experiments described in this thesis 
demonstrate that the principle of combinatorial chemistry also applies to the 
relation between n-3 fatty acids and endocannabinoids.  
 
Increases of DHEA and EPEA following a fish oil diet: what are the 
consequences? 
Changes in metabolite patterns following a fish oil diet are descriptive, and it thus 
remains relevant to establish biological effects of n-3 fatty acid metabolites and, 
more particularly, patterns of n-3 and other fatty acid-derived metabolites. To the 
best of our knowledge, we were the first to report biological effects of n-3 derived 
NAEs. Using adipocytes, we demonstrated in chapter 3 that DHEA and EPEA have 
anti-inflammatory properties, thus suggesting that DHEA and EPEA play a role in 
the anti-inflammatory properties associated with fish oil intake [10]. As adipocytes 
play a key role in the pathophysiology of obesity, these findings might have 
implications for obesity research [11-14]. As for DHEA and EPEA, only anti-
proliferative [15] and synaptogenic [16] properties are described in recent 
literature besides the anti-inflammatory effects we have reported, and clearly 
more work is needed to understand the biological effects of these fish oil derived 
endocannabinoids, especially in in vivo situations. 
It should not be ignored that anti-inflammatory properties have been described 
for the other NAEs which were decreased by the fish oil diet. For instance, 
previous work from Cencioni et al. pointed to anti-inflammatory properties for 
arachidonoyl ethanolamide (AEA) [17]. This raises questions concerning the 
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relative efficacy of NAEs. When DHEA, EPEA, and AEA were compared in their 
effects on nitric oxide (NO) release from stimulated macrophages, DHEA and EPEA 
proved to inhibit NO release at lower doses compared to AEA [18]. Thus, fish oil 
replaces AEA for DHEA and EPEA, being more potent anti-inflammatory 
compounds compared to AEA in at least in vitro models of inflammation, and this 
might be one of the explanations for the anti-inflammatory effects of n-3 fatty 
acids in vivo.  
Anti-inflammatory properties have also been described for oleoyl ethanolamide 
(OEA), palmitoyl ethanolamide (PEA) and stearoyl ethanolamide (SEA), and it has 
been hypothesized that the endocannabinoid system is part of a protective 
response against inflammatory stress [17, 19-26]. The effects observed for DHEA 
and EPEA are in line with this general finding, and the superior efficacy of these 
molecules suggests that dietary n-3 fatty acids exert their anti-inflammatory 
properties at least partly through fine-tuning the NAE profile towards increased 
proportions of DHEA and EPEA. In view of the effect of diet and inflammation on 
the levels of DHEA and EPEA, combined with their anti-inflammatory properties, it 
seems that these endocannabinoids are linking dietary n-3 fatty acids to their anti-
inflammatory effects. Therefore, endocannabinoids represent a new branch to 
the tree which summarizes the pathways linking dietary n-3 fatty acid intake to 
anti-inflammatory effects (see Figure 8.1). 
 
Fish oil fatty acids and their metabolites: other classes of 
metabolites besides NAEs  
Repeating the experiments with the adipocytes using deuterated fatty acids 
revealed that only a small fraction of the n-3 fatty acids is converted to NAEs 
(chapter 3). The question emerges about the metabolic fate of the majority of the 
n-3 fatty acids. They could be left unchanged and dissolved in the medium, 
incorporated in cell membranes, or metabolized to other mediators which were 
not included in the MS platform used at that time. For instance, cyclo-oxygenase 
(COX) was shown to metabolize AEA to prostaglandin ethanolamides, and it has 
been speculated that cytochrome P450 (CYP) could convert AEA to 20-HETE-
ethanolamide [27, 28]. In parallel to this, it could be that DHEA and EPEA are also 
substrates for COX or CYP, potentially yielding other metabolites with interesting 
biological properties. Another publication reported effects of a fish oil diet on 2-
docosahexaenoyl glycerol and 2-eicosapentaenoyl glycerol levels [29], pointing to 
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the notion that n-3 fatty acids are also converted to other classes of metabolites 
besides eicosanoids and NAEs. In a recent paper we demonstrated the presence, 
formation, and putative effects of serotonin derivates of DHA and EPA in the 
intestinal tract [30]. Together these data  show that fatty acids are converted to a 
(still expanding) variety of compounds, which can subsequently be converted to 
other metabolites with currently largely unknown biological effects. Thus, 
focusing on DHEA and EPEA will not be sufficient to understand the anti-
inflammatory effects of n-3 fatty acids, and clearly more research is needed to 
identify and characterize other n-3 derived metabolites.  
 
Targeted lipidomics combined with a multi-compartment approach 
revealed tissue- and compound specific effects of dietary fatty acids 
and inflammation 
In order to investigate the effects of diet and inflammation on endocannabinoid 
profiles in more detail, an analytical method capable of quantifying a broad range 
of compounds was needed. At the start of the project, such methods were 
scarcely available. Therefore, we developed and validated an LC-MS/MS based 
analytical method for the quantification of a broad range of endocannabinoids 
and related structures, including several NAEs, 2-arachidonoyl glycerol (2-AG), 
fatty acid dopamines, and N-arachidonoyl glycine (NAGly) (chapter 2). Although 
similar in structure to a certain degree, the structural differences between these 
molecules made that the recoveries for these compounds were strongly 
dependent on the type of solid phase extraction (SPE) column used. As discussed 
in chapter 2, also the evaporation technique proved to be critical for recovery, 
with the dopamines and NAGly being the most difficult to recover. Nevertheless, 
by combining C8 SPE columns with vacuum concentration, we were able to 
quantify endocannabinoids and related compounds in plasma, and also from cell 
culture media and tissues. The versatility of the developed method was 
demonstrated with the addition of DHEA and EPEA in a later stage, since these 
compounds were not available at the time of initial method development and 
validation. The broad range of compounds which are included in this method 
proved to be critical to demonstrate that dietary fatty acid alter profiles of 
endocannabinoids rather than levels of individual compounds. 
The combination of the LC-MS/MS methodology with a multi-compartment 
approach revealed additional information which would have been overlooked 
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when only plasma was investigated.  In chapters 5 and 6, we describe that effects 
of lipopolysaccharide (LPS) and fish oil can not be generalized for certain 
metabolites, but can be opposite and site-specific. This holds important 
implications for research in this field, because effects on plasma levels of 
endocannabinoids or eicosanoids clearly do not reflect effects in peripheral 
tissues, and extrapolation from e.g. plasma values to tissue levels is thus not 
justified. Studying the plasma and multiple tissues endocannabinoid levels 
provides additional information and should be considered for future studies in 
this field. 
Using multivariate data analysis we were able to show that adipose tissue 
contained a large number of metabolites which could separate the different diet 
groups under inflammatory conditions, clearly demonstrating increased levels of 
n-3 derived eicosanoids and endocannabinoids. This suggests that adipose tissue 
endocannabinoid and eicosanoid levels are reactive to changes in dietary 
patterns, especially during inflammatory conditions. As with adipokines, 
adipocyte-derived lipid mediators might be released to the bloodstream to act 
systemically, which might also be relevant for inflammatory processes elsewhere 
in the body. Perhaps, these mediators might also be relevant during normal 
conditions for maintenance of health. The data show that adipose tissue is an 
important and reactive site of synthesis for both endocannabinoids and 
eicosanoids, underlining the need to use multi-compartment approaches when 
investigating effects of diet on metabolism. 
 
High n-3 fatty acid intake and acute inflammation 
To study the effects of nutrition on health and disease, clear and practical 
definitions of health and disease are required. In many cases, the boundaries 
between health and disease are not well defined. Increased knowledge on how 
diseases develop and improved diagnostics have demonstrated that there is often 
a continuum between a healthy state and disease. Diseases are often diagnosed 
or measured based on a relatively small number of variables which are considered 
to be deviant or outside the normal range. At the same time, “health” refers a 
multi-dimensional, dynamic and time-dependent situation which is difficult to 
quantify, in particular when only a limited number of biomarkers are measured. 
Based on the classical principles of homeostasis and biological evolution, it is 
proposed that the term ‘health’ be defined as ‘the ability to adapt’ to internal and 
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external stimuli [31]. New methods and models are currently being developed 
that better take into account the complexity and balance of homeostatic 
 
 
 
 
 
 
 
 
 
 
Figure 8.1: Revised representation of the mechanisms through which n-3 fatty acids 
modulate inflammatory processes. In addition to the established mechanisms, the data in 
this thesis point to a role for endocannabinoids as mediators of the anti-inflammatory 
effects of n-3 fatty acids. 
 
 
mechanisms. These models are based on dynamic processes instead of single 
endpoints. Recent advances in genomics and systems biology enable researchers 
to measure and model biomarker profiles and to translate these into dynamic 
processes. According to these concepts, healthy individuals are better able to 
cope efficiently with stressors they encounter, meaning that they recover quickly 
from any disturbance of homeostasis. Strategies to measure health include 
“challenge” or “stress” tests in which individuals are subjected to a stressor and 
their reaction (biochemical, physiological, immunological) is monitored [32]. 
Several models to ‘stress’ individuals have been developed, subjecting individuals 
to nutritional stress (e.g. high glucose or fat intake in a short period of time) or 
functional stress (e.g. vigorous exercise or induction of inflammation by LPS) [32]. 
In the animal experiment described in chapter 6 we exposed animals to LPS and 
observed that the animals who received 3% fish oil (FO) showed more severe 
signs of illness when challenged with LPS compared to the control and 1% FO 
groups. Clearly, the 3% fish oil intake suppressed the animal’s capability to 
overcome the LPS challenge. We were not the first to report that relatively high 
intakes of fish oil impair the hosts’ immunological response to e.g. infection [33-
n-3 fatty acids Eicosanoid synthesis 
Transcription factors / receptors 
Resolvin synthesis 
Endocannabinoid synthesis 
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35]. Dietary n-3 fatty acid intake has been shown to reduce inflammation under 
conditions of chronic low-grade inflammation, such as rheumatoid arthritis or 
chronic inflammatory bowel disease [3, 4]. However, there are now several 
indications that high n-3 fatty acid intakes impair the resilience towards acute 
inflammatory stress. This should have implications on the way we look at 
beneficial effects of n-3 fatty acids as these might have adverse effects in certain 
situations, at least under acute inflammatory stress. It must be noted here that 
the 3% fish oil diet represents a rather high intake: allometric scaling from mouse 
(30 gr mouse; consuming 2 gr/day of a diet containing 3% fish oil of which 36% 
DHA + EPA) to a 75 kg human and a metabolic conversion factor of 6 would result 
in a daily dose of 9 gr DHA + EPA. This dose strongly exceeds the recommendation 
from the National Health Council, currently advising a daily intake of 450 mg. This 
also relates to the effects on the endocannabinoid and eicosanoid metabolomes, 
and it would be interesting to repeat this study using lower, more representative 
intakes of fish oil, and to make an effort to relate alterations in metabolomes to 
biomarkers of health or disease. Nevertheless, our data support previous 
observations that (very) high fish oil intakes can disturb the capability to recover 
from an acute inflammatory stimulus. 
 
Endocannabinoid levels are personal and depend at least on diet 
EPEA is normally not detected in plasma from mice fed a standard diet, but is 
present at quantifiable levels after the mice were fed a fish oil diet (chapter 6), 
indicating that endocannabinoid levels can depend on dietary patterns. In chapter 
4, we described a positive correlation between serum free fatty acid levels and 
plasma NAE levels in women. The differences in NAEs and fatty acids between the 
subjects might be explained by differences in dietary habits, but this was not 
investigated here. Nevertheless, this shows that endocannabinoid levels are quite 
‘personal’ as their levels are influenced by diet and postprandial status, 
demanding  study designs which preferably do not compare different intervention 
groups in parallel, but rather use cross-over designs because this takes inter-
subject variation more into account. As a consequence, it is difficult to define 
‘normal’ values of endocannabinoid levels and it is better to refrain from using or 
defining such values.  
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Directions for future research 
 
Advances in the field of analytical chemistry 
As discussed above, it is clear that at present (n-3) fatty acid derived metabolites 
are still being identified, such as the fatty acid serotonin conjugates and further 
COX or CYP metabolites of NAEs. This suggests that there are still numerous 
compounds waiting to be discovered. The scientific community will not be able to 
fully understand the biology n-3 fatty acids unless a complete overview of their 
metabolism is available. Thus, the field of analytical chemistry should focus on the 
identification and characterization of novel (n-3) fatty acid derived metabolites, 
methods that enable to measure several metabolites in one sample, and 
statistical models to interpret these complex lipidomic data sets.  
 
Advances in the field of biology 
It is clear from our data that dietary fatty acids alter the profile of 
endocannabinoids, but it is unclear how this would affect health and disease. A 
better understanding of the relation between dietary fatty acids and health 
requires more knowledge on the biological effects of fatty acid metabolites, and 
special attention should be given to biological effects of endocannabinoid profiles 
rather than individual compounds. As for the endocannabinoids, AEA and 2-AG 
are the best studied compounds, and far less is known about e.g. DLE, DHEA, and 
EPEA. This gap needs to be closed, thus requiring more functional characterization 
of at least DHEA and EPEA, but also other n-3 derived metabolites. In line with the 
notion that diet affects endocannabinoid profiles, it would be interesting to test 
the effect of combinations of e.g. endocannabinoids on inflammation instead of 
testing only single compounds. Exposure to multiple compounds at the same time 
is also a more relevant representation of the in vivo situation as 
endocannabinoids are co-existing. Related to this, the individual 
endocannabinoids and NAEs have a distinct pharmacodynamic signature, 
targeting receptors like CB1, CB2, TRPV-1, and the PPARs with different affinities 
[36-41]. Thus, as these endocannabinoids are present at the same time, their 
concentration profile determines the biological outcome as different receptors 
might be more or less stimulated. Diet has an effect on the balance of the 
endocannabinoid metabolome, increasing levels of certain compounds at the 
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expense of others, supporting the importance of testing combinations or patterns 
of endocannabinoids rather than individual compounds.  
 
Towards a role for nutrition-based modulation of endocannabinoids in health and 
disease in humans using n-3 fatty acids 
To the best of our knowledge, no data has been published that points to a role for 
nutrition-based modulation of endocannabinoids in health and disease using n-3 
fatty acids. Considering the regulatory role of endocannabinoids in metabolism 
and inflammation, and their dependence on at least nutritional habits and 
inflammatory status, a role as a biomarker is at hand. There is a limited amount of 
literature available on this topic, pointing to such a relation with cardiometabolic 
risk factors and obesity [42-44]. Increased plasma AEA and 2-AG levels are 
observed in obesity [45, 46], and one report demonstrated that life style 
intervention in obesity improves cardiometabolic risk factors in parallel to 
decreases in plasma AEA and 2-AG levels [43]. For most risk factors, correlations 
with 2-AG were established, but this might be explained by the fact that DHEA 
and EPEA are often not reported. An exception to this is the publication from Sipe 
et al., pointing to decreased DHEA levels in obese persons compared to normal-
weight counterparts [44]. Considering the above-mentioned correlations in the 
obese state, it would be interesting to investigate whether endocannabinoid 
levels have a predictive capacity regarding the future development of disease in 
apparently healthy individuals, e.g. whether the development of disease is 
preceded by (early) alterations in endocannabinoid profiles. In addition to this and 
considering the findings presented in this thesis, it is very interesting to explore 
whether dietary n-3 fatty acids modulate the endocannabinoid system in humans, 
and to investigate how a possible alteration correlates with the maintenance of 
health and the development of disease. Of course, such a (descriptive) correlation 
would only point to a role as a biomarker, and a causal relation between altered 
endocannabinoid levels and effects on health still remain to be established. The 
relation between dietary n-3 fatty acid intake and in vivo endocannabinoid levels 
in obese subjects was published by Banni and coworkers in 2010 [8], but no data 
on DHEA or EPEA were included in that report, and associations with 
cardiometabolic risk factors were not investigated. Nevertheless, the established 
endocannabinoids are interesting biomarkers, and DHEA and EPEA might also 
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have potential use as biomarkers of health and disease and might causally link 
dietary n-3 fatty acids to health effects. 
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Samenvatting 
 
 
Gezonde voeding is een van de belangrijkste factoren die van invloed zijn op onze 
gezondheid. Van veel voedingsstoffen is bekend dat ze een negatieve invloed 
hebben op onze gezondheid, maar tegelijkertijd zijn er ook voedingsstoffen die 
een gunstig effect kunnen hebben. Een voorbeeld hiervan is visolie, waarvan 
gebleken is dat het ontstekingsremmende eigenschappen heeft. De mechanismen 
hierachter zijn nog niet geheel doorgrond, maar het is duidelijk dat de 
zogenaamde omega-3 (ook wel genoteerd als n-3 of ω-3) vetzuren die in visolie 
zitten van invloed zijn op de vorming van eicosanoïden, een groep vetzuur-
afgeleide verbindingen die ontstekingsprocessen reguleren. Vetzuren kunnen ook 
omgezet worden tot de zogenaamde N-acyl ethanolamines (NAEs), waarvan de 
endocannabinoïd anandamide (AEA) een bekend voorbeeld is. Ook NAEs hebben 
invloed op ontstekingsprocessen, maar een verband tussen inname van visolie, 
vorming van NAEs, en ontsteking was nog niet eerder onderzocht. Dit proefschrift 
beschrijft een reeks studies die zijn uitgevoerd om een verband tussen vetzuren 
uit het dieet, de vorming van endocannabinoïden/NAEs, en ontsteking te 
onderzoeken.  
 
Om de invloed van dieet op de vorming van endocannabinoïden/NAEs te 
bestuderen, is het nodig om een analysemethode te hebben waarmee een breed 
aantal verbindingen gemeten kan worden. Hiervoor is een analysemethode op 
basis van vloeistofchromatografie gekoppeld aan massaspectrometrie (LC-
MS/MS) ontwikkeld. Met behulp van deze methode is aangetoond dat n-3 
vetzuren door vetcellen (adipocyten) in vitro kunnen worden omgezet naar hun 
endocannabinoïde analogen. Deze n-3 afgeleide NAEs, genaamd docosahexaenoyl 
ethanolamide (DHEA) en eicosapentaenoyl ethanolamide (EPEA), bleken tevens 
ontstekingsremmende eigenschappen te hebben in lipopolysaccharide (LPS)- 
gestimuleerde adipocyten, waarbij de secretie van de cytokines interleukine-6 (IL-
6) en momocyte chemotactic protein (MCP-1) verminderd werd. Vervolgstudies 
toonden aan dat er een correlatie was tussen serum vetzuurconcentraties en 
plasma NAE concentraties, en ook bleek dat plasma AEA en oleoyl ethanolamide 
(OEA) concentraties correleerden met de ‘body mass index’ (BMI). 
Gezien de complexiteit van het metabolisme van endocannabinoïden en 
eicosanoïden is het waarschijnlijk dat de concentraties ervan dynamisch en 
weefsel-specifiek zijn gedurende ontsteking. De meerderheid van eerder 
gepubliceerde studies waren echter gericht op slechts enkele verbindingen en in 
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een beperkt aantal weefsels. Daarnaast was nog niet bekend wat het effect van 
ontsteking op DHEA en EPEA zelf was. Om beter inzicht hierin te krijgen, werd in 
een dierstudie het tijdsafhankelijke effect van ontsteking op endocannabinoïden 
en eicosanoïden in plasma, lever, ileum en vetweefsel in detail bestudeerd 
(‘multi-compartment targeted lipidomics approach’). De resultaten lieten zien dat 
de concentraties DHEA en EPEA werden verhoogd door LPS, maar er werden ook 
tijds- en weefselafhankelijke effecten gevonden. Op basis van deze data werd een 
tweede dierstudie uitgevoerd, waarin het gecombineerde effect van verschillende 
visoliediëten én ontsteking op de profielen van endocannabinoïden en 
eicosanoïden werd bestudeerd met behulp van dezelfde ‘targeted lipidomics 
approach’. Uit deze studie bleek dat n-3 vetzuren en ontsteking de profielen van 
endocannabinoïden en eicosanoïden beïnvloedden waarbij er hogere 
concentraties van n-3 afgeleide metabolieten aanwezig waren, hetgeen ten koste 
ging van metabolieten die afkomstig zijn van andere vetzuren. Multivariate data 
analyse liet zien dat er scheiding was van de verschillende dieetgroepen bij zowel 
normale condities en tijdens ontsteking. Tijdens normale condities werd de 
scheiding tussen de dieetgroepen voornamelijk verklaart door een afname van 
anders dan n-3 afgeleide metabolieten. Echter, tijdens ontsteking werd scheiding 
tussen de dieetgroepen voornamelijk verklaart door een toename van n-3 vetzuur 
afgeleide metabolieten. Tot slot bleek uit aanvullende analyses dat plasma en 
bloedcellen aanzienlijke hoeveelheden veresterde NAEs bevatten. De 
hoeveelheden veresterde NAEs waren ongeveer 20 tot 60 keer hoger dan de vrije 
NAE waarden, en de profielen ervan komen overeen met die van vrije NAEs. 
 
Samenvattend verhogen n-3 vetzuren uit het dieet de concentraties van DHEA en 
EPEA, en deze verbindingen hebben ontstekingsremmende eigenschappen. 
Hoewel de n-3 vetzuren waarschijnlijk naar nog meer klassen van metabolieten 
omgezet kunnen worden, suggereert het werk in dit proefschrift dat ‘visolie-
afgeleide’ endocannabinoïden een nieuwe verbinding vormen tussen visolie en 
ontstekingsremmende eigenschappen. Meer onderzoek is nodig om een verband 
aan te tonen tussen de verandering van profielen van endocannaboïden door 
middel van dieet en effecten hiervan op ziekte en gezondheid.  
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doen. Bedankt voor je prettige manier van begeleiden en je betrokkenheid bij het 
onderzoek. 
Daarnaast ook een woord van dank aan mijn promotor, Renger Witkamp. Beste 
Renger, bedankt voor het vertrouwen dat je in me hebt en je begeleiding. Je 
energie en enthousiasme voor wetenschap zijn aanstekelijk, en ik heb veel 
geleerd van je. Hopelijk wordt het vervolgonderzoek net zo’n succes, en blijft je 
groep doorgroeien! 
Dan ook dank aan mijn kamergenoten Koko en Maarten. Dear Koko, I have 
enjoyed our conversations about being a PhD student and other stuff very much. 
Hopefully, you will finish your PhD soon. Good luck with your new job in Leiden! 
Beste Maarten, jouw komst naar kamer 4.1.05 was zeker goed voor de sfeer en 
daar heb ik goede herinneringen aan! Bedankt voor je collegialiteit en de vele 
leuke koffiepauzes. Gelukkig heb je meer verstand van massaspectrometrie dan 
van voetbal (Ajax… kom op man!).  
Ook van de andere collega’s bij AR heb ik veel opgestoken van MS. Beste Hugo, als 
beheerder van de Quantum heb je me vaak uit de brand geholpen bij lekkende 
pompen, doorgebrande vacuümsensoren en spontaan verdwenen sensitiviteit. 
Bedankt hiervoor! Richard, je bent een echte vakman op het gebied van MS, 
bedankt voor je collegialiteit. Als er ooit een gek smaakje aan de koffie zit, dan is 
het goed om te weten dat jij in een mum van tijd weet wat de oorzaak is!  
Beste Henk, Ria, Angelique, Machiel, Marieke en Lisette, het was altijd leuk om bij 
jullie op het lab te werken! Ook een woord van dank aan Joyce, Raymond, Marc, 
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Leon, Elwin, Ivana, Cor, Leo, Albert, Bianca, Rinke, Jack en Eric voor de gezelligheid 
aan de lab- of lunchtafel. Beste Sabina en Carina, jullie kennis van statistiek is 
goed van pas gekomen bij de verwerking van de data van de dierstudies. Dank 
voor de prettige samenwerking en jullie bijdrage aan deze studies! 
Tijdens het onderzoek heb ik ook weer vele uurtjes doorgebracht op het kweeklab 
van gang ‘6.2’. Gelukkig was de sfeer daar nog net zo als toen ik er stage liep! 
Richard, Wilfred, Birol, Mariska, Harm, Irene, Bert, Bianca, Rianne, Astrid, en 
Mary-lène: bedankt voor jullie collegialiteit en de leuke sfeer in de koffiehoek.  
Voor het opzetten van de analyse-methoden zijn ook heel wat buisjes plasma 
nodig geweest, en gelukkig kon ik daarvoor altijd in gebouw 11 terecht! Beste 
Angelique, Henriëtte en Ineke: fijn dat ik altijd bij jullie terecht kon om bloed te 
laten prikken! Gelukkig heeft dit ook geleid tot twee mooie analysemethoden die 
ook al in de praktijk zijn gebracht bij TNO. Beste Alwine en Ellen, fijn dat ik 
hiermee kon meewerken aan de ‘Fat Load Study’, hopelijk komt er leuke data uit! 
 
Ook een plekje voor de stagiaires die aan het project hebben bijgedragen. Beste 
Karin, je had al nuttig voorwerk verricht aan adipocyten waar ik zeker profijt van 
heb gehad! Beste Laura, je kwam er al snel achter dat onderzoek doen niet altijd 
makkelijk is, maar dat heeft je niet tegengehouden om zelf ook AIO te worden. 
Bedankt voor inspanningen, en veel succes met het je eigen promotie! Beste 
Renate, ook jij hebt veel werk verzet, bedankt hiervoor en veel succes met het 
afronden van je opleiding! 
 
Ook in Wageningen heb ik een hoop leuke collega’s leren kennen, ondanks dat ik 
veel in Zeist was. Beste Jocelijn, dank voor je kritische blik en hulp bij het 
uitvoeren van de dierstudies. Het is mooi dat je inspanningen de basis zijn 
geweest voor de groei van de ‘Witkamp’ groep! 
In dit dankwoord een bijzonder plaatsje voor mijn paranimfen. Beste Mieke, met 
al je kennis en ervaring ben je van onschatbare waarde voor de groep! Bij de 
volgende dieetproef zal ik er rekening mee houden dat je niet zo’n ochtendmens 
bent ;-). Klaske, met jouw komst heeft de onze groep er een hele goede 
wetenschapper bij gekregen. Het glas van de ICRS heb ik nog steeds! Ik vind het 
erg leuk dat jullie mijn paranimfen willen zijn op de grote dag! 
Officieel waren de mensen van de NMG groep al collega’s, maar de afstand tussen 
Zeist en Wageningen was toch wat groot. Ondanks dat heb ik een aantal van jullie 
toch beter leren kennen tijdens de voedingscongressen en de  PhD tour naar het 
Noorden! Beste Noortje, succes met de laatste loodjes van jouw proefschrift. 
Lydia, bedankt voor alle keren dat ik mee kon liften naar Nijmegen. Beste 
Diederik, Vera, Katja, Ohid, Mylène, Danielle, Frits, Anastacia, Jvalini en Nikkie, 
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heel veel succes met jullie onderzoeken! Dear Pierluigi, your work on the chemical 
synthesis of fatty acid ethanolamides (or are they amines??) has fueled the ‘fish 
oil endocannabinoid’ research. Thank you for the pleasant collaboration, and I am 
looking forward on seeing you again in Wageningen! Saskia, de FIGON dagen 
zouden zonder jou een stuk minder leuk geweest zijn. Alle andere mensen van de 
NMG groep: bedankt voor jullie collegialiteit en de leuke sfeer in Wageningen 
waar ik sinds kort van kan genieten! 
Zonder de medewerkers van het CKP hadden we de dieetstudies niet kunnen 
doen. Bedankt voor jullie ondersteuning en goede zorgen tijdens de studies! 
 
Gelukkig was ik bij TNO niet de enige AIO. Beste Michel, je hebt zeker bijgedragen 
aan de lol die ik bij TNO heb beleefd, en uit onze samenwerking is zelfs een mooi 
artikel gekomen. Bedankt voor de gezelligheid bij TNO en tijdens de PhD tour! 
Beste Dina, gelukkig ga jij verder met het analyseren van endocannabinoïden. 
Heel veel succes met je onderzoek! 
 
Gelukkig was er ook buiten het werk ook een leven. Beste Theo, wij kennen elkaar 
al sinds de basisschool. Toch leuk dat we allebei via onze eigen weg in het 
onderzoek terecht zijn gekomen! Bastiaan, we kennen elkaar ook al heel wat 
jaartjes, en hopelijk blijven we elkaar nog vaak zien! Veel geluk met Selfina en 
Tobias samen.  
Tijdens mijn studie in Nijmegen heb ik een fantastische groep mensen ontmoet. 
Beste Jurrian, Esther, Anil, Jennie, Anthony, Ilker, Erik, Sabrina, Ivar, Johan, Marc, 
Susan, Reinier en Lisette, met jullie is het altijd leuk! Beste Antoinette, veel succes 
met jouw verdediging, en daarna door richting de halve marathon. Beste Miriam 
en Isaac, ik geniet altijd erg van de gesprekken die we hebben onder het genot 
van een kop koffie of een glas wijn. Helaas zal dat binnenkort niet meer zo 
vanzelfsprekend zijn, maar daar zullen we vast wat op vinden! Anke, dank voor je 
steun en de mooie herinneringen, en het ga je goed.  
 
Tot slot mijn familie. De grootste dank aan mijn ouders Jos en Veerle, jullie 
hebben Carla en mij op de goede weg gezet en ons altijd gemotiveerd het beste 
uit onszelf te halen. Dank voor jullie onvoorwaardelijke steun, vertrouwen en de 
fijne thuisbasis! Beste Carla, ook al lijken we soms totaal tegenovergesteld, ik vind 
het altijd weer leuk om jou en Maarten te zien, en de komst van Lotte heeft dat 
alleen maar leuker gemaakt! 
 
 
 
 202 
 
  
 
 
About the author 
 
 
 
 
  
About the author 
204 
 
Curriculum vitae 
 
Michiel Gerard Juliaan Balvers was born on June 28, 1981 in ‘s-Hertogenbosch, 
the Netherlands. After completing secondary school at the Jeroen Bosch College 
in ‘s-Hertogenbosch in 2000, he started studying Biomedical Sciences at the 
Radboud University Nijmegen and specialized in pathobiology and toxicology. He 
completed traineeships at the department of Pathology of the Radboud University 
Nijmegen Medical Centre, and department of Physiological Sciences at TNO 
Quality of Life (Zeist, the Netherlands), where he gained experience in molecular 
biology, in vitro experiments, and analytical chemistry. After obtaining his MSc 
degree in 2005, he first completed a one-year teacher training course before 
being appointed as a PhD candidate at the division of Human Nutrition of 
Wageningen University and TNO to work on the so-called ‘Balance project’. This 
research project investigated the relation between dietary fatty acids, 
endogenous fatty acid metabolites, and inflammation as described in this thesis. 
The experimental work was largely performed at TNO and involved the 
development and implementation of lipidomic analyses, in vitro experiments, and 
dietary studies in animals.  
Michiel currently works in the group of Prof. dr. Renger Witkamp (division of 
Human Nutrition, Wageningen University) where he investigates the effects of 
newly discovered fatty acid metabolites on intestinal physiology and inflammatory 
processes.  
  
About the author 
205 
 
List of publications 
 
Balvers MGJ, Verhoeckx KCM, Meijerink J, Bijlsma S, Rubingh CM, Wortelboer HM, and Witkamp RF. 
Fish oil and inflammatory status alter the n-3 to n-6 balance of the endocannabinoid and oxylipin 
metabolomes in mouse plasma and tissues. Accepted for publication, Metabolomics 
 
Balvers MGJ, Verhoeckx KCM, Meijerink J, Bijlsma S, Rubingh CM, Wortelboer HM, and Witkamp RF. 
Time-dependent effect of in vivo inflammation on eicosanoid and endocannabinoid levels in plasma, 
liver, ileum and adipose tissue in C57BL/6 mice fed a fish oil diet. Accepted for publication, 
International Immunopharmacology 
 
Verhoeckx KCM, Voortman T, Balvers MGJ, Hendriks HF, Wortelboer HM, and Witkamp RF. 
Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid 
derived mediators, in the intestinal tract. Biochimica Biophysica Acta - Molecular and Cell Biology of 
Lipids (2011) 
 
Meijerink J, Plastina P, Vincken J-P, Poland M, Attya M, Balvers MGJ, Gruppen H, Gabriele B, and 
Witkamp RF. The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows 
immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new 
link between fish oil and inflammation. British Journal of Nutrition (2011) 
 
Balvers MGJ, Verhoeckx KCM, Plastina P, Wortelboer HM, Meijerink J, and Witkamp RF. 
Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl 
ethanolamines with anti-inflammatory properties. Biochimica Biophysica Acta - Molecular and Cell 
Biology of Lipids (2010) 
 
Joosten MM, Balvers MGJ, Verhoeckx KCM, Hendriks HF, and Witkamp RF. Plasma anandamide and 
other N-acyletanolamines are correlated with their corresponding free fatty acid levels under both 
fasting and non-fasting conditions in women. Nutrition & Metabolism (2010) 
 
Balvers MGJ, Verhoeckx KCM, and Witkamp RF. Development and validation of a quantitative 
method for the determination of 12 endocannabinoids and related compounds in human plasma 
using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B (2009) 
 
Wortelboer HM, Balvers MGJ, Usta M, van Bladeren PJ, and Cnubben NH. Glutathione-dependent 
interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2. 
Environmental Toxicology and Pharmacology (2008) 
 
van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MGJ, Adema GJ, 
and de Mulder PH. Intratumoral recombinant human interleukin-12 administration in head and neck 
squamous cell carcinoma patients modifies locoregional lymph node architecture and induces 
natural killer cell infiltration in the primary tumor. Clinical Cancer Research (2005) 
  
About the author 
206 
 
Overview of completed educational activities 
 
 
Discipline specific activities 
  
Dutch Society for Massaspectometry (NVMS) annual meetings (2007 & 2011) 
 Avans Plus LCMS training course (2007) 
 NUTRIM course Regulation of food intake and satiety (2008) 
Thermo Scientific LCMS user meeting (2008) 
 ECO 2008 conference (2008) 
NWO Nutrition annual meetings (2008-2011) 
Federation Innovative Medicine Research (FIGON) annual meetings (2008-2010) 
International Cannabinoid Research Society (ICRS) annual conferences (2009-2011) 
 ISSFAL conference (2010) 
Pharma-Nutrition conference (2011) 
 
 
General activities 
 
 TNO Good Laboratory Practice (GLP) introduction course & SOP writing (2007-2008) 
 VLAG PhD week (2008) 
TNO Time Management workshop (2011) 
 TNO Reporting and communicating with clients (2010-2011) 
 TNO Technician training & technical support (2011) 
 
 
Optionals 
 
 Preparation Research proposals  
 Human Nutrition PhD tour (2009) 
 TNO Scientific colloquia (2007-2011) 
  
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research described in this thesis was financially supported by TNO 
(VP9/Balance). 
 
 
Financial support from Wageningen University and TNO for printing this thesis is 
gratefully acknowledged. 
 
Cover design by Michiel Balvers. 
 
 
Printing 
Ipskamp Drukkers, Enschede, the Netherlands. 
 
 
Copyright © Michiel Balvers, 2012. 
 
